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The organic cation transporter 1 (OCT1) is most extensively expressed in the human liver. OCT1 
is involved in the hepatic uptake of several drugs and endogenous compounds, which then 
undergo bioactivation, recycling, metabolism, or elimination. 
The aim of this work was to extend the knowledge about OCT1 substrates and non-substrates of 
endogenous and exogenous origin. Establishing an in vitro model for studying uptake and 
subsequent metabolism was an additional goal, as well as finding an endogenous biomarker for 
OCT1 activity. These studies should contribute to our basic understanding of the biological role 
of this transporter and to the understanding of the role of OCT1 in pharmacology and toxicology. 
Influx transport of 18 psychostimulant or hallucinogenic compounds, which all meet the 
conventional physicochemical criteria of OCT1 substrates, was investigated for OCT1 and related 
transporters. Mescaline was newly identified as a substrate of OCT1. To more systematically and 
comprehensively search for additional substrates, a machine learning-based model was used. This 
approach exploited existing knowledge about OCT1 substrates. Machine learning-aided 
prediction of new substrates was highly reliable as subsequent in vitro validation showed. The in 
silico prediction, which was based on two-dimensional structures, did not include three-
dimensional information, which is important for enantiomers. Therefore, stereoselectivity of 
OCT1 transport was investigated in vitro. It revealed a surprisingly stereoselective cell uptake for 
some substrates, e.g. fenoterol, but not all, e.g. salbutamol.  
For the purpose of in vitro-to-in vivo translation in more complex biological systems, a cell model 
was developed, which allowed the chromosomal integration of two genes of interest in a targeted 
manner, to investigate uptake and metabolism in a more holistic fashion. Both genes can be 
transfected simultaneously and are expressed with equal strength. As a first proof of the value, the 
sequential uptake of proguanil and subsequent CYP-dependent activation to cycloguanil 
resembled indeed the uptake and metabolism in primary hepatocytes. Several European and 
American investigators have already expressed their interest to adopt the system for their research. 
Thiamine (Vitamin B1) had been proposed as a biomarker for in vivo OCT1 activity. Although 
thiamine was a substrate of OCT1 in vitro, thiamine was rejected as a suitable biomarker for OCT1 
activity through a human clinical trial. After the intake of a large thiamine dose, neither thiamine 
trough concentrations nor maximum concentrations showed any correlation with individual 
OCT1 activity according to genotype. Results suggested that other transporters play the central 
role in thiamine uptake into the liver and other organs. 
In total, I could add more than 20 previously unknown substrates to the list of well characterized 
OCT1 substrates. I could show that OCT1 transport can be quite different depending on subtle 
structural differences between enantiomers. Moreover, the developed cell model may serve as an 
interesting tool to mimic the complex interplay between hepatic uptake and metabolism, and 
human pharmacokinetics of thiamine is not dependent on OCT1 - at least not in a quantitatively 
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relevant fashion. Together, these findings may contribute to a gradually improving understanding 





Compartmentation is a prerequisite for life. Without biological barriers, separation of functional 
compartments would not exist and development of life as we know would not have been possible. 
This separation, however, has some disadvantages. At least, vital nutrients and harmful 
metabolites need to pass these barriers for an organism to survive. In single cells as well as higher 
developed living beings, transport proteins realize the task of taking up compounds, which are not 
able to cross lipid bilayers. In humans, this is essential when it comes to nutrient uptake, reuptake 
of neurotransmitters, translocation of a variety of compounds across cellular but also intracellular 
barriers, renal or biliary elimination of metabolites, and many more. 
Three quarters of the top 200 prescribed drugs in the United States require uptake into the liver 
for metabolism or direct biliary excretion, and only about 30 % are cleared unchanged via urine 
(Morrissey et al. 2013; Williams et al. 2004). Numerous of those drugs are organic cations, 
meaning weak bases, which are positively charged at physiologic pH. Their elimination requires 
protein-mediated transport across cell membranes. In the liver, this is achieved, amongst others, 
by transport proteins of the SLC22 family, primarily by the organic cation transporter 1 (OCT1). 
 
2.1 OCT1 – A member of the SLC22 family 
The organic cation transporter 1 (OCT1) is a transport protein encoded by the SLC22A1 gene. 
OCT1 has been studied since its discovery in the late 1990s, when it was successfully cloned and 
characterized (Gorboulev et al. 1997; Zhang Lei et al. 1998). The SLC22 family further comprises 
the organic cation transporters OCT2 (SLC22A2), OCT3 (SLC22A3), OCTN1 (SLC22A4), and 
OCTN2 (SLC22A5) (Figure 1). 
 
 
Figure 1: Amino acid sequence comparison of selected organic cation transporters. The identity matrix of 
the organic cation transporters from the SLC22 family (OCT1, OCT2, OCT3, OCTN1, OCTN2) and two 
multidrug and toxin extrusion proteins MATE1 (SLC47A1) and MATE2-K (SLC47A2) shows the amino acid 
sequence identity from pairwise comparisons in percent (left). The phylogenetic tree indicates evolutionary 
distances of these transporters (right). Amino acid sequences were analyzed by “Multiple Sequence 
Comparison by Log-Expectation” (MUSCLE) provided by the European Bioinformatics Institute, Hinxton 
(https://www.ebi.ac.uk/), and the phylogenetic tree was created from resulting data via the “Interactive 
Tree Of Life” (iTOL) online tool version 6 (https://itol.embl.de/). 
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Together with many other transporters, OCT1 is expressed in the human liver (Figure 2). More 
specifically, it is expressed in the sinusoidal membrane facing the space of Disse and the 
bloodstream in the liver (Meyer-Wentrup et al. 1998; Zamek-Gliszczynski et al. 2018). It serves 
for the hepatic uptake allowing for subsequent hepatobiliary elimination of a variety of exogenous 
drugs and toxins as well as endogenous amines (Meijer et al. 1990; Oude Elferink et al. 1995). 
 
 
Figure 2: Transport proteins relevant for hepatic uptake and elimination. Both, SLC (blue circles) and ABC 
(pink hexagons) transporters are involved in uptake and elimination in the liver. Figure inspired by 
Figure 1 in the 2018 White Paper of the International Transporter Consortium (Zamek-Gliszczynski et al. 
2018). BSEP, bile salt export pump; BRCP, breast cancer resistance protein; ENT, equilibrative nucleoside 
transporter; MATE, multidrug and toxin extrusion protein; MDR, multidrug resistance protein; MRP, 
multidrug resistance-associated protein; NTCP, sodium taurocholate cotransporting peptide; OAT, 
organic anion transporter; OATP, organic anion transporting polypeptide; OCT, organic cation 
transporter; OST, organic solute transporter. 
 
The other SLC22 family members (OCT2, OCT3, OCTN1, and OCTN2) are known for the 
uptake of organic cations and/or zwitterionic substances like carnitine (Tamai et al. 1997; Tamai 
et al. 1998; Yabuuchi et al. 1999). The transporters OCTN1 and OCTN2 stand out because they 
do not mediate electrogenic transport of cations like the other three transporters OCT1, OCT2, 
and OCT3. OCTN1 and OCTN2 translocate organic cations or (together with Na+) carnitine in 
exchange with protons. 
In contrast to the predominantly hepatic expression of OCT1, OCT2 is expressed in the basolateral 
membrane of renal tubular epithelial cells, where it mediates the uptake of organic cations prior 
to luminal excretion (Motohashi et al. 2002; Nies et al. 2009; Tzvetkov et al. 2009; Zhang L. et al. 
1997). OCT3 is expressed more broadly and was detected in brain, heart, liver, lung, kidney, 
placenta, and skeletal muscle (Gründemann et al. 1998; Verhaagh et al. 1999; Wu et al. 2000). 
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OCTN1 and OCTN2 are expressed in several tissues, such as heart, kidney, placenta, prostate, and 
skeletal muscle (Koepsell et al. 2003; Wu et al. 1998). Amino acid identities among the SLC22 
family members with OCT1 range from 32 % for OCTN1 to 70 % for OCT2 (Koepsell et al. 2003). 
One commonality among the SLC22 family members is the structural arrangement of 
twelve transmembrane domains (TMD), including one large extracellular loop (connecting TMD 
1 and 2) and a large intracellular loop (connecting TMD 6 and 7, Figure 3). These 12 
transmembrane domains are thought to form the central binding pocket (Bednarczyk et al. 2003). 
 
 
Figure 3: Three-dimensional homology model of OCT1. The OCT1 homology model by Dakal et al. shows 
the arrangement of the 12 TMD and the formation of a central binding cleft (Dakal et al. 2017). 
 
The substrate translocation by OCT1 has been described with the alternating access model 
(Koepsell 2011; Volk et al. 2009). The substrate binds to the transporter in its outward-open 
conformation and induces subsequent changes in protein conformation (Figure 4). In a non-ATP-
dependent manner (‘facilitated diffusion’), the protein changes to the outward-occluded and 
inward-occluded state, in which the substrate is trapped inside the transporter, before it gets 
released from the transport protein in its inward-open state (Abramson et al. 2003; Koepsell 2015; 
Koepsell und Keller 2016). This process of facilitative diffusion depends on substrate 
concentration and membrane potential (Egenberger et al. 2012). In contrast to antiporters, such 
as OCTN1 and OCTN2, transport by OCT1 is electrogenic, meaning charged molecules (cations) 
are transported across the cell membrane without compensation (Busch et al. 1996). It was shown 
that OCT1 and other OCTs as well are able to facilitate not only uptake but also efflux of cations 
(Busch et al. 1996; Jensen et al. 2021b; Kim et al. 2017; Nagel et al. 1997). Besides transport, 
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previous work also focused on inhibition (Ahlin et al. 2008; Chen EC et al. 2017), as translocation 
of substrates can be restricted by inhibitors on the one hand and genetic variants on the other. 
 
 
Figure 4: Substrate translocation by OCT1 described with the alternating access model. The substrate binds 
to the transport protein in the outward open conformation. Subsequent conformational changes lead to 
formation of the inward- and outward-occluded states and the release of the substrate from the inward-
open conformation. This model is based on findings, which differentiate OCT1 from an ion channel 
(Koepsell et al. 2003). 
 
2.2 Genetic variability of OCT1 
The OCT1 gene is highly polymorphic, particularly in its coding region. Among all genes of organic 
cation transporters of the SLC22 and SLC47 family, OCT1 showed the highest variability, 
especially for non-synonymous polymorphisms (Leabman et al. 2003; Tzvetkov et al. 2016). Until 
today, 16 different OCT1 haplotypes and additional sub-haplotypes have been described and 
functionally characterized (Seitz et al. 2015; Shu et al. 2007; Shu et al. 2003). 
Besides the most prevalent reference (wild-type) allele, five distinct haplotypes are present in the 
European population (Table 1). This includes the alleles OCT1*2 to *6, which are defined by a 
deletion of Met420 and/or amino acid substitutions. All these haplotypes can also be found in 
North Africa and the Middle East, as well as the two haplotypes OCT1*7 and *8. The latter ones 
have also been identified in populations of sub-Saharan Africa, where they exist next to the 
reference and the *2 allele. Even more diverse in the genetic landscape of OCT1 are Central Asia, 
East Asia and Oceania, where variants OCT1*9 to *16 can be found. A special exception in the 
worldwide distribution of OCT1 alleles is South America, where the reference allele and the *2 




Table 1: OCT1 haplotypes and their prevalences 
 
Polymorphisms defining haplotypes according to Seitz et al. (Seitz et al. 2015) are indicated and highlighted 
with red circles. Prevalences ≥ 0.05 % of haplotypes in major populations are indicated in percentages. AM 
– Central and Southern America; EU – Europe; NA – North Africa and Middle East; SA – Southern Africa; 
OC – East Asia and Oceania; CA – Central Asia 
 
Distribution differences have consequences as OCT1 variants lead to functional impairments 
(Jensen et al. 2020a; Jensen et al. 2020b; Matthaei et al. 2019; Matthaei et al. 2016; Seitz et al. 2015; 
Shu et al. 2003; Tzvetkov et al. 2012; Tzvetkov et al. 2018). The most common variant OCT1*2 is 
associated with a substrate-specific loss-of-function. Depending on the substrate, transport 
activity ranges from a complete loss of function to activity above reference OCT1 (Kerb et al. 2002; 
Saadatmand et al. 2012; Shu et al. 2007; Tzvetkov et al. 2013). The haplotypes OCT1*3 and *4 
show a strong reduction (70 and 80 %, respectively) of transport activity in the vast majority of 
substrates (Seitz et al. 2015; Tzvetkov et al. 2016). However, it is to note that measurements at 
single concentrations do not reveal the complete picture. For example, uptake of fenoterol by 
OCT1*4 is reduced (compared to reference OCT1) at low concentrations, but vmax by OCT1*4 is 
increased. The haplotypes OCT1*5 and *6 both consist of a SNP and the Met420 deletion. Both 
haplotypes are characterized by impaired localization into the plasma membrane (Seitz et al. 2015). 
The haplotype OCT1*7, which is present in African, Middle Eastern and Central Asian 
populations, is often associated with reference OCT1-like transport. For some substrates, 
however, a strong reduction has been observed. OCT1*8 is the only variant, which has 
consistently been described with transport activity at the same level as the reference allele or even 
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above (Seitz et al. 2015). The less common variants *9 to *16 have only rarely been studied and 
summary statements about these are not possible at this point in time. 
 
2.3 Substrate spectrum and polyspecificity of OCT1 
While many known transport proteins serve a distinct function and facilitate the uptake of a 
specific substrate, there is no specific or prototypic substrate for OCT1. Instead, it is a so-called 
polyspecific transporter, which means that OCT1 translocates a number of heterogeneous 
molecules. This polyspecificity is common amongst the SLC22 family. For OCT1, major criteria 
for substrates are compound size, charge, and lipophilicity. A certain size should not be exceeded 
in order to ensure the fit of the molecule into the transporter. Positive charge is somehow essential 
and the most prominent commonality between known substrates (even though there are 
exceptions). Low lipophilicity is associated with the need of transport across the lipid bilayer. 
Lipophilic compounds will diffuse through cell membranes. The logD value (octanol-water-
partition coefficient) is an indicator to determine the lipophilicity of ionizable compounds, and 
thus a predictor for the possibility of substances being taken up into cells via diffusion. While 
previous studies showed that OCT1 transports a large number of cationic compounds, it was also 
shown that not all cationic substances are substrates for OCT1 (Figure 5). 
It was shown that molecular volume is one major descriptor of OCT1 uptake and that compounds 
with a volume > 500 Å3 were unlikely to be transported (Hendrickx et al. 2013). However, 
Hendrickx et al. did not find correlation between OCT1 uptake of compounds and their logD or 
polar surface area (PSA). A striking commonality of OCT1 substrates is the positive charge. The 
pKa values of ionizable moieties provide information about the (total) charge of a molecule at a 
certain pH. Positively charged bases and compounds with quaternary amine groups (positively 
charged independent of the surrounding pH) belong to the favorable OCT1 substrates (Hendrickx 
et al. 2013) (Figure 5). Quaternary amines have been identified as good molecular fingerprint to 
identify OCT1 substrates (Baidya et al. 2020). Other favorable molecular fingerprints included the 





Figure 5: The OCT1 protein facilitates the uptake of many substrates. Dashed line (function x = y) indicates 
case, in which uptake is only influenced by diffusion and not by additional transport. Data by Hendrickx 
(Hendrickx et al. 2013), reduced to non-experimental molecules. 
 
Previous descriptions of OCT1 substrates include hydrogen bond donors (e.g. by an hydroxyl 
group), ion pair interaction sites (e.g. via a positively charged nitrogen), and hydrophobic 
interaction sites (e.g. via aromatic structures) (Moaddel et al. 2005). These descriptors, however, 
are by no means part of all OCT1 substrates, nor do they sufficiently explain the different transport 
rates of different substrates. 
Probe substrates commonly used for OCT1 studies include MPP+ (Shu et al. 2003; Zhang L. et al. 
1997), TEA+ (Sakata et al. 2004), and ASP+ (Ahlin et al. 2008). These substrates are not among the 
substrates with the highest affinities or transport rates, but their use is historically justified. The 
range of OCT1 substrates overall is highly diverse and includes dozens of substrates from different 
drug classes (Koepsell 2020) (Figure 6). Small substrates, such as TEA+ with a mass of 
130.3 g × mol-1 and amifampridine, which is a K+/Na+ channel blocker with a mass of 
109.1 g × mol-1, are considered OCT1 substrates. On the other hand, also large compounds, such 
as the anticholinergic butylscopolamine (440.4 g × mol-1) and the most bitter chemical compound 
known, denatonium (446.6 g × mol-1), are OCT1 substrates. However, not just sizes and molecular 
masses of substrates differ significantly, also structural components do. Known substrates vary in 
their composition. The number of phenyls, for example, ranges from zero to three, and the 
number of hydroxyl groups range from zero to four. The most common denominator of all OCT1 




Figure 6: Selection of OCT1 substrates illustrates marked polyspecificity. Molecule structures of substrates 
with uptake ratio ≥ 3 (uptake into cells overexpressing OCT1/uptake into empty vector-transfected cells) 
and Clint ≥ 5 are shown in alphabetical order and grouped into drug classes by background colors. 
 
The polyspecific nature of OCT1, might be caused by different binding sites within the binding 
pocket of the transporter. These binding sites could separately or in combination facilitate 
substrate recognition (Gorboulev et al. 2005; Gorboulev et al. 1999; Popp et al. 2005; Volk et al. 
2009). Several studies indicate that the different binding sites differ in their affinities to the 
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investigated substrates (Gorbunov et al. 2008; Keller et al. 2019; Minuesa et al. 2009). By targeted 
mutageneses, it was shown, that the loss of specific amino acids can alter substrate affinity or 
transport velocity (Koepsell 2019). Targeted mutageneses suggested a role for the amino acids 
Phe159, Trp217, and Asp474 for binding (Figure 7). The exchange by other amino acids decreased 
(D475E for TEA+; W217Y for MPP+) or increased Km (F159A/Y for MPP+; W217F for TEA+) or 
the IC50 (for different model substrates) in a substrate-dependent manner (Gorboulev et al. 2018; 
Popp et al. 2005). 
 
 
Figure 7: View from the extracellular side into the binding cleft of OCT1 in the outward-open 
conformation. Transmembrane helices are colored in ‘wheat’ and the amino acids F159, W217, and D474 
are highlighted in purple, yellow, and olive green, respectively. For optimal experience use anaglyph 3D 
glasses, such as the ones enclosed with the printed version. Structure Model by Dakal et al. (Dakal et al. 
2017), generation of the anaglyphic rendering with The PyMOL Molecular Graphics System, Version 2.2.0 
Schrödinger, LLC. 
 
At the current time, there is no crystal structure data of human OCT1 available and homology 
models used as a substitute rely on sequence identity of as low as 20 % to the closest crystallized 
protein (Dakal et al. 2017). The protein structure-based approach, analyzing the effects of 
mutageneses, is a proper way to study the structure-to-function relationship of OCT1 (Meyer 
2020; Popp et al. 2005). In addition, ligand-based approaches are a way to circumvent the lack of 
a crystal structure by putting known substrates in the foreground of the analyses (Baidya et al. 
2020). Still, these analyses are often based on two-dimensional representations. Therefore, ligand-
based approaches often do not account for enantiomeric differences. 
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2.4 Pharmacological relevance of OCT1 
The possible pharmacological relevance of OCT1 was shown in several in vitro studies for different 
substrates. Main distinction needs to be made between drugs, which act in the liver (e.g. 
metformin) or require hepatic uptake for metabolism into the active compound (type IB prodrugs, 
e.g. proguanil), and drugs, which are taken up into hepatocytes and subsequently eliminated via 
the bile. Loss-of-function variants of OCT1 will lead to reduced uptake and efficacy in the first 
and increased blood concentration leading potentially to increased side effects in the second case. 
With OCT1, genetic effects on pharmacokinetics and -dynamics have to be considered in addition 
to drug-drug interactions that have to be considered for all transporters. In addition to a large 
number of in vitro studies, also clinical studies were carried out to investigate the influence of 
OCT1 on the pharmacokinetics of numerous drugs in the real context of a living human organism. 
One of the best-known OCT1 substrates is the antidiabetic biguanide metformin (Christensen et 
al. 2011; Pernicova und Korbonits 2014; Wang et al. 2002; Zolk 2009). It was shown in vitro that 
the effect of metformin correlated with the activity of OCT1 variants (Shu et al. 2007). 
Furthermore, in healthy human volunteers and patients treated with metformin, OCT1 variants 
lead to reduced response, indicated by higher glucose and HbA1c levels (Becker et al. 2009; Shikata 
et al. 2007; Shu et al. 2008). However, this data was not unequivocally confirmed by other studies. 
Concerning systemic exposure, the extrarenal clearance of metformin was not significantly altered 
by OCT1 variants, as 99.9 % of intravenously administered metformin is eliminated via the 
kidneys (Pentikäinen et al. 1979; Tzvetkov et al. 2009). Interestingly enough, recent experiments 
could even demonstrate a possible metformin efflux activity of OCT1 (Jensen et al. 2021b). 
Many beta-adrenergic agonists, such as fenoterol, salbutamol, and terbutaline were shown to be 
transported by OCT1 in vitro (Hendrickx et al. 2013). In addition, for fenoterol, it was shown 
in vivo that loss-of-function OCT1 variants lead to increased fenoterol plasma concentrations and 
even to measurably increased plasma glucose and heart rates (Tzvetkov et al. 2018). 
The impact of loss-of function OCT1 variants on transport activity was also shown by in vitro 
studies for the antihistaminic ranitidine as well as the 5-HT receptor antagonists ondansetron and 
tropisetron (Meyer et al. 2017; Tzvetkov et al. 2012). The same holds true for the active metabolite 
of the pain medication tramadol, O-desmethyltramadol (Tzvetkov et al. 2011), for which in vivo 
increased plasma concentrations were shown in OCT1-deficient individuals even after reduced 
tramadol consumption (Stamer et al. 2016). 
In healthy volunteers, hepatic uptake of the opiate morphine by OCT1 was shown to be affected 
by common polymorphisms after codeine intake (Tzvetkov et al. 2013). Genetic variants also 
influence morphine clearance in children (Fukuda et al. 2013). However, the association of OCT1 
variants and morphine pharmacokinetics and pharmacodynamics was not found in all studies 
(Nielsen et al. 2017). 
Introduction 
13 
Another commonly prescribed OCT1 substrate is sumatriptan, an anti-migraine drug. 
Sumatriptan is eliminated after inactivating metabolism by MAO-A in the liver (Dixon et al. 1994; 
Fowler et al. 1991). Loss-of function OCT1 variants were shown to affect sumatriptan 
pharmacokinetics, and results of in vitro uptake experiments pointed towards potential interaction 
with other triptans as well (Matthaei et al. 2016). 
Pharmacokinetics – and even more pharmacodynamics – are difficult to predict, because reliable 
in vitro models are rare or imprecise, and large interspecies differences in transporter expression 
and activity profiles complicate the exploration. In the end, only studies in humans can elucidate 
the role of transporters for pharmacokinetics, including the impact of loss-of-function variants. 
Apart from therapeutic drugs, OCT1 also mediates the uptake of several toxic agents, such as 
aflatoxin B1 or ethidium (Tachampa et al. 2008). The lack of endogenous substrates, for which 
OCT1 could be considered as the only hepatic transporter, allows only speculation about the 
reasons for evolutionary conservation of OCT1. The general hepatic detoxification of all kinds of 
differently shaped organic cations could be a reason for its preservation (Zhang L. et al. 2006). 
 
2.5 Physiological relevance of OCT1 
Compared to pharmaceuticals, there is little information available about the OCT1-mediated 
uptake of endogenous substances. In the last few years, the knowledge on thiamine as a possible 
substrate for OCT1 has improved. It was shown that OCT1 is a high-capacity thiamine (vitamin 
B1) transporter (Chen L et al. 2014). In Oct1-deficient mice, hepatic steatosis was observed, 
probably due to thiamine deficiency (Chen L et al. 2014; Liang X et al. 2018). However, much of 
this data was supported by murine Oct1 only and there is a substantial difference between rodent 
and human OCT1 concerning substrate specificity and tissue expression. 
Serotonin transport was first only discovered for rodent Oct1, but later for human OCT1 as well 
(Amphoux et al. 2006; Jensen 2017). Other monoamines, such as adrenaline, dopamine, 
noradrenaline, and tyramine were reported as OCT1 substrates and inhibitors of OCT1 transport 
as well (Amphoux et al. 2006; Bednarczyk et al. 2003; Breidert et al. 1998). However, these studies 






2.6 Aims of this study 
The goals listed below encompass the central aspects of this work and will be addressed in the next 
chapter by published articles. 
 
1. The expansion of the known OCT1 substrate spectrum should contribute to a better 
understanding of the possible biological roles of OCT1 and can be carried out by further 
exploration of the chemical space on substances which are even not highly structurally 
related to previously known substrates. Many psychostimulants and hallucinogens are 
organic cations and reasonably hydrophilic. These water-soluble compounds most likely 
require transporter-mediated uptake into the brain to exert their effects. Influx 
transporters like OCT1 might be involved in the uptake of these psychostimulants. 
Therefore, psychostimulant and hallucinogenic compounds, such as, amphetamine, 
cocaine, and mescaline were investigated for their potential of transport by OCT1. This 
should contribute to our toxicological understanding of the impact of OCT1 on potentially 
dangerous psychostimulant and hallucinogenic substances. 
 
2. The list of already known OCT1 substrates is long, and this knowledge can be exploited to 
find additional substrates. The traditional approach to find new substrates would utilize 
all the chemical knowledge and ingenuity of the chemist, but nowadays a significant part 
of this can be performed using computational assistance. Large databases can be screened 
more systematically and less error-prone. Our traditional approach considered substances 
with a molecular weight below 600 Da, a pKa > 7.4 and a logD < 1 as likely candidates of 
OCT1 substrates. However, as shown in the psychostimulant project many substances 
fulfilling these criteria were nevertheless no (good) substrates of OCT1. Therefore, 
apparently additional criteria are needed to describe OCT1 substrates and a machine 
learning-guided approach was used to predict additional OCT1 substrates. Still, the gold-
standard to identify a substrate of an enzyme or transporter is the experimental proof. 
Therefore, validation of newly suggested compounds was performed by in vitro transport. 
 
3. As machine learning approaches are often restricted to two-dimensional representations 
of molecules, predictions of enantiomeric effects are limited. About one third of all drugs 
are still marketed as racemic mixtures, containing both enantiomers. Little is currently 
known about whether enantiomers are transported equally well or with certain 
stereoselectivity. In comparison to many enzymes, which are highly substrate- and 
enantiospecific, the broad specificity of OCT1 might be accompanied by reduced 
stereoselectivity. Therefore, potential stereoselective transport by OCT1 was tested in vitro 




4. Modern systems biology tries to comprehensively understand the complex interactions of 
processes in the human body. Understanding the entire interplay between thousands of 
enzymes and transporters may start with more simple models including only two or three 
partners. Loss of OCT1 expression in most hepatocyte-derived cell lines makes it difficult 
to predict in vivo uptake and subsequent metabolism from in vitro experiments if not 
primary hepatocytes are used. Therefore, a cell model for the uptake and subsequent 
metabolism was developed. Overexpression of multiple genes in one cell is not an entirely 
new technique, but the technique developed here has particular advantages: Successfully 
double-transfected cells can be selected with one antibiotic, the cell line generation is 
relatively quick, and it results in equally strong overexpression of two proteins and can 
almost universally be applied. 
 
5. The final validation of in vitro findings can only be achieved by in vivo studies. This is 
especially true for potential endogenous biomarkers, which are thought to reflect the 
phenotype of metabolizing enzymes or transport proteins. For OCT1, thiamine had been 
suggested as a biomarker on the basis of previous in vitro and animal experiments. 
Therefore, the role of OCT1 in the uptake of thiamine was studied in vitro and its relevance 
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Cellular Uptake of Psychostimulants –
Are High- and Low-Affinity Organic
Cation Transporters Drug Traffickers?
Ole Jensen*, Muhammad Rafehi *, Lukas Gebauer and Jürgen Brockmöller
Institute of Clinical Pharmacology, University Medical Center Göttingen, Göttingen, Germany
Psychostimulants are used therapeutically and for illegal recreational purposes.Many of these
are inhibitors of the presynaptic noradrenaline, dopamine, and serotonin transporters (NET,
DAT, and SERT). According to their physicochemical properties, some might also be
substrates of polyspecific organic cation transporters (OCTs) that mediate uptake in liver
and kidneys for metabolism and excretion. OCT1 is genetically highly polymorphic, with
strong effects on transporter activity and expression. To study potential interindividual
differences in their pharmacokinetics, 18 psychostimulants and hallucinogens were
assessed in vitro for transport by different OCTs as well as by the high-affinity
monoamine transporters NET, DAT, and SERT. The hallucinogenic natural compound
mescaline was found to be strongly transported by wild-type OCT1 with a Km of 24.3 µM
and a vmax of 642 pmol ×mgprotein−1×min−1. Transport wasmodestly reduced in variants *2
and *7, more strongly reduced in *3 and *4, and lowest in *5 and *6, while *8 showed a
moderately increased transport capacity. The other phenylethylamine derivatives
methamphetamine, para-methoxymethamphetamine, (-)-ephedrine, and cathine
((+)-norpseudoephedrine), as well as dimethyltryptamine, were substrates of OCT2 with
Km values in the range of 7.9–46.0 µM and vmax values between 70.7 and 570 pmol ×
mg protein−1 ×min−1. Affinities were similar or modestly reduced and the transport capacities
were reduced down to half in the naturally occurring variant A270S. Cathine was found to be a
substrate for NET and DAT, with the Km being 21-fold and the vmax 10-fold higher for DAT but
still significantly lower compared toOCT2. This study has shown that several psychostimulants
and hallucinogens are substrates for OCTs.Given the extensive cellular uptake ofmescaline by
the genetically highly polymorphic OCT1, strong interindividual variation in the
pharmacokinetics of mescaline might be possible, which could be a reason for highly
variable adverse reactions. The involvement of the polymorphic OCT2 in the renal
excretion of several psychostimulants could be one reason for individual differences in toxicity.
Keywords: membrane transport, monoamine transporter, OCT1, organic cation transporter, psychostimulant,
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Abbreviations: CYP, cytochrome P450; DAT, dopamine transporter; DET, diethyltryptamine; DMT, dimethyltryptamine;
DOI, 2,5-dimethoxy-4-iodoamphetamine; MATE2-K, multidrug and toxin extrusion protein 2 kidney-specific; MBDB,
N-methyl-1,3-benzodioxolylbutanamine; MDAI, 5,6-methylenedioxy-2-aminoindane; MDEA, 3,4-methylenedioxy-N-ethyl-
amphetamine; MDMA, 3,4-methylenedioxymethamphetamine; MPP+, 1-methyl-4-phenylpyridinium; NET, noradrenaline
(norepinephrine) transporter; OCT, organic cation transporter; PCR, polymerase chain reaction; PMA, para-methox-
yamphetamine; PMMA, para-methoxymethamphetamine; SERT, serotonin transporter; SLC, solute carrier; WT, wild-type.
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INTRODUCTION
Psychostimulants modulate wakefulness and mental
performance. They function as indirect sympathomimetics by
raising synaptic concentrations of monoamine neurotransmitters
through stimulating their release from presynaptic vesicles and/or
inhibiting reuptake. Psychostimulants can also interfere with
monoaminergic neurotransmitter metabolism and interact
with monoaminergic receptors and other targets (Luethi and
Liechti, 2020; Reith and Gnegy, 2020). Amphetamine and other
phenylethylamine derivatives (Figure 1 top) form a large group of
such indirect sympathomimetics. They are used in the treatment
of attention deficit hyperactivity disorder and narcolepsy but are
also frequently found in illicit drugs (e.g., “speed”, “ecstasy”,
“crystal meth”) (Sharma and Couture, 2014; Luethi and Liechti,
2020). Another indirect sympathomimetic is cocaine (Figure 1
bottom left), a tropa-alkaloid and, historically, the first local
anesthetic. Its (widely illegal) use as a psychostimulant
nowadays far exceeds its therapeutic application in local
anesthesia. Psychostimulants are among the most popular drugs
of abuse. A related and partially overlapping class of psychoactive
substances are the hallucinogens (psychedelics), which alter
perception, cognition, and mood. These include tryptamine
derivatives, such as the alkaloid dimethyltryptamine (DMT). It
FIGURE 1 | Psychostimulant and hallucinogenic drugs assessed for cell uptake by OCTs and high-affinity monoamine transporters.
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is a main constituent of ayahuasca, the plant brew used
traditionally by indigenous inhabitants of the Amazon region
for spiritual and religious ceremonies. DMT and its diethyl
analogue (Figure 1 bottom right) show structural resemblance
to the neurotransmitter serotonin and thereby function as agonists
at 5-HT2A and related receptors (Nichols, 2016; Luethi and Liechti,
2020). Another traditional hallucinogen is mescaline, a
phenethylamine alkaloid found in cacti (Ogunbodede et al.,
2010; Nichols, 2016; Luethi and Liechti, 2020). It is a partial
agonist at 5-HT2A and 5-HT2B receptors and a full agonist at
the 5-HT2C receptor (Dinis-Oliveira et al., 2019).
Many psychoactive substances are substrates or inhibitors of
the noradrenaline (norepinephrine) transporter (NET), the
dopamine transporter (DAT), and/or the serotonin transporter
(SERT) (Luethi and Liechti, 2020). These high-affinity transport
proteins are expressed at presynaptic neurons, where they
mediate the reuptake of monoamine neurotransmitters from
the synaptic cleft to terminate synaptic signal transmission
and for recycling (Torres et al., 2003). They are members of
the large Solute Carrier (SLC) superfamily and coded for by the
genes SLC6A2 (NET), SLC6A3 (DAT), and SLC6A4 (SERT).
Organic cation transporters (OCTs) are also SLCs with a
broad, partially overlapping substrate spectrum that is
predominantly comprised of hydrophilic, organic cationic
substances (including monoamine neurotransmitters as well as
many drugs) (Busch et al., 1998; Gründemann et al., 1998; Wu
et al., 1998; Koepsell et al., 2007). OCT1 (SLC22A1) and, to a
lesser extent, OCT3 (SLC22A3) are expressed on the sinusoidal
membrane of hepatocytes, where they mediate cellular uptake for
hepatic metabolism (Nishimura and Naito, 2005; Nies et al.,
2009). A high degree of genetic variation exists for SLC22A1,
and several of these variants strongly impact transporter
expression and function (Koepsell et al., 2007; Seitz et al.,
2015). This may affect the pharmacokinetics of compounds
that are substrates of OCT1, as has been shown, for example,
for the opioid analgesics morphine and O-desmethyltramadol
(Tzvetkov et al., 2011; Tzvetkov et al., 2013; Venkatasubramanian
et al., 2014; Stamer et al., 2016), the antimalarial prodrug
proguanil (Matthaei et al., 2019), the anti-asthma drug
fenoterol (Tzvetkov et al., 2018), sumatriptan that is used for
the treatment of migraine (Matthaei et al., 2016), and, to a minor
extent, for the antidiabetic drug metformin (Tzvetkov et al., 2009;
Yee et al., 2018). The psychoactive substances studied here
(Figure 1) were selected based on physicochemical properties
(organic cations with pKa > 8.4 and relatively hydrophilic
substances with a logDpH 7.4 < 2; Table 1) that make them
potential substrates for OCTs. Consequently, their
pharmacokinetics could potentially be affected by OCT
polymorphism as well. OCT2 (SLC22A2) is mainly found on
the basolateral membrane of kidney epithelial cells (Motohashi
et al., 2002; Motohashi et al., 2013). Together with multidrug and
toxin extrusion protein 2 kidney-specific (MATE2-K, SLC47A2),
an efflux transporter expressed on the brush-border membrane of
the proximal tubule, it mediates transport across the epithelium
for renal excretion (Motohashi et al., 2013). SLC22A2 variants are
less frequent compared to the gene coding for OCT1, and only a
few affect OCT2 expression or function. The most frequent of
these is Ala270Ser, which causes a moderate decrease in OCT2
activity (Zolk et al., 2009). As many psychoactive substances are
structurally related to the neurotransmitters and OCT substrates
noradrenaline, dopamine, and serotonin and have
physicochemical properties in line with typical OCT
substrates, their pharmacokinetics may be determined by
OCTs and influenced by OCT1 (and possibly OCT2)
polymorphism.
Although mainly expressed in peripheral tissues, OCT2 and
OCT3 are also found on postsynaptic neurons (and OCT3 in
astrocytes) predominantly in aminergic regions of the central
nervous system. There, they may be involved in reuptake of
monoamine neurotransmitters in brain areas lacking the high-
affinity transporters, at distance from the aminergic nerve
endings, or as an alternative when the high-affinity
transporters are saturated or inhibited (Wu et al., 1998; Vialou
et al., 2008; Bacq et al., 2012; Couroussé and Gautron, 2015).
OCT2 appears to be involved in the uptake of noradrenaline and
serotonin in particular, while OCT3 was found to be more
strongly responsible for dopamine clearance (Vialou et al.,
2008; Bacq et al., 2012). Interestingly, it has also been shown
that amphetamines can induce neurotransmitter release through
OCT3, which is capable of bi-directional transport (Mayer et al.,
2018;Mayer et al., 2019). Thus, OCTsmay not only determine the
pharmacokinetics of psychoactive drugs but appear to be also
involved in their actions.
Given the potential dual role of OCTs with respect to
psychoactive drugs and the current lack of understanding of
the pharmacokinetics and pharmacogenetics for these
compounds, we characterised the transmembrane transport by
polyspecific OCTs as well as high-affinity monoamine reuptake
transporters. Of particular interest are those psychostimulants
that are stereoisomers of one another (ephedrine, norephedrine,
their enantiomers and diastereomers), because the impact of
TABLE 1 | Physicochemical properties of investigated psychoactive compounds
(predicted using MarvinSketch, version 19.8, ChemAxon, Budapest,
Hungary).
Test compound LogDpH 7.4 pKa % Positively charged
at pH 7.4
Amphetamine −0.67 10.01 99.76
Methylamphetamine −0.44 10.21 99.85
PMA −0.85 10.04 99.77
PMMA −0.52 10.03 99.76
Cathinone 0.79 7.55 58.59
Phentermine −0.55 10.25 99.78
(-)-Ephedrine −0.78 9.53 99.26
Cathine −1.05 9.37 98.94
DOI 0.02 9.90 99.69
Mescaline −1.37 9.77 99.58
MDMA −0.76 10.14 99.82
MDEA −0.46 10.22 99.85
MBDB −0.34 10.28 99.87
MDAI −1.33 9.96 99.73
Cocaine 0.82 8.85 96.54
Methylecgonine −1.86 9.04 97.76
DMT 0.17 9.55 99.29
DET 0.39 10.08 99.79
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stereospecificity on membrane transport is as yet not well
understood but previous results suggest partially strong
enantiopreferences (Jensen et al., 2020).
MATERIALS AND METHODS
Test Compounds
The psychoactive compounds studied here were selected based on
their physicochemical properties that would make them likely
substrates for OCTs. Selection criteria included hydrophilicity
(logD at pH 7.4 of less than 2), at least 90% positively charged at
physiological pH (pKa > 8.4), and molecular mass not higher than
500 Da. The reasons for these were that lipophilic compounds
permeate membranes mostly by diffusion, while membrane
transport is mostly relevant for more hydrophilic compounds, as
well as the observation that typical OCT1 substrates are usually
positively charged and of low to moderate size. Cathinone (pKa of
7.55) did notmeet our selection criteria but was nonetheless included
due to a low renal elimination (2–7% unchanged in urine) and,
consequently, high rate of metabolism which, if taking place in the
liver, might depend on hepatic uptake via OCT1 (Kalix and
Braenden, 1985; Toennes and Kauert, 2002). Ranitidine-d6 was
purchased from Toronto Research Chemicals (Toronto, Canada)
and Tulobuterol from Santa Cruz Biotechnology (Darmstadt,
Germany); all other test compounds and internal standards were
bought from Sigma-Aldrich (Taufkirchen, Germany).
Generation of Transporter-Overexpressing
Cell Lines
Transport experiments were done using HEK293 cells stably
transfected to overexpress OCT1*1 (wild-type), OCT1*2
(M420del), OCT1*3 (R61C), OCT1*4 (G401S), OCT1*5
(M420del, G465R), OCT1*6 (C88R, M420del), OCT1*7
(S14F), OCT1*8 (R488M), as well as wild-type OCT2, OCT3,
NET, DAT, SERT, or MATE2-K. All cell lines were generated
using the Flp-In system (Thermo Fisher Scientific, Darmstadt,
Germany) as previously described (Saadatmand et al., 2012; Seitz
et al., 2015; Chen et al., 2017), except for the OCT3-
overexpressing HEK293 cells that were a kind gift from Drs.
Koepsell and Gorbulev (University of Würzburg, Germany). The
cells were kept in culture for no more than 30 passages.
The high-affinity monoamine transporters were also stably
transfected into HEK293 cells by use of the Flp-In system
(Thermo Fisher Scientific, Darmstadt, Germany). Coding
sequences of SLC6A2 (NET), SLC6A3 (DAT), and SLC6A4
(SERT) were obtained from Source BioScience (Nottingham,
United Kingdom; pBluescriptR:SLC6A2) or Addgene
(Watertown, MA, United States; pcDNA3.1-hDAT was a gift
from Susan Amara, Addgene plasmid # 32810, http://n2t.net/
addgene:32810, RRID:Addgene_32810 and hSERT pcDNA3 was
a gift from Randy Blakely, Addgene plasmid # 15483, http://n2t.
net/addgene:15483, RRID:Addgene_15483 (Ramamoorthy et al.,
1993)). After sequence correction and cloning into the pcDNA5
vector, generation and characterization of the cell lines were
carried out as described before for the above-mentioned cell lines
(Saadatmand et al., 2012; Seitz et al., 2015). Genomic integration was
validated for two independent cell clones by three polymerase chain
reactions (PCR; Figure 2) to verify proper integration (integration
PCR) and exclude multiple integration (multiple integration PCR).
The presence of the gene of interest was verified by Sanger
sequencing of the product of the third PCR (gene-of-interest
PCR) after gel extraction (Figure 2). Overexpression of
monoamine transporters was compared between cell clones by
TaqMan® gene expression assays (Thermo Fisher Scientific,
Darmstadt, Germany; Figure 2). Functional validation of newly
generated cell clones was performed using noradrenaline and
serotonin as probe drugs and one clone for each transporter was
chosen for further transport studies.
In vitro Cellular Uptake Experiments
The HEK293 cells were cultered in DMEM medium
supplemented with 10% (v/v) fetal bovine serum as well as
penicillin (100 U/ml) and streptomycin (100 μg/ml) obtained
from Thermo Fisher Scientific (Darmstadt, Germany). Cells were
seeded on 12-well plates coated with poly-D-lysine (Sigma-
Aldrich, Taufkirchen, Germany) 48 h before the transport
experiments and incubated at 37°C, 95% relative humidity,
and 5% CO2. Cell lines overexpressing MATE2-K were
incubated with 30 mM NH4Cl in HBSS+ (10 mM HEPES in
HBSS, pH 7.4; Thermo Fisher Scientific, Darmstadt, Germany)
for 30 min prior to the assay to invert the direction of transport.
All cell lines were washed with 37°C HBSS+ and subsequently
incubated with the pre-warmed substrate in HBSS+ at 37°C. The
time points for measuring substrate uptake were 1 min for
MATE2-K and 2 min for the other SLCs. The uptake rate was
experimentally determined to be linear for at least 10 min for
OCT1*1. It was assumed to be linear for the other transporters as
well, based on previous experience with these expression systems.
The reaction was stopped by adding ice-cold HBSS+, and the cells
were washed twice with ice-cold HBSS+ before lysis with 80%
acetonitrile (LGC Standards, Wesel, Germany) including an
internal standard. Subsequently, the intracellular substrate
accumulation was determined using LC-MS/MS.
Concentration Analyses
Intracellular accumulation was measured by HPLC-MS/MS using a
Shimadzu Nexera HPLC system with a LC-30AD pump, a SIL-30AC
autosampler, a CTO-20AC column oven, and a CBM-20A controller
(Shimadzu, Kyoto, Japan). Separation was done on a Brownlee SPP
RP-Amide column (4.6 × 100mm inner dimension with 2.7 μm
particle size) with a C18 pre-column. The aqueous mobile phase
contained 0.1% (v/v) formic acid and either 3% (v/v) organic additive
(acetonitrile:methanol 6:1 (v/v)) for methylecgonine, 8% for
amphetamine, methylamphetamine, cathinone, cathine,
(-)-ephedrine, mescaline, MDAI, and DMT, or 20% for PMA,
PMMA, DOI, phentermine, MDMA, MDEA, MBDB, cocaine, and
DET. Chromatography was done at a flow rate of 0.3ml/min. For
detection, an API 4000 tandem mass spectrometer (AB SCIEX,
Darmstadt, Germany) was used in MRM mode. The analytes,
corresponding internal standards, and detection parameters are
listed in the Supplementary Table S1. Peak integration and
quantification of the analytes was done using the Analyst software
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(Version 1.6.2, AB SCIEX, Darmstadt, Germany) and determined by
simultaneous measurement of standard curves with known
concentrations.
Calculations
For the screenings, cellular uptake measured in cell lines
overexpressing the respective transporter was divided by the
uptake measured in an empty vector control cell line to
calculate normalised ratios to enable comparisons between test
compounds. For studying transport kinetics, the net transport
mediated by the overexpressed transporters was calculated by
subtracting the cellular uptake measured in an empty vector
control cell line from the uptake in cell lines overexpressing the
respective transporter. The parameters Km and vmax were
estimated by regression analysis using the Michaelis-Menten
equation (GraphPad Prism version 5.01 for Windows,
GraphPad Software, La Jolla, CA, United States). Means and
standard errors were calculated from individual Km and vmax
values of at least three independent experiments. The kinetic
parameters vmax and Km were tested for statistical significance over
empty vector control cells using Student’s t-test with an alpha value
of 0.05.
RESULTS
Screening of Transport Activity at OCTs,
Monoamine Transporters, and MATE2-K
Eighteen psychostimulants and hallucinogens were initially
screened for their potential to be substrates for different
polyspecific OCTs and high-affinity monoamine
neurotransmitter transporters (Figure 3), as well as for the
efflux transporter MATE2-K (Supplementary Figure S1). The
compounds were assessed at a concentration of 1 μM, because it is
unlikely that low-affinity transport at higher concentrations may
have any medical relevance and the relative contribution of
FIGURE 2 | Validation of HEK293 cell clones overexpressing monoamine neurotransmitter transporters (A) Schematic representation of the expression plasmid
pcDNA5 (green) and the host cell line genome (blue) at the FRT site showing the target positions of the three conducted PCRs (B) Results of the three validation PCRs
that show a successful integration (Integration PCR) for all newly created cell clones that overexpress the high-affinity monoamine transporters. The absence of
amplicons in the Multiple Integration PCR indicate a single integration of the pcDNA5 plasmid. The correctness of amplified genes in the Gene of Interest (GOI) PCR
was validated by Sanger sequencing (C)Quantitative real-time PCR results to confirm comparable overexpression of monoamine transporters, shown as transcripts per
transcript of the TATA-binding protein. Only one cell clone was selected per transporter for experiments.
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carrier-mediated transport over passive diffusion is significantly
greater at lower compared to higher substrate concentrations, as
was previously shown for morphine (Tzvetkov et al., 2013).
Although the test compounds were selected based on
physicochemical properties that are in accordance with those
of typical OCT substrates, OCT1 showed high transport activity
at this concentration only for mescaline. A cellular uptake in
transporter-transfected cells of at least 3-fold higher than in non-
overexpressing control cells was selected as the threshold for
further studies, as this ratio is suitable to distinguish substrates
from non-substrates. Cellular uptake of mescaline was more than
8-fold higher in OCT1-overexpressing cells, which was the
highest transport activity that was observed altogether in this
study. Interestingly, mescaline was not transported much at 1 µM
by any of the other transporters. In contrast to the substrate-specific
but very strong transport activity exhibited by OCT1, moderate (4-
to 6-fold) cellular uptake by OCT2 was seen for methamphetamine,
(-)-ephedrine, and cathine ((+)-norpseudoephedrine) and
approximately 3-fold for para-methoxymethamphetamine
(PMMA) and DMT. OCT3 and MATE2-K (Supplementary
Figure S1) showed little or no transport activity with any of the
18 psychoactive compounds studied here at 1 µM. Our observation,
that amphetamine does not appear to be a substrate of OCT3, is in
accordance with previous reports (Zhu et al., 2010).
FIGURE 3 | Transport of different psychostimulant and hallucinogenic substances at a concentration of 1 µM by OCTs and high-affinity monoamine transporters,
shown as the ratios of uptake after 2 min in transporter-transfected cells over empty vector control cells. Shown are the mean values of ≥3 independent experiments
+SEM. The horizontal dotted line indicates an uptake ratio of 3, which was set as the minimum threshold for more detailed characterisation. Statistical significance over
empty vector control cells was determined using Student’s t-test with *p < 0.05, **p < 0.01, and ***p < 0.001.
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The OCTs are known as low-affinity, high-capacity solute
carriers with a very broad substrate spectrum that comprises
structurally diverse compounds. In contrast, the monoamine
neurotransmitter reuptake transporters NET, DAT, and SERT
show high affinities to their respective endogenous substrates and
a more narrow substrate profile than the OCTs. Cathine was
transported modestly (4-fold) by NET and higher (7-fold) by
DAT. No notable transport activity was observed for the other
compounds, and none by SERT altogether. Cathine and
(-)-ephedrine (as well as their stereoisomers) have been described
previously as substrates for NET and DAT in vitro experiments with
very different setup (Rothman et al., 2003). The slightly higher (albeit
still low) uptake of PMA and PMMA by SERT compared to DAT is
in line with literature reports that substitution in para-position of the
phenyl ring of amphetamine derivatives shifts substrate preference
toward SERT (Simmler et al., 2014).
Concentration-dependent Transport of
Mescaline by OCT1 Genetic Variants
Mescaline was found in our substrate screenings to be strongly
transported by OCT1 and, therefore, it was studied in more detail.
Given the high degree of genetic polymorphism and the large
differences in transporter activity and expression for some variants,
cellular uptake of mescaline was not only characterised for wild-type
(OCT1*1) but forOCT1 variants *2 to *8 as well. OCT1*1 transported
mescaline with a Km of 24.3 ± 6.3 µM and a vmax of 642 ± 57 pmol ×
mg protein−1 × min−1 (Figure 4A, Table 2). Time-dependent uptake
of 1 µMmescaline showed a faster uptake rate within the first minute
of incubation and a constant, linear uptake rate for 2 to at least 10min
(Figure 4B). The apparently more rapid initial uptake rate is likely a
result of high-affinity binding to OCT1, but a short-lived more rapid
transport might also be possible. The constant transport rate after
2min of incubation might be the more relevant transport rate for
pharmacokinetics because the exposure of the liver and other organs
to drugs and other substances usually occurs for several hours.
Mescaline uptake could be completely inhibited by the competitive
OCT1 inhibitor 1-methyl-4-phenylpyridinium (MPP+; Figure 4C).
The Kmwas slightly higher and the vmax slightly lower for *2, which is
analogous to literature data on reduced transport activity for *2 (Seitz
et al., 2015; Koepsell, 2020). This was even more pronounced (Km of
93.6± 110.8 and 98.2± 46.7 µM; vmax of 391± 266 and 329± 92 pmol
× mg protein−1 × min−1) for *3 and *4, which are known to have
strongly reduced transport activity (Seitz et al., 2015; Koepsell, 2020).
For the variants *5 and *6 that result in impaired translocation to the
plasma membrane (Seitz et al., 2015), very low transport activity was
observed. Consequently, Km and vmax values could not be reliably
calculated. OCT1*7 exhibited a similar Km and a modestly reduced
vmax thanOCT1*1. OCT1*8, on the other hand, showed a higher vmax
than the wild-type, which has been reported previously for a number
of substrates as well (Seitz et al., 2015; Koepsell, 2020). To summarise,
transport activity ofmescalinewas slightly lower thanwild-typeOCT1
in variants *2 and *7,more drastically reduced in *3 and *4, and lowest




Cathine, and DMT by OCT2 Wild-type and
A270S Variant
Whereas only mescaline appeared to be a substrate for OCT1,
transport via OCT2 was seen for methamphetamine, PMMA,
FIGURE 4 | (A) Transport of mescaline at different concentrations by OCT1*1 (wild-type) and genetic variants, shown as the cellular uptake in transporter-
overexpressing cells with substracted uptake in non-overexpressing control cells. Shown are the mean values of ≥3 independent experiments ±SEM. Km and vmax values
are given in Table 2. (B) Time-dependent uptake of 1 µM mescaline in OCT1*1-overexpressing (blue) and non-overexpressing control (pcDNA5, gray) cells, shown as
the mean values of 3 independent experiments ±SEM (C) Mescaline transport by OCT1 could be completely inhibited by 1 mM MPP+ to values not significantly
different from the unspecific cellular uptake observed in empty vector-transfected cells (control).
TABLE 2 | Kinetic parameters for the transport of mescaline by different OCT1
genetic variants.
Variant Km [µM] vmax [pmol ×
mg protein−1 ×
min−1]
OCT1*1 (WT) 24.3 (±6.3) 641.7 (±57.1)
OCT1*2 (M420del) 34.7 (±7.4) 500.7 (±42.1)
OCT1*3 (R61C) 93.6 (±110.8) 390.7 (±265.8)
OCT1*4 (G401S) 98.2 (±46.7) 329.4 (±91.6)
OCT1*5 (M420del, G465R) Not determinable Not determinable
OCT1*6 (M420del, C88R) Not determinable Not determinable
OCT1*7 (S14F) 20.2 (±7.9) 514.6 (±63.8)
OCT1*8 (R488M) 18.6 (±3.7) 837.2 (±51.5)
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(-)-ephedrine, cathine, and DMT. These compounds were
subsequently assessed in greater detail (Figure 5). For
methamphetamine, the vmax for wild-type OCT2 was only
70.7 ± 8.3 pmol × mg protein−1 × min−1, whereas it was
between 225 and 570 pmol × mg protein−1 × min−1 for the
other four compounds. The Km values were around 10 µM
except for cathine (46.0 ± 17.3 µM). For the A270S variant,
the vmax values were slightly to moderately lower (except for
PMMA) and the Km values either similar ((-)-ephedrine and
DMT) or up to 4-fold higher (methamphetamine, PMMA,
cathine) compared to wild-type OCT2, in agreement with
literature reports that the A270S exchange can lead to a
moderate decrease in OCT2 activity (Zolk et al., 2009).
Concentration-dependent Transport of
Cathine by NET and DAT
Cathine was the only compound for which notable cellular uptake
was observed by the high-affinity monoamine transporters NET
and DAT. Further characterisation and a comparison between
NET and DAT revealed that the Km was 21-fold and the vmax 10-
fold higher for DAT (Figure 6). Yet, both Km and vmax were still
FIGURE 5 | Transport of cathine, (-)-ephedrine, PMMA, DMT, and methamphetamine at different concentrations by wild-type OCT2 (red) and the variant A270S
(orange), shown as the cellular uptake in transporter-overexpressing cells with substracted uptake in non-overexpressing control cells. Shown are the mean values of ≥3
independent experiments ±SEM.
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significantly lower compared to OCT2, in line with the general
description of NET and DAT as high-affinity and low-capacity
transporters.
DISCUSSION
In this study, three groups of psychostimulants and hallucinogens
(14 phenylethylamine derivatives, the tropanes cocaine and
methylecgonine, and the substituted tryptamines dimethyl-
and diethyltryptamine) were assessed for their substrate
properties for OCTs as well as for high-affinity monoamine
transporters. OCTs are known to have a very broad substrate
profile that comprises many different structural classes. It is
therefore surprising that only relatively few of the 18
psychoactive compounds studied here were moderate or good
OCT substrates, especially because these were selected based on
physicochemical properties that were in accordance with those of
typical OCT substrates. Other transporters, such as OCTN1 and
OCTN2, the proposed H+-organic cation antiporter, or ATP-
binding cassette efflux transporters might potentially be more
relevant for some of the tested psychoactive compounds.
Only mescaline was transported significantly at 1 µM by
OCT1, and that this was the highest transport activity
observed here altogether. With a pKa of 9.77, a logDpH 7.4 of
-1.37, and a molecular mass of 211.3 g/mol, its physicochemical
properties are not significantly different from those of the other
compounds (Table 1). It is thus reasonable to wonder what
properties make mescaline the only substrate at this
concentration compared to the 17 other compounds studied
here. Possible explanations are not evident from its chemical
structure, as it is an amphetamine derivative structurally
relatively similar to many of the other phenylethylamines.
Mescaline is an alkaloid biosynthesised from tyrosine in
different cacti, where it is found at concentrations of
0.05–4.7% by dry weight (Ogunbodede et al., 2010).
Lophophora williamsii (peyote cactus) and several Echinopsis
species (e.g., Echinopsis pachanoi and Echinopsis peruvianus,
also known as the San Pedro and the Peruvian torch cacti)
have a long-standing use in religious ceremonies and
traditional medicine of South American indigenous
populations. The hallucinogenic effects of these cacti were
attributed to their relatively high mescaline contents
(Ogunbodede et al., 2010; Dinis-Oliveira et al., 2019; da
Silveira Agostini-Costa, 2020). Interestingly, OCT1 deficiency
or reduced activity is more frequently found in Central and
South American populations than in most other parts of the
FIGURE 6 | Transport of cathine at different concentrations by (A) NET and (B) DAT, shown as the cellular uptake in transporter-overexpressing cells with
substracted uptake in non-overexpressing control cells. Shown are the mean values of ≥3 independent experiments ±SEM.
FIGURE 7 | Schematic representation of the frequency distributions of
active and inactive OCT1 alleles in local populations and natural habitats of the
high mescaline-containing cacti Lophophora williamsii (peyote), Echinopsis
pachanoi (San Pedro), and Echinopsis peruvianus (Peruvian torch). The
white dashed lines broadly illustrate the migration pattern during the first
population of the continent by humans.
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world and the prevalence of inactive alleles generally increases
further south on the American continent (Figure 7) (Seitz et al.,
2015). It is likely that OCT1 deficiency was somehow
advantageous, e.g., in connection with dietary ingredients that
are OCT1 substrates (or perhaps mescaline?), and inactive alleles
thus dominated as the first human inhabitants of the continent
migrated south.
Typical mescaline dosages are in the range of 170–400 mg,
which induce a psychedelic state that may involve visual
hallucinations, altered perception, synesthaesia, and euphoria.
The lifetime prevalence of mescaline use over the past 3 decades
was estimated to be between 3–4% in the United States (Dinis-
Oliveira et al., 2019; Johnson et al., 2019). Being a high-affinity
partial agonist for the 5-HT2A receptor, potential therapeutic uses
for mescaline were proposed for disorders associated with
serotonin deficiency, such as addiction, anxiety, and
depression (Kyzar et al., 2017; Johnson et al., 2019). Based on
the key finding of this study, that mescaline is a strong substrate of
the genetically highly polymorphic OCT1, large interindividual
variations in mescaline pharmacokinetics might be possible. This
could lead to intoxication and other adverse effects due to
decreased elimination in carriers of alleles with reduced or
absent OCT1 activity (e.g., OCT1 variants *2 to *6, which are
particularly common in European populations, or OCT1*7 that is
frequently found in Africans and Afro-Americans (Seitz et al.,
2015)). However, a substance being identified as OCT1 substrate
in vitro may not necessarily be affected by OCT1 genetic
polymorphism in vivo, as illustrated by the example of the
indirect sympathomimetic compound tyramine (Rafehi et al.,
2019). Thus, the effects of OCT1 genotype on mescaline should
be studied in vivo and its clinical implications taken into
consideration when developing therapeutic interventions
involving mescaline.
Another key result of this study was that methamphetamine,
PMMA, (-)-ephedrine, cathine, and DMT were substrates of
OCT2 and that their transport was moderately reduced in the
A270S variant. OCT2 is strongly expressed in the kidneys, where it
contributes to transepithelial transport of usually hydrophilic
substances and thereby renal elimination. Cathine was excreted
unchanged in urine to 46–65% in four healthy volunteers and the
renal elimination was reported to be 70% for (-)-ephedrine and
30–54% for methamphetamine (Toennes and Kauert, 2002; www.
dosing.de and www.drugbank.ca, both accessed on September 16,
2020). The reduced transport by the A270S variant of OCT2 might
thus possibly result in a decreased elimination of these compounds.
Besides variation due to inherited polymorphisms, variation in renal
elimination of these psychostimulants may additionally arise from
drug-drug interactions or conditions associated with increased blood
concentrations of endogenous organic cations. DMT, on the other
hand, is extensivelymetabolised and excreted unchanged in urine only
to a very low extent (e.g., 0.16% following intramuscular
administration) (Sitaram et al., 1987; Barker, 2018). OCT2
polymorphism is thus unlikely to have any significant effects on
DMT pharmacokinetics but might still influence local concentrations
of DMT as well as of methamphetamine, PMMA, (-)-ephedrine, and
cathine in the central nervous system due to OCT2 expression in
postsynaptic neurons.
OCT1 and OCT2 polymorphism is not the only form of
genetic variation that may affect the above-mentioned
compounds. Metabolising enzymes and target receptors may
also be polymorphic. A few examples regarding the
pharmacogenetics of these compounds are given in Table 3. A
good example for discussing the general importance of genetic
polymorphism is MDMA, as this psychostimulant has been
studied in greater detail. MDMA is widely used as the
recreational drug “ecstasy” but therapeutic use for the
treatment of posttraumatic stress disorder has also been
proposed (Mithoefer et al., 2011; Mithoefer et al., 2013;
Amoroso and Workman, 2016; Mithoefer et al., 2016). It is a
substrate of the polymorphic enzymes cytochrome P450 (CYP)
2C19, 2B6, and 1A2, which catalyze the conversion to 3,4-
methylenedioxyamphetamine. Carriers of genetic variants that
result in increased activity of these enzymes showed higher
metabolism and CYP2C19 poor metabolisers had greater
cardiovascular effects in response to MDMA consumption
(Schindler et al., 2014; Vizeli et al., 2017). Poor metabolisers
for the highly polymorphic CYP2D6 also showed higher
cardiovascular responses, but only to a minor extent due to
the inhibition of CYP2D6 (Schmid et al., 2016). Based on
in vitro data, the effect of CYP2D6 polymorphism was
previously predicted to be higher (La Torre et al., 2012).
MDMA has a basic secondary amine group that is protonated
to 99.8% at physiological pH (Table 1). It would thus require a
transport mechanism for efficient passage across cell membranes
and into hepatocytes for metabolism. Our results suggest that
OCTs only contribute to a minor extent. Although MDMA is not
a good OCT substrate, its metabolites might possibly be (as we
had previously shown analogously for different opioids, where
their more hydrophilic metabolites were better OCT substrates
(Meyer et al., 2019)). For example, the main metabolites 3,4-
dihydroxyamphetamine and 3,4-dihydroxymethamphetamine
are more hydrophilic than MDMA and might thus potentially
be better OCT substrates, as they would likely rely more strongly
on transport mechanisms to traverse cell membranes. However,
the present study has shown that substrate specificity cannot
always be predicted based on physicochemical properties alone.
Although a number of contributors to the serotonergic system are
polymorphic, significant variation in MDMA effects were not
seen in healthy humans (Vizeli et al., 2019). NET polymorphism
also showed only minor effects on the cardiovascular response to
MDMA in clinical studies (Vizeli et al., 2018). To summarise this,
genetic polymorphism significantly determines the
pharmacokinetics but not so much the pharmacodynamics of
MDMA (and possibly of other psychostimulants as well).
A concept that has so far not received much attention is
stereoselectivity in membrane transport. Recent results from our
laboratory have shown that transmembrane transport of
adrenergic drugs by OCTs can show strong enantiospecificity
(Jensen et al., 2020). The phenylethylamine derivatives cathine
(also referred to as (+)-norpseudoephedrine) and (-)-ephedrine
that were assessed in this study are chiral compounds and
structurally very closely related. If it were not for the methyl
substitution at the amino group (Figure 1), both compounds
would be stereoisomers of one another. With this in mind, it
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appears astonishing that cathine was found to be a good substrate
of DAT whereas (-)-ephedrine was not, despite their close
structural resemblance. Whether this difference in transport
was due to the opposite steric orientation of the hydroxyl
group or due to the methyl substitution at the amino group
cannot be deduced from this study.
To summarise, this study has shown that the classic
hallucinogen mescaline is a strong substrate of the genetically
highly polymorphic OCT1 (Figure 8) and that genetic variants
show altered cell uptake, which may have clinical implications. It
was also found that the psychoactive compounds
methamphetamine, PMMA, (-)-ephedrine, cathine, and DMT
are substrates of OCT2 with partially moderate reductions in cell
uptake in the A270S variant. Cathine was also discovered to be a
substrate of NET and DAT. As to the question of whether OCT1
is a drug trafficker or not, we would argue that it is one indeed.
However, it is a very selective one with a clear preference for the
hallucinogenic compound mescaline, which is rather unusual for
OCT1 given its generally broad substrate profile.
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TABLE 3 | Pharmacogenetics of methamphetamine, PMMA, (-)-ephedrine, cathine, mescaline, and DMT (this list is not exhaustive).
Test compound Substrate of Polymorphic targetsa References
OCT1 OCT2 Polymorphic enzymesa
Methamphetamine − ++ CYP2D6, FMO3 TAAR1, VMAT2, MAO Cashman et al. (1999), Eiden and Weihe (2011), Miller 2011,
Smith et al. (2012), and Matsusue et al. (2018)
PMMA − + CYP2D6 TAAR1, 5-HT2A Simmler et al. (2014), and Vevelstad et al. (2017)
(-)-Ephedrine − ++ ß2-adrenoceptor Rao et al. (2019)
Cathine − +++ ß1- and a2A-adrenoceptors Adeoya-Osiguwa and Fraser (2007)
Mescaline +++ − Possibly MAO 5-HT2A,5-HT2C,TAAR1 Spector (1961), Lerer et al. (2001), Mulder et al. (2007),
Kling et al. (2008), Hoekstra et al. (2010), Rickli et al. (2015), and
Dinis-Oliveira et al. (2019)
DMT − + MAO-A 5-HT2A,5-HT2C,TAAR1 Keiser et al. (2009), Rickli et al. (2016), and Barker (2018)
aAbbreviations: 5-HT, 5-hydroxytryptamine; CYP2D6, cytochrome P450 subtype 2D6; FMO3, Flavin-containing monooxygenase 3; MAO, monoamine oxidase; TAAR1, trace amine-
associated receptor 1, VMAT2, vesicular monoamine transporter 2
FIGURE 8 | Illustrated summary of key findings of this study and their
potential biological relevance.
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Figure S1 Transport of different psychostimulant and hallucinogenic substances at a 
concentration of 1 µM by MATE2-K, shown as the ratios of uptake after 1 min in transporter-
transfected cells over empty vector control cells. Shown are the mean values of ≥ 3 independent 
experiments + SEM. The horizontal dotted line indicates an uptake ratio of 3, which was set as 
the minimum threshold for more detailed characterisation. The uptake in OCT1-overexpressing 
cells was not found to be significantly different to control cells, according to Student’s t-test. 
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ABSTRACT: OCT1 is the most highly expressed cation transporter in the
liver and affects pharmacokinetics and pharmacodynamics. Newly
marketed drugs have previously been screened as potential OCT1
substrates and verified by virtual docking. Here, we used machine learning
with transport experiment data to predict OCT1 substrates based on classic
molecular descriptors, pharmacophore features, and extended-connectivity
fingerprints and confirmed them by in vitro uptake experiments. We
virtually screened a database of more than 1000 substances. Nineteen
predicted substances were chosen for in vitro testing. Sixteen of the 19
newly tested substances (85%) were confirmed as, mostly strong,
substrates, including edrophonium, fenpiverinium, ritodrine, and ractop-
amine. Even without a crystal structure of OCT1, machine learning
algorithms predict substrates accurately and may contribute not only to a
more focused screening in drug development but also to a better molecular
understanding of OCT1 in general.
■ INTRODUCTION
OCT1 is the most strongly expressed organic cation trans-
porter in the sinusoidal membrane of the human liver1,2 and
has numerous effects on endogenous substrate concentrations
and pharmacokinetics of many drugs.3−9 These effects of the
highly polymorphic OCT1 on pharmacokinetics may translate
into highly variable drug effects or adverse drug reactions.10−12
Known OCT1 substrates are highly polymorphic in their
molecular structures.3,13 Nevertheless, although numerous
drugs are transported by OCT1, so far they mainly belong
to a limited number of drug classes. These drug classes include
H2-receptor antagonists, anticholinergic drugs, serotonin
receptor agonists and antagonists, sympathomimetic drugs,
and a few opioids.
The physicochemical and structural features of OCT1
substrates have been studied extensively.13,14 Typical substrates
of OCT1 are smaller than 500 Å in volume.13 Structural
characteristics of major importance for the OCT1 substrate
include a positively charged nitrogen either as a basic group or
as a quaternary amine, an aromatic group, and moieties which
increase hydrophilicity. The need for carrier-mediated trans-
port across the lipid bilayer increases for any cell uptake
(required for absorption, pharmacologic action, and/or
elimination) with positively charged and hydrophilic groups.
Based on these findings, screening for new substrates by a
traditional approach relies on molecular weight, log D7.4, pKa,
the percentage of charged substrate molecules at pH 7.4, and
the presence of structural features commonly found in known
substrates.
Since there are no X-ray crystallography data from OCT1
available yet, in silico screening for substrates of OCT1 can
primarily be achieved using ligand-based approaches or
homology modeling and virtual docking. The latter has been
successfully performed by several groups,15−17 but one
limitation is the relatively small protein sequence homology
between OCT1 and those transporters (approximately 20%15),
for which crystal structural data do exist and which were used
as the basis of OCT1 homology modeling.
Ligand-based machine learning approaches have been
applied for the identification of OCT1 substrates and for the
analysis of the molecular interactions between the transporter
and its substrates.18,19 Extensive research has been performed
on other transporters as well, such as OAT1, OAT3, and
URAT1.20−23 Two-dimensional virtual screening using ex-
tended-connectivity fingerprints and molecular descriptors is a
standard approach with widely appreciated capabilities and has
been shown to lead to good model performance in general as
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well as specifically in the case of OCT1.8 In a recent
publication, two-dimensional virtual screening was performed
and newly predicted substrates were successfully tested via
virtual docking.19 This approach, however, includes the
uncertainties of a potentially not valid transporter model
derived from homology modeling with proteins having low
sequence homology to OCT1. Therefore, testing of substrates
in actual transport experiments with cells overexpressing
OCT1 can still be considered the gold standard for validation
in this specific situation. While we use the ligand-based
approach here, the combination of different approaches, which
complement each other, is highly valuable and may ultimately
lead to the best possible results, as is also discussed in the
recent literature.24
For OCT1, as for many other transporters, there are much
data from screening substances for inhibition of transport of
model substrates.15,25 As screening for substrates of influx or
efflux transporters is laborious, there are significantly less
experimental data on transport. For OCT1, nonetheless, there
is a large enough high-quality data pool of active transport in
HEK293 to allow for virtual screening. Therefore, when
interested in novel substrates of OCT1, it is apparently more
promising to perform a virtual screening on this set of
substrates for which OCT1-mediated influx transport has been
truly experimentally verified instead of screening based on
inhibition data. The usefulness of inhibition data to identify
substrates is limited by the fact that inhibitory properties of a
substance do not imply at all that the substance is also
transported.14,15,21 This problem is well known and a subject of
current discussions. For prediction of transporter activity,
substrate activity assays, implying the direct measurement of
substrate uptake, are essential.26
In this study, we combined published data from OCT1-
mediated transport with unpublished data from our laboratory
to create a comprehensive database of molecular structures,
physicochemical descriptors, and experimentally determined
transport-kinetics data of more than 250 molecules. We trained
a machine learning classifier based on physicochemical
descriptors as well as pharmacophore features (descriptors of
spatial relation of molecular features) and chemical fingerprints
(descriptors of spatial relation of chemical structures);
screened a database of more than 1000 substances for possible
new substrates of OCT1; tested 19 randomly chosen drugs
predicted as substrates in a concentration-dependent manner
providing vmax, Km, and intrinsic clearance data; and analyzed
the new substrates’ structural relationship with known
substrates of OCT1.
■ RESULTS
First, we define a substrate/non-substrate cutoff for the ratio
(of cell uptake with over without OCT1 overexpression) and
intrinsic clearance (vmax/Km) data as a basis for screening for
potential new substrates (leading to around 44% substrates and
56% non-substrates in the overall data set). Second, we present
the validation of our final model based on a holdout validation
set. Third, we present the experimental in vitro validation of
our final model. Fourth, we describe the final model as well as
commonalities and differences of the newly found substrates.
Fifth, we characterize the set of OCT1 substrates now, also
including the newly found substrates. This process is depicted
in Figure 1. The complete set of experimentally verified OCT1
substrates and non-substrates is provided in Table S2 (.pdf),
Table S3 (.csv), and an sd-file in the Supporting Information,
S1, allowing for structure-based analyses.
Common Cutoff between OCT1 Substrates and Non-
substrates. Although the Food and Drug Administration
(FDA) guidance for drug−drug interactions advises on further
in vivo investigation if in vitro studies show ratios ≥2 (uptake
in OCT1 overexpressing cells divided by uptake in mock-
transfected cells),27 the intrinsic clearance (Clint) is more
robust as it is based on more measurements and integrative
parameter estimation. Therefore, we decided to use Clint data
wherever available and needed a common cutoff (substrate−
non-substrate) for Clint and the ratio.
We set an intrinsic clearance of 5 mL × g protein−1 × min−1
as a cutoff between substrates and non-substrates. The decision
not to choose a cutoff at any Clint slightly but significantly
above 0 was made based on the expected medical relevance.
An OCT1-mediated drug clearance slightly above 0 is
medically of minor interest as it will most probably not
translate into clinical effects.
The ratio cutoff was based on the subset of drugs where
both ratios and clearances were available. Plotting clearances
against ratios (Figure S1A), with a cutoff at a clearance of 5 mL
× g protein−1 × min−1 and a cutoff at a ratio of 3, leads to
overly congruent classification into substrates and non-
substrates (Figure S1B,C). In cases where there was a
discrepancy between ratio- and clearance-based classification
into substrates and non-substrates, we relied on the Clint data
(because it is usually based on much more measurements).
Model Performance in Cross-Validation and the
Holdout Set. The model was reduced to the 33 most
important predictive features based on their importance in the
trainings set. Hyperparameters were also established based on
the trainings set (estimators = 1000, learning rate = 0.01,
Figure 1. Flowchart illustrating the course of the study with the number of substances within the respective step shown in the upper part.
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subsample = 0.7, maximum depth = 1, feature sample per tree
= 0.5; all other hyperparameters were set to default). The
hyperparameters were chosen as to achieve high areas under
the curve (AUCs) for the validation sets in repeated 5-fold
cross-validation, while avoiding overfitting for the training sets
in repeated 5-fold cross-validation.
The final model achieved an AUC of 0.88 for the holdout
validation set (Figure S1D) and an AUC of 0.96 for the
training set, which was in line with the performance of another
published OCT1 model based only on the data published by
Hendrickx et al.13 (AUC validation: 0.81, AUC training:
0.9319). We set the cutoff for the predicted substrate versus the
predicted non-substrate so that with a share of 40% substrates
in the screening set (in line with the percentage of substrates
among single-charged cations with log D7.4 below 1 among the
substances in our database so far), the positive predictive value
was >0.8. As substrates of OCT1 are mostly single-charged
cations (pKa > 7.4) and a log D7.4 above 1 lowers the
probability of the need for active transport due to increased
membrane permeability, we in vitro tested only single-charged
cations with log D7.4 ≤ 1.0. The complete list with predicted
substances beyond our scope of log D7.4 < 1 and charge = 1 is
provided in Table S4. A summary of model parameters,
performances, and predictors is illustrated in Figure S1E,F.
In Vitro Validation of Predicted Substrates. Nineteen
randomly selected substances from the set of predicted
substrates were tested [an additional selection of predicted
substrates is provided in Table S4 as well as the complete list,
including those substances previously considered as unlikely
OCT1 substrates (log D7.4 > 1 and no positive charge)]. The
transport kinetic constants and concentration ratios measured
with overexpressing over empty vector-transfected cell lines at
a concentration of 2.5 μM are provided in Table 1. Additional
four substrates of OCT1 were tested in our lab prior to
modeling as these results have not been shown so far, and the
data are also included in Table 1. Of these additional four
substrates, milnacipran, a noradrenaline−serotonin reuptake
inhibitor; dobutamine, a β1-receptor agonist; and amifampri-
dine, a potassium channel inhibitor to our knowledge have not
been reported as OCT1 substrates earlier. Dobutamine has
been reported as an OCT1 inhibitor earlier.15
Overall, 19 substances predicted by the final model were
tested. Structures of these compounds, grouped by their
pharmacological actions, are shown in Figure 2. For all
substances showing OCT1-mediated influx transport, data
from concentration-dependent experiments are presented in
Figure 3 [additionally also for mepenzolate, Km = 29.5 μM
(±11.6), vmax = 2194 pmol mg protein
−1 min−1 (±180), Clint =
74.4, ratio = 30.7, which is a known substrate,13 but kinetic
data have not been published to our knowledge].
All but three substances, namely, labetalol, norphenylephr-
ine, and sematilide, proved to be OCT1 substrates according
to our strict criteria (a clearance of ≥ 5 mL × g protein−1 ×
min−1 or a ratio ≥ 3). While labetalol was not actively
transported at all, sematilide and norphenylephrine were
actively transported but at a very low rate (3.3 mL × g
protein−1 × min−1 and ratio 3.5, and 4.6 mL × g protein−1 ×
min−1 and ratio 2.1, respectively), and with a more liberal
definition, they can be called substrates. With this, the
prediction of OCT1 substrates was correct even with 95% of
the tested substances.
Famotidine, mepenzolate, and meta-iodobenzyl-guanidine
(mIBG) had already been reported as OCT1 substrates.3,38
However, the direct measurement of uptake kinetics of
famotidine and mepenzolate by OCT1 has not been reported
before to our knowledge.34 mIBG uptake has previously been
described without empty-vector control.47 This has been
accepted as sufficient evidence elsewhere.48 mIBG data on
OCT1 transport were published, while our experiments
presented here were already completed.38 Therefore, mIBG
serves as a validation of our final model, even though this is not
the first study presenting it as a substrate. Intrinsic clearances
and OCT1/vector-transfected ratios for the overall data set,
the non-substrates, and substrates according to our criteria
(including the newly tested substances) are shown in Figure
4A.
Model Predictors and Characteristics of Validated
and Predicted Substrates. Among the 33 features with the
best predictive value (Figure S1F), 19 were structural features
and all but 1 of them were pharmacophores (the remaining
one was a Morgan fingerprint), and the rest were general
descriptors including strongest acidic pKa, log D7.4, heavy atom
count, and strongest basic pKa. The top six features were all
pharmacophores, followed by strongest acidic pKa. The top five
pharmacophore features are shown in Figure 4B, together with
their frequencies among OCT1 non-substrates and substrates
(according to our criteria) in the overall data set.
The newly validated drugs with high and very high OCT1-
mediated intrinsic clearance were from various therapeutic
classes. Interestingly, the algorithm has identified OCT1
substrates withon averagehigher intrinsic clearance
compared with the thus far known OCT1 substrates (Figure
5). Including newly validated as well as known substrates,
among the classes with the highest median ratios and
clearances were anticholinergics, H2-antagonists, triptans, and
β2-agonists. Interestingly, the category “others” also performed
quite well, showing that OCT1, while being important for
specific drug classes, is also important for a wide range of
substances from other classes. As four of the newly identified
substrates fall within the “others” category, one can conclude
that the algorithm used here is well able to identify OCT1
substrates beyond structural analogues in already known drug
classes. The ranking of our newly identified substrates among
the already known substrates shows that an enrichment of
substrates with high clearances and ratios could be achieved
[for the newly identified substrates, the mean Km, vmax, Clint,
and ratio were 127 μM (±50), 2358 pmol × mg protein−1 ×
min−1 (±473), 70 mL × g protein−1 × min−1 (±15), and 20
(±4), respectively].
In addition to the screening database, another database with
drugs including information on the drug class they belong to
was built. Class names and assignment to classes identical to
the PharmAction category in the PubChem advanced search
were used. Classes with members already known to be
substrates of OCT1, for example, were included, and additional
common drug classes were added. Duplicates within classes
were removed, and duplicates between classes were kept as
categories, which were not mutually exclusive. Drugs already
known to be OCT1 substrates were not removed.
For predicted substances with regard to drug classes,
especially high percentages can be found within cholinergic
agents (including agonists and antagonists), adrenergic
agonists, and the related classes of sympathomimetics and
vasoconstrictor agents (Figure 6). This is mainly in line with
the classes already known substrates come from. Interestingly,
a relevant number of predicted substrates were also found
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
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among antiarrhythmics, which are also in line with our results
on sotalol and amifampridine (a potassium-channel blocker
even though not prescribed as an antiarrhythmic) as well as
sematilide (which was no substrate according to our strict
criteria but showed active transport).
For four classes that contain especially strong OCT1
substrates, namely, triptans, β2-sympathomimetics, H2-antago-
nists, and anticholinergics, an overview on how our newly
tested substance is structurally related to previously tested
substances from the same classes is provided in Figure 7.
Frovatriptan differs from already tested triptans in that the
positively charged nitrogen is closer to the indoline group
(although there is high flexibility in the tested triptans, except
for naratriptan). In addition, it is apparent that compared with
all other triptans tested so far, frovatriptan is more rigid due to
its ring closure. Frovatriptan is an above-average triptan-class
substrate of OCT1, second only to naratriptan. In the class of
β2-agonists, ritodrine and ractopamine contain adrenaline
almost entirely as a substructure just as most β2-agonists do.
They do not show close resemblance to any of the already
known substrates differing at several positions. Interestingly,
ritodrine and ractopamine turned out to have an at least 2-fold
increased Clint compared to the other β2-agonists (except
fenoterol). The H2-antagonists are structurally diverse. The
newly reported famotidine is the best OCT1 substrate among
them. Famotidine shows some resemblance to the non-
substrate nizatidine, but nizatidine has no positively charged
nitrogen at pH 7.4, which is the obvious explanation. Several
anticholinergic drugs rank among the best OCT1 substrates.
With the exception of scopolamine (not positively charged at
pH 7.4), atropine, and tolterodine (as well as methoctramine,
which is structurally far different), all the anticholinergics fare
far above average. The newly tested fenpiverinium differs from
all other antimuscarinic substrates of OCT1 by the missing
ether and relatively short linker between charged nitrogen and
the rings. Only tolterodine as an anticholinergic non-substrate
does not have an ether group and does have a short linker
region either. In addition to the ether, a hydroxy group at the
c-atom combining the rings is considered relevant for binding
to the mACh receptor. For fenpiverinium, missing both does
obviously prevent neither binding to the mACh receptor nor
being a substrate of OCT1. Methylscopolamine (clearance
51.6 mL × g protein−1 × min−1), when compared to
butylscopolamine (clearance 31.8 mL × g protein−1 ×
min−1), shows that while a bulky configuration around the
charged nitrogen is not impedimental for being a substrate (see
also trospium, ipratropium), the butyl chain might be
compared to a methyl group. As others of the novel substrates
are much more different from substrates known so far, we do
not discuss them here structurally. To classify them within the
body of OCT1-tested substrates nonetheless, we provide a
similarity clustering on a wallpaper (Figure S2). There, m-IBG
appears in a cluster with other guanidines, namely, phenformin,
proguanil, cycloguanil, and guanfacine. Amifampridine clusters
relatively late with a group including the aforementioned
guanidines as well as amiloride as another guanidine. With a
molecular mass of 109 g × mol−1, amifampridine is among the
smallest substrates of OCT1, and as compared with other low-
molecular-weight substances, it is a distinctly good substrate [a
clearance of 18.8 mL × g protein−1 × min−1, for comparison:
tetraethylammonium (TEA), molecular weight 130 × g mol−1,
clearance 5.46 mL × g protein−1 × min−1]. Famotidine is
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edrophonium, octopamine, norphenylephrine, phenylephrine,
ritodrine, ractopamine, and prenalterol cluster together mainly
with β-agonists, whereas sotalol, sematilide, and frovatriptan
join this cluster later. Octopamine, phenylephrine, and
norphenylephrine are structurally highly similar and therefore
cluster closely together (norphenylephrine is not shown in
Figure S2 as only substrates with a clearance ≥ 5 mL × g
protein−1 × min−1 or a ratio ≥ 3 according to our criteria are
included). Interestingly, while octopamine and phenylephrine
are good substrates (clearance 9.1 and 17.3 mL × g protein−1
× min−1), norphenylephrine had only a clearance of 4.6 mL ×
g protein−1 × min−1.
Milnacipran first clustered with norfentanyl abide relatively
late, clustering with the anticholinergics afterward. Interest-
ingly, norfentanyl clusters with milnacipran earlier than with
other opioid substrates. The structures for milnacipran,
norfentanyl, and noroxycodone from the larger opioid cluster
are shown together in Figure 7.
Finally, N-ethyl-lidocaine and denatonium cluster together
early as they share a large common substructure (Figure 2),
subsequently clustering with the newly tested benzyltriethy-
lammonium (which is a substructure of denatonium, see
Figure 2) as well as with the model substrate TEA.
Characteristics of the Overall Database after Addi-
tion of New Substrates and Non-substrates. The
database here with its reliance purely on directly measured
transport is a useful addition to larger data sets with more
lenient consideration of data.3 Therefore, a short summary of
the basic characteristics of the overall data set including 286
substances (after addition of the novel substrates and non-
substrates, see Table 2) appears appropriate.
The median molecular weight of substrates and non-
substrates in the data set does not differ substantially, as
seen in Table 2. The maximum weight of non-substrates was
much higher than that of substrates. The median number of
hydrogen donors was higher in substrates than in non-
substrates. The median number of hydrogen acceptors was the
same in substrates and non-substrates. While the ring count in
substrates was on the median one lower than in non-substrates,
the median number of aromatic rings was the same.
With regard to the position of the positive charge, substrates
had a guanidinium group in 9% of cases and non-substrates in
2%. Regarding positively charged nitrogen in general,
substrates had positively charged nitrogen with four, three,
two, and one non-hydrogen bond in 18, 11, 45, and 13%,
respectively, as compared to 2, 34, 27, and 15% in non-
substrates, respectively.
■ DISCUSSION AND CONCLUSIONS
Here, we will discuss the usefulness of our model for prediction
of further OCT1 substrates specifically and the importance of
virtual screening in search of OCT1 substrates in general.
Furthermore, we will discuss new substrates with regard to
potential clinical implications.
Usefulness of Model-Based Searches for New OCT1
Substrates. The model was successful in enriching substrates
among tested candidates. Given that only about 200 freely
available substances were tested with the same methodology,
we consider the addition of 23 substances with many of them
way above average substrates as substantial (overall, we
actually added 97 substances to the data previously used by
Baidya et al.19). A confirmation rate of 84% substrates among
the tested substances, as found among the newly tested
substances in this publication, is above what is usually
experienced in screening for OCT1 substrates. Prior to use
of the model, only 40% of the substances among the subset
Figure 2. Molecules investigated in this study grouped by drug classes. (1) Dobutamine, (2) ritodrine, (3) labetalol, (4) ractopamine, (5)
prenalterol, (6) guanfacine, (7) octopamine, (8) phenylephrine, (9) norphenylephrine, (10) amifampridine, (11) sotalol, (12) sematilide, (13) N-
ethyl-lidocaine, (14) dimethylphenylpiperazinium, (15) fenpiverinium, (16) edrophonium, (17) methylscopolamine, (18) denatonium, (19)
frovatriptan, (20) m-iodobenzylguanidine, (21) milnacipran, (22) benzyltriethylammonium, and (23) famotidine.
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with a single positive charge, a log D7.4 below 1, and a
molecular weight between 104 and 766 g × mol−1 were
substrates (using our strict criteria for the ratio and Clint).
Simple binomial testing proves that given an expected success
rate of 40%, 16 or more substrates within 19 tested substances
is not considered coincidence (p = 0.0001). One might object
that searching handedly for structures similar to known
substrates would have also increased the success rate, but it
Figure 3. Total and net uptake into empty vector-transfected HEK293 cells (“HEK293-EV”) and HEK293 cells overexpressing OCT1 (“HEK293-
OCT1”) reveal transport kinetics of known and newly identified substrates, listed in alphabetical order (octopamine: intrinsic/endogenous
concentrations affect total uptake).
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is nevertheless exciting that the algorithm could do similarly
well or even better than an experienced investigator.
Obviously, the overall database of 263 substances before our
screening was no result of purely random testing either. The
previous selection of tested substances will have already been
biased by similarity searches.
Screening only drugs from groups already proven to include
OCT1 substrates might also improve the success rate, but
neither do we assume that this was never done while
contributing to the data set before nor will manual search
for drug classes be as efficient and complete. Finally, while
some newly identified substrates were structurally very similar
to known substrates (e.g., methylscopolamine to butylscopol-
amine), for the majority, this was not the case. Either they were
not highly similar to the training set, for example, N-ethyl-
lidocaine (as lidocaine was not a part of the training set) or
they were not highly similar to any known substrate and do not
belong to substance classes majorly associated with OCT1, for
example, edrophonium as a cholinesterase inhibitor.
Using a model within a limited chemical space comes with
disadvantages as well. As opposed to Baidya and colleagues,19
we restricted the scope of model predictions on cationic
substances with a net charge of +1. Baidya and colleagues
applied their model to newly FDA-approved drugs in general.
Figure 4. (A) Distribution of the general descriptors, log D7.4 and molecular weight; the transport properties Clint and uptake ratio; and the total
polar surface area for all compounds included in the data set as well as the OCT1 non-substrates and substrates. (B) Distribution of total charge at
pH 7.4, given as percentage of the most represented group, and distribution of the top five pharmacophore features (given as matrices of their two-
dimensional configurations) in the data set as well as the OCT1 non-substrates and substrates (ARaromatic ring, HAhydrogen acceptor,
HDhydrogen donor; numbers describe the binned spatial distance between the features according to RDKit60).
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While we see problems with usage in a broad chemical space
and within extrapolation from the chemical space a model was
built on, it is of course in no way sure that this is doomed to
fail. The methods used might actually also help to find non-
charged or even negatively charged substrates. Therefore, we
also find expanding the horizon of OCT1 toward less probable
candidate substrates appealing.
As great science is (at least sometimes) guided by
coincidence, reducing coincidence by a systematic search will
deprive us from finding some surprisingly great results.
Therefore, we consider model-guided search for OCT1
substrates useful but emphasize that we also find random
testing beyond the scope of known substrates extremely
important. This was what, for example, led to identification of
amifampridine and milnacipran as interesting OCT1 sub-
strates.
Most probably guided by the high threshold we used for the
distinction of substrates and non-substrates (clearance ≥ 5 mL
× g protein−1 × min−1 and/or ratio ≥ 3), the novel substrates
presented here were mostly extraordinarily good substrates.
This will be beneficial for future search of high-Clint substrates
and might generally contribute to a better understanding of the
substrate binding sites of OCT1. A regression model not only
predicting substrates but also hinting at the respective
clearance/ratio is an obvious next step. With the initial data
set, one major problem was a lack of high-Clint substrates, at
least when fenoterol with a clearance of 120 was considered
the benchmark of high Clint.
Not in focus of this study was the differentiation of
substrates of OCT1 and the highly similar organic cation
transporters, such as OCT2, OCT3, OCTN1, and OCTN2,
and also efflux transporters like MATE1 and MATE2-K.
Therefore, in spite of the high transport rates, firm conclusions
about OCT1 selectivity of the newly identified substrates of
OCT1 cannot be drawn. Our approach was to identify OCT1
substrates irrespective of their selectivity. This is especially
medically relevant in situations when the substrate is known to
be metabolized in the liver (and a significant renal elimination
Figure 5. Uptake ratios (A) and intrinsic clearances (B) by drug classes. A classification according to PubChem PharmAction categories was used,
and substances known earlier as substrates of OCT1 are printed in black, while substances newly identified are printed in blue. The antidiabetic
drug metformin, as the best-known but obviously not the “best” substrate of OCT1, is highlighted in green.
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has been excluded). Further modeling of the differential
selectivity of transporters and experimental validation is an
important future perspective. It is especially important as it
points toward structural differences of closely related trans-
porters, having in mind that with stereoisomers, there was
quite an astonishing partial selectivity between OCT1- and
OCT2-mediated transport.49 For differential modeling, as a
starting point, it has to be known that a substance is at least a
substrate of one of the transporters in question. This usually
requires hierarchical modeling, even though in some cases, this
problem has been solved creatively by the use of in vivo
phenotyping.22
Of course, machine learning and other in silico approaches
have not only been used for the prediction of substrates for
organic cation transporters but for other transporters as
well.20,22,23 For all transporters, machine learning approaches
have not been the only successful in silico methods for
predicting new substrates/inhibitors. Long-established non-
machine-learning approaches, such as knowledge-based
pharmacophore modeling and others, should not be
disregarded as they have delivered and will deliver valuable
results.20,21,23 Of course, it is of value not only to quantitatively
predict ligand activities but also to develop a further
understanding of the structural mechanisms upon ligand
binding and translocation. Transport is not the same uniform
process for each substrate. Especially, considering evidence for
different binding sites in transporters,26,50 it is important to
continue with elucidation of their true molecular structures
and with structural modeling. This knowledge cannot
singularly be derived from ligand-based approaches. The
ligands presented in this study might fall into groups of
already known binding modes and might further elucidate the
understanding of those when combined with structure-based
approaches.24
We are aware that we have proven the usefulness of the
model only for a chemical subspace (log D7.4 < 1, charge = 1).
It will be interesting to expand the validation onto substances
not associated with cation transporters, implying more
lipophilic and/or non-cationic compounds. However, at
present, the database of experimentally well-characterized
non-cationic substrates of OCT1 is relatively small, making
reliable predictions in this part of the chemical space difficult.
The future goal is to expand the database toward more diverse
and maybe even better substrates and to elucidate the
structural basis for efficient transport based on them. Our
enrichment of this set with high-affinity substrates will
hopefully assist in finding even better substrates, implying
higher clearance, possibly higher affinity, higher transport
capacity, and higher clinical relevance.
Clinical Implications of Newly Found OCT1 Sub-
strates. Here, we tested potential substrates of OCT1 based
on the model’s suggestion to learn more about structure−
activity relationships. When searching for clinically relevant
substrates of OCT1, one has to consider additional factors: (1)
is the drug commonly used? (2) Does the drug require
transporter-mediated uptake into the liver for biliary secretion
or hepatic biotransformation with subsequent renal elimi-
nation, and/or does the liver accumulate relevant amounts of
the drug serving as a reservoir? If (1) and (2) hold true, one
has to answer the question whether common OCT1
polymorphisms or OCT1-inhibiting comedication influences
the patients’ exposure to the drug. While none of the
substances tested here are blockbuster drugs, some are
prescribed frequently and shall be discussed.
Radiolabeled mIBG is used for diagnostic purposes and
treatment of neuroendocrine tumors. While some guanidines
are long known to be substrates of OCT1,3,51 for mIBG, some
but no conclusive evidence had been reported.47 While writing
Figure 6. (Left) Illustration of the database composition. Small pie charts around show the same information separately by drug class. Histamine
antagonists did not include any suggested substrates as the non-screening database only included H1-antagonists. (Right) Underlying database
consisted of drugs outside the range of charge (=+1) and log D7.4 (<1) considered for testing (gray) as well as those within the range predicted as
non-substrates (orange) and those within the range predicted as substrates (blue).
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this article, OCT1-conclusive evidence has been reported
elsewhere.38 Therefore, mIBG validates our model, while our
data now only add to a very recent publication proving mIBG
as a substrate.38 Uptake of mIBG by OCT1 is interesting
because one might be able to reduce its unwanted and
potentially harmful accumulation in normal tissues by OCT1
inhibition.38,48 We furthermore want to add that OCT1
polymorphisms should also be studied with regard to their
influence on mIBG pharmacokinetics, pharmacodynamics, and
adverse effects. From a purely structural point of view, one
might also be interested in in vitro testing of benzylguanidine
as a substrate of OCT1 to further examine if iodine contributes
to the high OCT1 clearance.
Frovatriptan is now an additional triptan proven as an
OCT1 substrate. Regarding potential influences of OCT1
polymorphisms on its pharmacokinetics, frovatriptan is an
interesting candidate as it is metabolized in the liver52 and with
26 h, it already has a very long half-life compared to other
triptans.53 This long half-life might even increase with
polymorphisms leading to OCT1 deficiency, and carriers
may suffer from more and prolonged adverse effects.
Sotalol is mainly excreted unchanged via the kidneys.54 If at
all, OCT polymorphisms may influence pharmacokinetics only
as they might exclude the liver as a reservoir. This
phenomenon of hepatic storage was impressively shown for
sumatriptan by autoradiography as well as by positron emission
Figure 7. Overview of structural relation of the newly identified substrates (encircled in red) to previously tested substances and the endogenous
agonist (encircled in blue).











number of hydrogen donors 3 (0−6) 2 (0−8)
number of hydrogen acceptors 4 (0−8) 4 (0−12)
number of rings 2 (0−6) 3 (0−8)
number of aromatic rings 2 (0−3) 2 (0−6)
percentage of substances with the guanidinium
group (within substrates/non-substrates)
9% 2%
percentage of substances with charged nitrogen
and four non-hydrogen bonds
(within substrates/non-substrates)
18% 2%
percentage of substances with charged nitrogen
and three non-hydrogen bonds
(within substrates/non-substrates)
11% 34%
percentage of substances with charged nitrogen
and two non-hydrogen bonds
(within substrates/non-substrates)
45% 27%
percentage of substances with charged nitrogen
and one non-hydrogen bond
(within substrates/non-substrates)
13% 15%
aAll data are provided as the median (minimum−maximum).
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tomography scans.55 It has also been shown for metformin.56
Milnacipran is also mainly excreted unchanged via the kidneys
so that polymorphisms may influence pharmacokinetics only as
they might exclude the liver as a reservoir here as well.57
Systemic amifampridine exposure has been shown to be
dependent on N-acetyltransferase 2 (NAT2) activity, with up
to 8.8-fold increase in AUC dependent on the kidney
function.58 NAT2 is highly expressed in the liver. The
influence of OCT1 polymorphisms on liver uptake could
further modulate systemic exposure to amifampridine.
In summary, we expanded the database of substances with
directly proven OCT1 transport by a double-digit percentage
and contributed high-affinity substrates, which might allow for
future regression modeling and for analyses of different binding
modes. Additionally, effects of polymorphisms on the in vitro
transport of the new substrates are worth studying. The same
holds true for in vivo pharmacokinetics and pharmacodynamics
in the case of some of these novel substrates. Apparently, the
algorithms currently available may significantly accelerate our
knowledge about the substrate spectrum of not only OCT1 but
also many other solute carrier transporters and beyond.
■ EXPERIMENTAL SECTION
Database Creation. Only data from transporter assays using
HEK293 cells overexpressing human OCT1 were added to our
database. We included ratio data (OCT1-overexpressing over control)
of transport experiments from Hendrickx et al. (ratios determined at a
concentration of 2.5 μM),13 a publication from Meyer and colleagues
(ratios determined at a concentration of 0.5 μM),14 and ratio and
clearance data from our lab. We did not include inhibition data.
Hendrickx and colleagues reported transport assay results for 354
substances, with 81 of them with a clear name and 273 experimental
substances with aliases.13 Baidya and colleagues used the clear-name
substances and additional 100 of the experimental substances for
successful modeling.19 The clear-named drugs used by Hendrickx et
al. and the experimental substances used by Baidya and colleagues
were added to our database. The additional experimental substances
were not added to not shift the focus of modeling and prediction too
much on this very specific subset. Adding 21 test substances from the
Meyer publication14 and ratio and clearance data from our laboratory,
we created a database of 286 drugs (this also includes the newly tested
substrates from this publication) with complete structural information
and data on transport via OCT1 either as ratios or as clearances. In
summary, we added around 100 substances to the database used by
Baidya earlier.19 The resulting data set still had the advantage that it
comprises data from highly homogeneous sources. The cell lines used
in the Meyer publication14 are of the same origin as ours. For the
Hendrickx13 results, we have shown a good overlap over years, and an
ad hoc analysis showed a high correlation of observed ratios (r2 =
0.94, n = 6). Files with structure information were downloaded as
structure data files (.sdf) from either the ZINC database59 or
PubChem. Drugs with only SMILES information were converted into
the .sdf format using the chemical identifier resolver from the NIH
website.
For screening of new substrates, libraries of structural files were
obtained from PubChem. The screening database included 2055
drug-like substances from PubChem (∼1500 after curation with, for
example, removal of duplicates).
A chemical database was created using Instant JChem (ChemAxon,
Budapest, Hungary), transport data were included, and molecular
descriptors were calculated.
The overall database was imported into RDKit (Python).60
Additional molecular descriptors and pharmacophore fingerprints
based on the definitions by Gobbi61 as well as Morgan fingerprints
(radius = 2, 2048 bits) were added.
Machine Learning. All steps were performed in Python using
pandas, scikit-learn, and XGBoost.62−64 At an initial stage, only the
originally accessible Hendrickx data set and our lab data were used. In
the later stages, the data from the Meyer publication as well as data
from substrates predicted by the model and already tested in our lab
were added. This was done to perform the prediction based on the
best data available at each point in time.
Consistent cutoff values for clearance and ratio were derived from
drugs with both measurements available (clearance ≥ 5 mL × g
protein−1 × min−1 and/or ratio ≥ 3 was set as the substrate definition,
and supporting data are presented in the first Results section and in
Figure S1).
The data set was split randomly into the training set (80%) and
holdout validation set (20%) using a stratified split (stratified with
regard to the proportion of substrates and non-substrates). The initial
model was built based on the training set and included all features and
descriptors calculated. The features were then reduced to those with
good predictive performance in repeated 5-fold cross-validation only
using the training set. The performance of the reduced models was
assessed based on AUCs in repeated 5-fold cross-validation still only
using the training set. Hyperparameters were also tuned based on
AUCs in repeated 5-fold cross-validation of the training set only. The
final model performance was then assessed using the holdout
validation set. Virtual screening was subsequently performed using
the validated model and the screening database.
In Vitro Uptake Experiments. Transport experiments were
performed as described earlier.49,65 In brief, 600,000 HEK293 cells
stably transfected with the empty pcDNA5 vector or to overexpress
human OCT1 were plated in poly-D-lysine pre-coated 12-well plates
48 h prior to the transport experiment. For this, cells were washed
once with 37 °C Hanks’ balanced salt solution (HBSS, Thermo Fisher
Scientific, Darmstadt, Germany) supplemented with 10 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid pH 7.4 (Sigma-Al-
drich, Taufkirchen, Germany)from here on termed HBSS+. Cells
were incubated with increasing concentrations of the respective drug
in HBSS+ at 37 °C. After 2 min, cells were washed with ice-cold
HBSS+ twice and lyzed with 500 μL of 80% (v/v) acetonitrile (LGC
Standards, Wesel, Germany) including an internal standard. The
intracellular accumulation of tested substances was measured by
liquid chromatography with tandem mass spectrometry (LC−MS/
MS). Normalization of cell numbers was performed by measuring the
total protein via a standard bicinchoninic acid assay. All tested
compounds suggested by virtual screening were tested negative for
pan assay interference (online filter: http://zinc15.docking.org/
patterns/home/).66 Among the substances presented in this study,
only dobutamine was reported as a possibly interfering compound.
This might be of minor relevance because normalization of uptake is
performed, controls were used, and uptake experiments are less prone
to interference compared to inhibition experiments.
LC−MS/MS Concentration Analyses. Cellular concentrations
were determined by high-performance liquid chromatography
(HPLC)−MS/MS using a Shimadzu Nexera HPLC system with an
LC-30AD pump, a SIL-30AC autosampler, a CTO-20AC column
oven, and a CBM-20A controller (all Shimadzu, Kyoto, Japan). Liquid
chromatography was performed on a Brownlee SPP RP-Amide
column (4.6 × 100 mm inner dimensions with a 2.7 μm particle size)
with a C18 pre-column. The aqueous mobile phase contained 0.1%
(v/v) formic acid and 3% (v/v) organic additive [acetonitrile/
methanol 6:1 (v/v)] in the case of edrophonium (Santa Cruz
Biotechnology, Heidelberg, Germany), amifampridine, norpheny-
lephrine, octopamine, and phenylephrine (all Sigma-Aldrich,
Taufkirchen, Germany); 8% (v/v) in the case of benzyltriethylammo-
nium, dimethylphenylpiperazinium, frovatriptan, sematilide (Sigma-
Aldrich, Taufkirchen, Germany), famotidine, prenalterol, and sotalol
(Santa Cruz Biotechnology, Heidelberg, Germany); 20% (v/v) in the
case of dobutamine (Eli Lilly, Indianapolis, USA), fenpiverinium, m-
IBG, methylscopolamine, milnacipran (Santa Cruz Biotechnology,
Heidelberg, Germany), N-ethyl-lidocaine, labetalol, ractopamine,
ritodrine (Sigma-Aldrich, Taufkirchen, Germany); or 35% (v/v) in
the case of denatonium (Sigma-Aldrich, Taufkirchen, Germany), and
chromatography was carried out with a flow of 0.3 mL/min. The
HPLC system was coupled to an API 4000 tandem mass spectrometer
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(AB SCIEX, Darmstadt, Germany), and detection was performed in
the MRM mode with parameters given in Table S1. Quantification
was performed using the Analyst software (version 1.6.2, AB SCIEX,
Darmstadt, Germany) and determined by the simultaneous measure-
ment of a standard curve with known concentrations. The net uptake
by OCT1 was calculated as the difference between the uptake by
OCT1 overexpressing and empty vector-transfected HEK293 cells. If
not stated otherwise, the results are given as mean values ± standard
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random performance = 0.5
Legend: (A) Plot of ratio (uptake in OCT1 overexpressing cells divided by uptake in mock-
transfected cells) against Clint , with lines indicating cutoffs at a clearance of 5 ml × g protein
-1 ×
min-1 and a ratio of 3. (B) Plot of scatters from Figure S1A as detailed view highlighting the
cutoff and (C) providing the compound names. Green squares indicating substrates and non-
substrates congruently assigned by ratio and Clint, red squares indicate non-congruent
classification. (D) Performance of the final model as quantified by area under the curve (AUC)
for the holdout validation set. (E) Model parameters and performance, as well as (F) predictors
of the reduced model in descending order of importance. Phores and fingerprints enumeration
according to RDKit assignment.
Ratio and Clint of substrates with cutoffs indicated
Figure S1 Page S2
Fourfold table of Figure S1A
Fourfold table of substances assigned by ratio and Clint Performance of the final model
Hyperparameters and model performance Ranking of predictors (reduced model)
Substrate Structure Clint Ratio
substance 25 - 69.1
substance 26 - 11.3
substance 27 - 13.9
substance 28 - 6.8
substance 29 - 2.7
substance 30 - 2.9
substance 31 - 23.5
substance 32 - 5.3
substance 33 - 5.1
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substance 35 - 14.6
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substance 37 - 7.2
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Cluster ing by f ingerpr int s imi lar i ty
Jensen, O, Brockmöller J, Dücker C: Identification of novel and high-affinity substrates of OCT1 using machine learning-guided virtual screening and experimental validation, Figure S2
substance 4 - 10.7
ZINC96932953 - 12.7
substance 5 - 13.9
substance 6 - 6.6
substance 7 - 7.1








































































substance 1 - 12.6
substance 2 - 3.7
Substrate Structure Clint Ratio
debrisoquin 7.1 -
4-hydroxydebrisoquine 21.2 -
- substrates tested in this publication
substance 8 - 21.5
substance 9 - 11.3
substance 10 - 4.6
substance 11 - 16.7
substance 12 - 5.3
substance 13 - 8.0
substance 14 - 35.4
substance 15 - 3.0
ZINC96932958 - 38.6
substance 16 - 10.0





substance 18 - 17.0
substance 19 - 12.5
ZINC96932951 - 52.7
substance 20 - 5.2
substance 21 - 2.5
substance 22 - 4.5
substance 23 - 8.6
substance 24 - 3.4
Legend:Wallpaper of substrates with a ratio ≥ 3 or Clint
≥ 5 clustered based on Tanimoto similarity of Morgan
fingerprints (radius = 2, 2048 bits) using SciPy hierarchi
cal clustering, showing molecular structures with the
respective ratio and Clint values.
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A B S T R A C T
Stereoselectivity is well described for receptor binding and enzyme catalysis, but so far has only been scarcely
investigated in carrier-mediated membrane transport. We thus studied transport kinetics of racemic (anti)
adrenergic drugs by the organic cation transporters OCT1 (wild-type and allelic variants), OCT2, OCT3, MATE1,
and MATE2-K with a focus on stereospecificity.
OCT1 showed stereoselective uptake with up to 2-fold higher vmax over their corresponding counterpart
enantiomers for (R,R)-fenoterol, (R,R)-formoterol, (S)-salbutamol, (S)-acebutolol, and (S)-atenolol.
Orciprenaline and etilefrine were also transported stereoselectively. The Km was 2.1-fold and 1.5-fold lower for
the (S,S)-enantiomers of fenoterol and formoterol, while no significant difference in Km was seen for the other
aforementioned drugs. Common OCT1 variants showed similar enantiopreference to wild-type OCT1, with a few
notable exceptions (e.g. a switch in enantiospecificity for fenoterol in OCT1*2 compared to the wild-type). Other
cation transporters showed strong differences to OCT1 in stereoselectivity and transport activity: The closely
related OCT2 displayed a 20-fold higher vmax for (S,S)-fenoterol compared to (R,R)-fenoterol and OCT2 and
OCT3 showed 3.5-fold and 4.6-fold higher vmax for the pharmacologically active (R)-salbutamol over (S)-sal-
butamol. MATE1 and MATE2-K generally mediated transport with a higher capacity but lower affinity compared
to OCT1, with moderate stereoselectivity.
Our kinetic studies showed that significant stereoselectivity exists in solute carrier-mediated membrane
transport of racemic beta-adrenergic drugs with surprising, and in some instances even opposing, preferences
between closely related organic cation transporters. This may be relevant for drug therapy, given the strong
involvement of these transporters in hepatic and renal drug elimination.
1. Introduction
While receptor binding and enzymatic catalysis are widely known to
often be highly stereospecific processes, stereoselectivity in membrane
transport by polyspecific solute carriers (SLC) is not so evident and
often not considered in research. Given the very broad substrate spec-
trum of many of these transporters, it may predominantly be the phy-
sicochemical properties of a substance that determine which trans-
porter is relevant [1]. In this study, we focus on stereospecificity in
organic cation transport of adrenergic and antiadrenergic drugs, since
many of these have chiral centres and are often administered as racemic
mixtures.
The importance of stereospecificity in pharmacodynamics has al-
ready been thoroughly studied for several (anti)adrenergic drugs. For
instance, the prototypic adrenergic substance (R)-adrenaline is over 20-
fold more potent than (S)-adrenaline. Also, the spasmolytic actions of
salbutamol (albuterol) and formoterol were attributed solely to (R)-
salbutamol and (R,R)-formoterol, while the counterpart enantiomers
showed significantly less agonist activity at the beta2-adrenergic re-
ceptor [2,3]. Stereoselectivity has also been extensively studied with
respect to drug metabolism [4], and it was strongly observed in the
sulfation of some beta-adrenergic drugs [5]. Before sulfate conjugation
or other metabolic reactions can take place in enterocytes, hepatocytes,
or renal tubular cells, these relatively hydrophilic drugs must first enter
the cell. Organic cation transporters (OCTs) are predominantly re-
sponsible for the transport of more hydrophilic cationic substances in
the liver and kidneys for metabolism and excretion [6]. Transport via
OCT1 and OCT3 may be particularly relevant in the context of hepatic
https://doi.org/10.1016/j.bcp.2019.113731
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metabolism [7], whereas OCT2 and MATE2-K are often involved in
renal elimination.
Only few studies investigating stereoselectivity in drug membrane
transport have been published so far [8]. For example, for the beta1-
adrenergic receptor partial agonist xamoterol, the (S)-enantiomer was
found to be 2-fold preferentially transported by OCT1 [1]. With regard
to other substrates of OCT1, literature data on stereoselectivity is
scarce. Here, we report a comprehensive characterisation of the extent
of stereospecificity in the transport of different beta-adrenergic receptor
agonists and antagonists (Fig. 1) by wild-type and genetic variants of
OCT1 as well as by the related transporters OCT2, OCT3, MATE1, and
MATE2-K.
2. Materials and methods
2.1. In vitro uptake experiments
Transport experiments were performed with HEK293 cells stably
transfected to overexpress OCT1*1 (wild-type), OCT1*2 (M420del),
OCT1*3 (R61C), OCT1*4 (G401S), OCT1*5 (M420del/G465R),
OCT1*6 (C88R/M420del), OCT1*7 (S14F), OCT1*8 (R488M), OCT2,
OCT3, MATE1, or MATE2-K. All cell lines were generated using the Flp-
In system (Thermo Fisher Scientific, Darmstadt, Germany) as previously
described [7,9,10], except for the OCT3-overexpressing HEK293 cells
that were a kind gift from Drs. Koepsell and Gorbulev (University of
Würzburg, Germany). Cells were kept in culture for no more than 30
passages. Tested drugs were purchased as racemates from Sigma-Al-
drich (Darmstadt, Germany; catalogue numbers: fenoterol, F1016; for-
moterol, F9552; salbutamol, S8250; orciprenaline, M2398; acebutolol,
A3669; atenolol, A7655) or Santa Cruz Biotechnology (Heidelberg,
Germany; pirbuterol, sc-476485; etilefrine, sc294579A). Internal stan-
dards were purchased from Sigma-Aldrich (desvenlafaxine, D-2069;
metoprolol, 80337), Santa Cruz Biotechnology (tulobuterol, sc-213131;
(S)-propranolol, sc-294579A), or Biozol Diagnostica (Eching, Germany;
fenoterol-d6, TRC-F248852).
Cells were seeded on 12-well plates coated with poly-D-lysine 48 h
before the transport experiments and incubated at 37 °C, 95% relative
humidity, and 5% CO2. Cell lines overexpressing MATE1 and MATE2-K
were incubated with 30 mM NH4Cl in HBSS+ (10 mM HEPES in HBSS,
pH 7.4; Thermo Fisher Scientific, Darmstadt, Germany) for 30 min prior
to the assay to invert the direction of transport. All cell lines were
washed with 37 °C HBSS+ and subsequently incubated with the pre-
warmed substrate in HBSS+ for one (MATE1, MATE2-K) or two (OCTs)
minutes at 37 °C. The reaction was stopped by adding ice-cold HBSS+,
and the cells were washed twice with ice-cold HBSS+ before lysis with
80% acetonitrile (LGC Standards, Wesel, Germany). Subsequently, the
intracellular substrate accumulation was determined using LC-MS/MS.
2.2. Stereoselective concentration analyses
Cell uptake was quantified by stereoselective HPLC and tandem
mass spectrometric detection using a Shimadzu NexeraTM HPLC system
Fig. 1. Beta-adrenergic receptor agonists and antagonists investigated for stereoselective transport by OCTs and transporters of the MATE-family. These were selected
for physicochemical properties (pKa > 8.0 and logDpH7.4 < 1) that renders them likely transporter substrates. Chiral centres are indicated by an asterisk.
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that included a LC-30AD pump, a SIL-30AC autosampler, a CTO-20AC
column oven, and a CBM-20A controller (Shimadzu, Kyoto, Japan). A
Chiral-CBH column (100 × 3 mm, 4.6 µm; Sigma-Aldrich, Darmstadt,
Germany) with a corresponding 10 × 3 mm guard column or an Astec
Chirobiotic T (15 cm × 2.1 mm, 5 µm; Sigma-Aldrich, Darmstadt,
Germany) column with a corresponding 2 cm × 1 mm guard column
was used (Table 1). Oven temperature was 25 °C for all methods, and
separation was achieved by isocratic elution. The order of enantiomer
elution was inferred from available literature, where the investigated
substrates had been separated by HPLC using identical columns and
similar mobile phases [11–15]. However, no reference literature was
found for etilefrine, orciprenaline, and pirbuterol. In these cases, the
enantiomers were only named by the order of elution, as the identifi-
cation of the enantiomers was not the focus of this study. Tested sub-
strates and suitable internal standards were detected using an API 4000
tandem mass spectrometer (AB SCIEX, Darmstadt, Germany) with the
parameters listed in Table 2.
2.3. Calculations
The net active transport by overexpressed transporters was calcu-
lated by subtracting the uptake measured in an empty vector control
cell line. The parameters Km and vmax were estimated by regression
analysis using the Michaelis-Menten equation. Means and standard
errors were calculated from individual Km and vmax values of at least
three independent experiments. The intrinsic clearance Clint was cal-
culated as the ratio of vmax over Km. The kinetic parameters vmax, Km,
and Clint were tested for statistical significance using Student’s t-test
with an alpha-value of 0.05.
3. Results
3.1. Stereoselective OCT1-mediated cellular uptake of adrenergic drugs
First, we analysed the extent of stereoselectivity in the OCT1-
mediated transport of eight clinically relevant beta-adrenergic receptor
agonists and antagonists. The test compounds were selected based on
their physicochemical properties (pkA > 8.0 and logDpH7.4 < 1),
because more lipophilic or acidic substances are mostly not transported
by OCTs to a relevant extent.
We observed a 1.9- and 1.7-fold (calculated as the ratio of the larger
over the smaller parameter) higher maximum transport velocity (vmax)
for the (R,R)-enantiomers of fenoterol and formoterol in comparison to
the corresponding (S,S)-enantiomers (Figs. 2, 3, Table 3). The Km values
were also higher for (R,R)-fenoterol and (R,R)-formoterol. We observed
a 1.1- to 1.7-fold difference in vmax between the enantiomers of sal-
butamol, pirbuterol, orciprenaline (metaproterenol), etilefrine, acebu-
tolol, and atenolol (Figs. 2, 3, Table 3). However, no notable differences
Table 1
HPLC settings for the separation of (anti)adrenergic drug enantiomers.
Drug Columna Mobile phaseb Flow rate [µl × min−1] Retention time A [min] Retention time B [min]
Fenoterol Chiral-CBH 10 mM NH4Ac, pH 5.8, 5% IPA 500 5.3 (R,R) 6.1 (S,S)
Formoterol Chiral-CBH 10 mM NH4Ac, 10% ACN 300 15.4 (R,R) 17.0 (S,S)
Salbutamol Chirobiotic T 20 mM NH4Ac, pH 4.5, 96% MeOH 1000 6.8 (R) 7.7 (S)
Pirbuterol Chiral-CBH 10 mM NH4Ac, pH 5.8, 5% IPA 300 3.3 (P1) 3.5 (P2)
Orciprenaline Chirobiotic T 20 mM NH4Ac, pH 4.5, 93% MeOH 500 9.2 (P1) 10.7 (P2)
Etilefrine Chirobiotic T 20 mM NH4Ac, pH 4.5, 93% MeOH 500 10.8 (P1) 11.6 (P2)
Acebutolol Chiral-CBH 10 mM NH4Ac, pH 5.8, 10% ACN 500 2.9 (R) 4.8 (S)
Atenolol Chiral-CBH 10 mM NH4Ac, pH 5.8, 5% IPA 300 3.8 (R) 5.1 (S)
a CBH, cellobiohydrolase
b ACN, acetonitrile; IPA, isopropanol; MeOH, methanol; NH4Ac, ammonium acetate
Table 2
Chemical properties pKa and logDpH7.4 and relevant data for mass-spectrometric detection of the substrates and analytical internal standards.
Drug pKa logDpH7.4 Q1 Massa [Da] Q3 Massb [Da] DPc [V] CEd [V] CXPe [V]
Substrates
Fenoterol1 9.63 0.33 304.1 (304.1) 107.1 (135.2) 70 (70) 44 (24) 12 (12)
Formoterol1 9.81 0.04 345.2 (345.2) 149.1 (121.1) 70 (70) 28 (42) 15 (15)
Salbutamol2 9.40 −1.32 240.2 (240.2) 148.2 (222.2) 60 (60) 24 (24) 15 (15)
Pirbuterol1 9.59 −1.78 241.3 (241.3) 149.1 (167.2) 65 (65) 30 (24) 15 (15)
Orciprenaline3 9.70 −0.94 212.1 (212.1) 152.0 (107.0) 56 (56) 23 (39) 10 (8)
Etilefrine4 9.73 −1.07 182.1 (182.1) 164.0 (91.0) 51 (51) 17 (37) 10 (6)
Acebutolol2 9.65 −0.68 337.2 (337.2) 116.0 (98.1) 91 (91) 31 (29) 8 (8)
Atenolol5 9.67 −1.80 267.2 (267.2) 145.2 (74.0) 130 (1 3 0) 38 (35) 10 (14)
Internal standards
Fenoterol-d6 – – 310.3 (310.3) 109.1 (141.0) 70 (70) 40 (26) 12 (12)
Desvenlafaxine – – 264.3 (264.3) 58.1 (107.2) 60 (60) 47 (50) 8 (8)
Metoprolol – – 268.2 (268.2) 116.1 (74.0) 86 (86) 27 (35) 8 (14)
(S)-Propranolol – – 260.2 116.2 85 30 10
Tulobuterol – – 228.1 (228.1) 153.9 (119.1) 60 (60) 23 (41) 10 (8)
a Q1, first quadrupole (qualifiers below in parentheses);
b Q3, third quadrupole (qualifiers in parentheses);
c DP, declustering potential;
d CE, collision energy;
e CXP, collision cell exit potential;
1 quantified with internal standard fenoterol-d6;
2 quantified with internal standard desvenlafaxine;
3 quantified with internal standard metoprolol;
4 quantified with internal standard (S)-propranolol;
5 quantified with internal standard tulobuterol
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in Km between the enantiomers of these drugs were seen. The intrinsic
clearance differed 1.1- to 1.7-fold between the enantiomers of salbu-
tamol, orciprenaline, etilefrine, acebutolol, and atenolol, whereas no
significant difference was seen between the enantiomers of pirbuterol.
To summarise, remarkable differences, particularly in the maximum
uptake velocity, were seen between the enantiomers of structurally
related (anti)adrenergic drugs, which is notably indicative of stereo-
specificity in the molecular interaction between substrate and
Fig. 2. Transport of (anti)adrenergic drug enantiomers by wild-type OCT1, determined using stably transfected HEK293 cells. Shown are the mean ± SEM of at least
three independent experiments for each drug. Enantiomers that could not be identified were numbered according to the order of HPLC elution.
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transporter. However, general conclusions about stereoselective uptake
by OCT1 cannot be deduced at present, and stereoselectivity must be
determined for every substrate individually.
3.2. Differential stereoselective transport among genetic variants of OCT1
Next, we investigated possible differences in stereospecific mem-
brane transport of a subset of (anti)adrenergic drugs with particular
clinical importance, namely fenoterol, formoterol, salbutamol, and
atenolol, between common naturally occurring variants of OCT1
(OCT1*2 to OCT1*8). With the exception of fenoterol uptake via
OCT1*4, a reduction in the transport velocity was observed for all
substrates in the variants OCT1*2, *3, *4, and *7 (Table 4). No trans-
port activity was detected in OCT1*5 and *6 (data not shown), which
are known to be non-functional [7]. In contrast, OCT1*8 showed a
transport capacity similar to wild-type (for salbutamol) or higher (for
fenoterol, formoterol, and atenolol). Generally, the stereoselectivity of
transport did not differ strongly between any of these common OCT1
variants, with a few notable exceptions further outlined below.
For fenoterol, the observed vmax but also the Km were approximately
twice as high for the pharmacologically active (R,R)-fenoterol in com-
parison to (S,S)-fenoterol in wild-type OCT1. Interestingly, for the
worldwide most common variant OCT1*2, the enantioselectivity was
completely opposite: the vmax was 1.6-fold higher and the Km almost 5-
fold higher for (S,S)-fenoterol. Notable is also the switch in affinity from
wild-type (2.1-fold lower Km for (S,S)-fenoterol) to OCT1*7 (3.1-fold
lower Km for (R,R)-fenoterol). There is little difference in the intrinsic
clearance between the two enantiomers of fenoterol for wild-type OCT1
and all studied variants, except for OCT1*4, where it is 1.7-fold higher
for (R,R)-fenoterol.
Fig. 3. Stereoselectivity in the OCT1-mediated transport of sympathomimetic and sympatholytic drugs. The ratios on the right were calculated as the quotients of the
higher and the lower values.
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Table 3
Kinetic parameters for the transport of racemic (anti)adrenergic drugs by wild-type OCT1.








OCT1 (R,R)-Fenoterol 1.7* (±0.3) 81.5** (± 2.6) 54.6 (±14.6) 2.13-fold for (R,R) 1.94-fold for (R,R) 1.04-fold for (S,S)
(S,S)-Fenoterol 0.8* (±0.2) 42.0** (± 3.5) 57.0 (±16.2)
(R,R)-Formoterol 28.3 (±6.2) 820.4* (± 102.8) 30.7 (±4.5) 1.48-fold for (R,R) 1.72-fold for (R,R) 1.23-fold for (R,R)
(S,S)-Formoterol 19.1 (±2.0) 476.1* (± 54.5) 25.0 (±1.3)
(R)-Salbutamol 224.2 (± 18.4) 1464.3* (± 157.6) 6.5** (± 3.8) 1.01-fold for (R) 1.12-fold for (S) 1.12-fold for (S)
(S)-Salbutamol 222.5 (± 20.5) 1637.3* (± 192.6) 7.3** (± 4.2)
Pirbuterol-1 75.3 (±11.4) 2942.7 (± 307.2) 40.9 (±7.2) 1.03-fold for (1) 1.08-fold for (1) 1.06-fold for (1)
Pirbuterol-2 72.9 (±12.3) 2724.3 (± 337.4) 38.7 (±5.3)
Orciprenaline-1 780.5 (± 285.9) 11106.3 (± 1579.8) 20.0* (± 3.5) 1.04-fold for (2) 1.31-fold for (1) 1.32-fold for (1)
Orciprenaline-2 808.8 (± 292.6) 8482.0 (± 1224.2) 15.1* (± 2.7)
Etilefrine-1 232.9 (± 29.8) 1667.1** (± 432.9) 7.7* (±2.3) 1.08-fold for (2) 1.35-fold for (2) 1.47-fold for (2)
Etilefrine-2 214.0 (± 24.9) 2253.8** (± 506.8) 11.3* (± 2.9)
(R)-Acebutolol 19.9 (±5.7) 161.5*** (± 41.9) 9.5** (± 2.7) 1.05-fold for (S) 1.72-fold for (S) 1.51-fold for (S)
(S)-Acebutolol 21.0 (±2.5) 277.9*** (± 45.1) 14.3** (± 2.9)
(R)-Atenolol 201.9 (± 33.1) 929.7*** (± 115.3) 5.1** (± 1.0) 1.03-fold for (R) 1.69-fold for (S) 1.69-fold for (S)
(S)-Atenolol 196.4 (± 23.1) 1567.4*** (±143.6) 8.6** (± 1.5)
SEM, standard error of the mean; asterisks indicate statistical significance of the differences between the two enantiomers (Student's t-test; * p < 0.05, ** p < 0.01,
and *** p < 0.001).
Table 4
Kinetic parameters for the transport of racemic (anti)adrenergic drugs by genetic variants of OCT1.
Transporter Substrate Km (± SEM) [µM] Vmax (± SEM)
[pmol × mg
protein-1 × min−1]
Clint ( ± SEM)




OCT1*2 (R,R)-Fenoterol 11.4 (±5.9) 49.6 (±14.4) 28.9* (± 25.3) 4.85-fold for (S,S) 1.55-fold for (S,S) 1.09-fold for (R,R)
(S,S)-Fenoterol 55.3 (±36.8) 77.0 (±34.0) 26.4* (± 25.0)
(R,R)-Formoterol 22.3* (±5.6) 278.5 (± 107.3) 12.1 (± 1.8) 2.53-fold for (R,R) 2.51-fold for (R,R) 1.08-fold for (S,S)
(S,S)-Formoterol 8.8* (± 5.1) 111.1 (± 61.6) 13.1 (± 0.4)
(R)-Salbutamol 338.2 (± 139.2) 597.6 (± 216.0) 2.2* (± 1.2) 1.30-fold for (R) 1.03-fold for (S) 1.23-fold for (S)
(S)-Salbutamol 260.8 (± 94.6) 614.7 (± 204.0) 2.7* (± 1.6)
(R)-Atenolol 410.1 (± 256.6) 536.0 (± 264.3) 1.7* (± 0.4) 1.83-fold for (R) 1.28-fold for (S) 2.12-fold for (S)
(S)-Atenolol 223.8 (± 79.8) 687.8 (± 190.6) 3.6* (± 0.8)
OCT1*3 (R,R)-Fenoterol no transport no transport no transport – – –
(S,S)-Fenoterol
(R,R)-Formoterol 77.8 (±27.5) 162.7 (± 43.6) 2.2 (± 0.2) 2.29-fold for (S,S) 1.27-fold for (S,S) 1.05-fold for (R,R)
(S,S)-Formoterol 178.5 (± 162.1) 205.9 (± 155.4) 2.1 (± 1.0)
(R)-Salbutamol no transport no transport no transport – – –
(S)-Salbutamol
(R)-Atenolol no transport no transport no transport – – –
(S)-Atenolol
OCT1*4 (R,R)-Fenoterol 9.6 (± 0.8) 151.7* (± 11.8) 16.3** (±2.1) 1.07-fold for (S,S) 1.72-fold for (R,R) 1.70-fold for (R,R)
(S,S)-Fenoterol 10.3 (±1.6) 88.4* (± 1.5) 9.6** (± 2.2)
(R,R)-Formoterol 52.8 (±7.4) 161.4* (± 35.9) 3.0 (± 0.4) 2.07-fold for (R,R) 1.74-fold for (R,R) 1.60-fold for (S,S)
(S,S)-Formoterol 24.5 (±19.7) 92.6* (± 63.3) 4.8 (± 1.3)
(R)-Salbutamol no transport no transport no transport – – –
(S)-Salbutamol
(R)-Atenolol no transport no transport no transport – – –
(S)-Atenolol
OCT1*7 (R,R)-Fenoterol 1.1 (± 0.5) 32.9 (±8.0) 38.7 (± 14.9) 3.09-fold for (S,S) 1.20-fold for (R,R) 1.10-fold for (S,S)
(S,S)-Fenoterol 3.4 (± 3.0) 27.5 (±7.4) 42.6 (± 25.8)
(R,R)-Formoterol 78.6 (±42.6) 788.7 (± 229.9) 14.3 (± 4.5) 2.00-fold for (R,R) 2.11-fold for (R,R) 1.28-fold for (R,R)
(S,S)-Formoterol 39.3 (±14.9) 373.8 (± 107.3) 11.2 (± 2.2)
(R)-Salbutamol 494.7 (± 222.4) 898.8 (± 218.3) 2.8** (± 1.6) 1.35-fold for (R) 1.01-fold for (R) 1.18-fold for (S)
(S)-Salbutamol 365.8 (± 136.9) 888.4 (± 154.0) 3.3** (± 1.9)
(R)-Atenolol 148.4 (± 63.9) 296.1** (± 53.2) 2.9* (± 1.0) 1.01-fold for (R) 2.01-fold for (S) 1.66-fold for (S)
(S)-Atenolol 146.6 (± 41.0) 596.0** (± 57.6) 4.8* (± 1.3)
OCT1*8 (R,R)-Fenoterol 3.1* (± 0.5) 204.2* (± 32.7) 68.8 (± 15.1) 1.48-fold for (R,R) 1.95-fold for (R,R) 1.17-fold for (R,R)
(S,S)-Fenoterol 2.1* (± 0.8) 104.7* (± 20.4) 58.9 (± 16.3)
(R,R)-Formoterol 44.5 (±5.6) 1589.3** (±188.1) 35.8* (± 1.0) 1.14-fold for (S,S) 1.45-fold for (R,R) 1.64-fold for (R,R)
(S,S)-Formoterol 50.8 (±3.4) 1099.0** (±200.8) 21.8* (± 4.3)
(R)-Salbutamol 210.9 (± 21.9) 1424.7** (±203.9) 6.8* (± 3.9) 1.06-fold for (S) 1.19-fold for (S) 1.12-fold for (S)
(S)-Salbutamol 223.4 (± 13.7) 1701.3** (±195.4) 7.6* (± 4.4)
(R)-Atenolol 299.3 (± 91.1) 1059.9** (±79.0) 4.0** (± 0.8) 1.10-fold for (S) 2.05-fold for (S) 1.73-fold for (S)
(S)-Atenolol 328.4 (± 49.7) 2177.0** (±60.8) 6.9** (± 0.9)
SEM, standard error of the mean; asterisks indicate statistical significance of the differences between the two enantiomers (Student's t-test; * p < 0.05, ** p < 0.01,
and *** p < 0.001).
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With regard to formoterol, allelic OCT1 variants with the exception
of OCT1*3 showed, similar to wild-type OCT1, a preference for the
pharmacologically active (R,R)-formoterol.
The uptake of salbutamol enantiomers by wild-type OCT1 and al-
lelic variants showed only minor stereoselectivity. It was reduced in
OCT1*2 and *7, and similar, or marginally higher, to the wild-type in
*8. An interesting observation was the markedly different substrate
affinity for OCT1*3 and *4: whereas fenoterol was transported to a
significant extent by *4, transport of salbutamol and atenolol was
completely absent in *3 and *4.
With atenolol, we observed a general preference for the pharma-
cologically active (S)-atenolol, both in terms of maximum transport
velocity and lower Km.
Our results indicate that stereoselectivity in transport is for the
OCT1 variants in most cases relatively similar to the wild-type, but a
few notable exceptions were found.
3.3. Differences in stereoselectivity between different organic cation
transporters
Beside OCT1, other cation transporters may also be involved in
cellular uptake and hepatic or renal elimination. We therefore studied
the extent of stereoselectivity in the transport of fenoterol, formoterol,
salbutamol, and atenolol by the related solute carriers OCT2, OCT3,
MATE1, and MATE2-K as well (Fig. 4, Table 5).
Fenoterol transport by OCT2 revealed the most drastic differences in
stereoselectivity: OCT1 showed an almost 2-fold higher vmax for (R,R)-
fenoterol. In contrast, OCT2 transported (S,S)-fenoterol with a 20-fold
higher vmax, while (R,R)-fenoterol transport was, in comparison,
negligibly low. This resulted in a 37-fold higher intrinsic clearance for
the presumably inactive (S,S)-enantiomer. The strong difference is
particularly surprising given the high (70%) protein sequence identity
shared between OCT1 and OCT2. For OCT3, the maximum transport
velocity for both fenoterol enantiomers was similar to that of OCT1,
while the Km was about 10-fold higher. The antiporters MATE1 and
MATE2-K transported fenoterol with significantly higher capacity but
also higher Km, whereby they showed a modest preference for the (R,R)-
enantiomer.
Transport of formoterol by OCT2, OCT3, MATE1, and MATE2-K was
completely absent or too low to determine pharmacokinetic parameters
reliably.
With salbutamol, a differential enantiopreference was observed for
both OCT2 and OCT3: While OCT1 and all OCT1 variants showed no
stereoselectivity or only a minor degree of stereoselectivity towards (S)-
salbutamol, OCT2 and OCT3 displayed significantly higher (3.5-fold
and 4.6-fold) vmax values for (R)-salbutamol relative to (S)-salbutamol.
This resulted in 1.9- and 5.9-fold greater intrinsic clearances for the
pharmacologically active (R)-enantiomer. Comparable to fenoterol,
MATE transporters showed a low affinity-high capacity transport of
salbutamol, in this case with a preference for (S)-salbutamol.
Transport of atenolol by OCT2 was characterised by a lower vmax
compared to OCT1 and a similar preference for (S)-atenolol. While
MATE2-K exhibited OCT1-like atenolol transport, it was particularly
surprising that MATE1 transported atenolol with a strongly increased
capacity and a preference for the pharmacologically inactive (R)-ate-
nolol.
In conclusion, unlike the relatively moderate differences in stereo-
selectivity among allelic variants of OCT1, a more complex picture
Fig. 4. Comparison of Km (left) and vmax (right) between wild-type OCT1 and related cation transporters for (a) fenoterol, (b) salbutamol, and (c) atenolol.
Formoterol transport kinetic parameters could not be determined with high precision and are given in Table 5 only.
O. Jensen, et al. Biochemical Pharmacology 171 (2020) 113731
7
with, in some instances, very strong degrees of stereoselectivity was
seen with other solute carriers. Particularly interesting was the ob-
served opposite stereoselectivity between the highly homologous (70%
shared amino acid sequence identity) transporters OCT1 and OCT2 for
some substrates. In addition, large changes in transport activity and
stereoselectivity were observed between the two hepatic uptake trans-
porters OCT1 and OCT3. These results indicate a completely non-uni-
form behaviour among relatively similar transporters with relatively
similar chemical compounds.
4. Discussion
In a comprehensive study on stereospecificity in OCT-mediated
transport, we have assessed a selection of beta-adrenergic receptor-
targeting drugs that are always or often administered as racemates in
clinical drug therapy. Our data is indicative of notable stereospecificity
in OCT1-mediated transport, with the most common genetic variants of
OCT1 showing similar enantiomer preferences to the wild-type in
overall but with exceptions. A general trend, however, was not evident,
and at present, stereoselective uptake by organic cation transporters
must be determined for every substrate individually. Enantiospecificity
between different solute carriers differed surprisingly strongly, with the
partially opposing enantiomer preferences between the closely related
OCT1, OCT2, and OCT3 being of particular interest. As proposed re-
cently, multiple substrate binding sites might contribute to the observed
stereoselectivity in transport by organic cation transporters [16,17],
and the amino acids in the substrate binding cleft are crucial for OCT
substrate recognition and transport [18]. Moreover, pharmacophore
modelling showed that organic cation transporters interact with mole-
cules with pronounced three-dimensional structures [19], compared to
organic anion transporters. The stereoselectivity in transport of some of
the substrates analysed in our study is compatible with a three-di-
mensional substrate recognition site.
Generally, the therapeutic effects for almost all beta2-adrenergic
receptor agonists currently in clinical use are attributed to the (R)-en-
antiomers, while the (S)-enantiomers were found to be almost inactive
at the beta2-adrenergic receptor [20]. Accordingly, for the anti-
adrenergic drugs atenolol and acebutolol, it is the (S)-enantiomers that
function as beta-adrenergic receptor antagonists [21].
As the pharmacokinetics of a drug are dependent on a number of
stereoselective processes in the organism, it is of great relevance to
compare how our in vitro results relate to clinical findings and data on
stereoselectivity in the biotransformation of the studied drugs.
For fenoterol, no data was found in the literature regarding ste-
reoselective pharmacokinetics in humans. However, in vitro sulfo-
conjugation of fenoterol was stereoselective, with the preferred en-
antiomer depending on the sulfotransferase and the site of sulfation
[22]. Our data showed that wild-type OCT1 transports the pharmaco-
logically active enantiomer, (R,R)-fenoterol, with almost double the
maximum transport velocity compared to the (S,S)-enantiomer but with
proportionally lower affinity. Interestingly, this was nearly the opposite
for OCT1*2, a variant that is particularly common in people of Central
and South American origin [7]. However, for both wild-type OCT1 and
the *2 variant, no stereoselectivity was seen in the intrinsic clearance.
Thus, it is difficult to predict from this data which implication the OCT1
related stereoselectivity will have on clinical pharmacokinetics and
Table 5
Kinetic parameters for the transport of racemic (anti)adrenergic drugs by OCT1-related transporters.








OCT2 (R,R)-Fenoterol 21.2 (±10.6) 9.9** (±2.7) 0.6** (± 0.2) 2.37-fold for (R,R) 19.6-fold for (S,S) 36.7-fold for (S,S)
(S,S)-Fenoterol 8.9 (± 0.6) 194.1** (± 11.6) 22.0** (± 2.6)
(R,R)-Formoterol no transport no transport no transport – – –
(S,S)-Formoterol
(R)-Salbutamol 679.0* (± 92.5) 11766.7** (± 1256.3) 17.5** (± 0.7) 1.88-fold for (R) 3.45-fold for (R) 1.86-fold for (R)
(S)-Salbutamol 361.1* (± 66.9) 3407.3** (±682.2) 9.4** (± 0.2)
(R)-Atenolol 290.6 (± 92.9) 609.0* (± 149.5) 2.4* (±0.6) 1.68-fold for (R) 1.23-fold for (S) 1.96-fold for (S)
(S)-Atenolol 172.9 (± 35.7) 749.3* (± 113.8) 4.7* (±0.9)
OCT3 (R,R)-Fenoterol 15.2 (±2.5) 76.5** (± 7.4) 5.3* (±0.8) 1.07-fold for (R,R) 1.85-fold for (R,R) 1.71-fold for (R,R)
(S,S)-Fenoterol 14.2 (±2.9) 41.3** (± 4.1) 3.1* (±0.5)
(R,R)-Formoterol no transport no transport no transport – – –
(S,S)-Formoterol
(R)-Salbutamol 356.8 (± 62.7) 2418.7* (± 317.4) 7.1* (±1.3) 1.45-fold for (S) 4.60-fold for (R) 5.92-fold for (R)
(S)-Salbutamol 518.9 (± 195.1) 526.3* (± 81.0) 1.2* (±0.3)
(R)-Atenolol no transport no transport no transport – – –
(S)-Atenolol
MATE1 (R,R)-Fenoterol 111.3 (± 16.3) 2091.3 (± 133.7) 19.8 (±3.5) 1.08-fold for (R,R) 1.15-fold for (R,R) 1.14-fold for (R,R)
(S,S)-Fenoterol 103.5 (± 18.0) 1822.3 (± 360.6) 17.4 (±1.4)
(R,R)-Formoterol 231.5 (± 114.7) 301.5 (± 152.3) 2.6 (± 1.6) 1.49-fold for (S) 1.48-fold for (S,S) 1.04-fold for (R,R)
(S,S)-Formoterol 343.8 (± 321.0) 447.3 (± 363.4) 2.5 (± 1.2)
(R)-Salbutamol 2545.7 (± 1079.7) 7313.3 (± 2260.4) 3.1* (±0.4) 2.00-fold for (S) 2.35-fold for (S) 1.19-fold for (S)
(S)-Salbutamol 5081.0 (± 3073.9) 17216.7 (±9812.9) 3.7* (±0.4)
(R)-Atenolol 381.5 (± 68.7) 8326.3** (±775.1) 22.6 (±2.4) 1.01-fold for (S) 1.19-fold for (R) 1.07-fold for (R)
(S)-Atenolol 384.7 (± 137.9) 7009.3** (±916.5) 21.2 (±4.3)
MATE2-K (R,R)-Fenoterol 76.4 (±4.1) 728.6* (± 92.9) 9.5** (± 0.8) 1.10-fold for (R,R) 1.42-fold for (R,R) 1.28-fold for (R,R)
(S,S)-Fenoterol 69.5 (±1.1) 511.7* (± 47.0) 7.4** (± 0.7)
(R,R)-Formoterol 181.7 (± 158.1) 77.6 (±38.5) 1.0 (± 0.7) 5.09-fold for (R,R) 2.30-fold for (R,R) 1.10-fold for (S,S)
(S,S)-Formoterol 35.7 (±12.5) 33.7 (±6.1) 1.1 (± 0.6)
(R)-Salbutamol 999.4 (± 709.7) 1855.8 (± 1069.2) 2.2 (± 0.5) 1.39-fold for (S) 1.88-fold for (S) 1.23-fold for (S)
(S)-Salbutamol 1386.2 (± 921.9) 3487.0 (± 2105.0) 2.7 (± 0.3)
(R)-Atenolol 150.1 (± 40.5) 1060.9* (± 128.7) 7.6* (±1.1) 1.04-fold for (S) 1.30-fold for (S) 1.26-fold for (S)
(S)-Atenolol 155.7 (± 45.2) 1383.7* (± 200.7) 9.6* (±1.2)
SEM, standard error of the mean; asterisks indicate statistical significance of the differences between the two enantiomers (Student's t-test; * p < 0.05, ** p < 0.01,
and *** p < 0.001).
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pharmacodynamics. At the very low therapeutic concentrations, the
differences in Km may have a stronger effect than those in vmax or in-
trinsic clearance. Very interesting is the large degree of stereospecificity
(37-fold higher intrinsic clearance for (S,S)-fenoterol) observed for
OCT2, a transporter that is highly expressed in the kidneys. However,
given the relatively low renal clearance of fenoterol, this may not be of
greater relevance in clinical therapy.
Formoterol plasma concentrations were 1.5-fold higher for the
(S,S)-enantiomer than for the (R,R)-enantiomer one hour following
inhalative dosing of the 1:1 mixture of (R,R)- and (S,S)-formoterol in
humans [23]. Both after inhalative and oral administration, the excre-
tion of unchanged drug in urine was greater for (S,S)- than for (R,R)-
formoterol, but excretion as formoterol glucuronide conjugate was
greater for (R,R)- over (S,S)-formoterol [14,24,25]. The latter is parti-
cularly interesting in light of the fact that glucuronide conjugation in
liver microsomes was found to be more than 2-fold higher for the (S,S)-
enantiomer [14]. The total excretion (unchanged and as glucuronide
conjugate) after oral dosage was greater for (R,R)-formoterol. There
appeared to be a significant difference between male and female par-
ticipants [26]. The enantiopreference for (R,R)-formoterol in metabo-
lism and the 1.2-fold higher OCT1-mediated intrinsic clearance of
(R,R)-formoterol could together contribute to higher plasma con-
centrations of (S,S)-formoterol.
Salbutamol is probably the most widely-used short-acting beta-mi-
metic drug. Upon administration of the racemate, significant differ-
ences in pharmacokinetics were found, with up to 8-fold higher sys-
temic exposure (AUC) for the (S)- versus the (R)-enantiomer after
inhalative dosage, and more than 20-fold following oral administration
[27–29]. The larger systemic (S):(R) ratio after oral dosage is mostly a
result of a stereoselective first-pass metabolism, but pH-dependent
chiral inversion of the (R)- to the (S)-enantiomer was also found to
occur to a smaller extent (ca. 6%) in the stomach but not following
inhalation [27,30–33]. The plasma levels of (R)- and (S)-salbutamol
were higher when given in enantiopure form compared to the racemate,
suggesting a possible influence of each enantiomer on the clearance of
the opposite enantiomer when administered as racemic mixture [28].
With respect to the biotransformation, sulphate conjugation in the in-
testine and liver was 12-fold higher for (R)-salbutamol [33–36]. Ste-
reospecificity in presystemic metabolism in the lungs was observed in
vitro but not confirmed in humans [36,37]. A common single nucleotide
polymorphism (rs1975350) in SULT1A3, the main metabolising en-
zyme, had no significant effect on the stereospecificity of the pharma-
cokinetics [33,38]. We observed a small but probably negligible en-
antiopreference for the (S)-enantiomer by OCT1, MATE1, and MATE2-
K, which, hence, do not appear to contribute to the higher systemic
exposure for (S)-salbutamol. However, the almost 6-fold higher in-
trinsic clearance of (R)-salbutamol observed for OCT3, another hepatic
uptake transporter, is in line with the clinical observations. In ac-
cordance is also the almost 2-fold higher intrinsic clearance of (R)-
salbutamol for OCT2, which may very well be of relevance, given the
comparatively high renal clearance of unchanged salbutamol (46% for
(R)-salbutamol; 55% for (S)-salbutamol [39]).
Acebutolol plasma and urine concentrations were both 1.2-fold
higher for the (S)-enantiomer following oral administration of racemic
acebutolol, which corresponded to a 1.2-fold higher oral clearance of
(R)-acebutolol. This may be explained by stereoselectivity in first-pass
metabolism and renal excretion of the main metabolite diacetolol. For
diacetolol, Cmax and renal clearance was greater for the (R)-enantiomer;
no significant difference was seen with respect to plasma AUC [40]. The
(S):(R) ratio for urinary excretion correlated with age in a subsequent
study involving elderly participants, possibly as a result of altered ste-
reoselectivity in tubular secretion [41]. A different study preceding the
above two found no stereoselectivity in the disposition of acebutolol
and diacetolol following single and repeated oral administration [42].
Plasma protein binding of acebutolol appears not to be stereoselective
and the majority of the drug (greater than 85%) is found in the
unbound fraction [21]. Our data showed a 1.5-fold higher intrinsic
clearance of (S)-acebutolol for OCT1.
With respect to atenolol, it was found in several independent studies
that the plasma AUCs were slightly (1.1-fold) higher for (R)-atenolol
following a single oral dose of the racemate [43–46]. In the study
conducted by Mehvar et al., a slightly (1.1-fold) but statistically sig-
nificantly higher renal clearance of the (S)-enantiomer was proposed as
possible underlying reason; however, no significant difference in the
renal clearance was seen in the study by Boyd et al. [43,45]. Intrigu-
ingly, exercise appeared to alter the stereoselectivity of atenolol phar-
macokinetics, as the (R):(S) ratio of the mean plasma concentrations
changed from 1.1 at rest to 0.7 following exercise [47]. Given its more
hydrophilic structure, atenolol is almost exclusively eliminated un-
changed in urine, a process that appears to be modestly stereoselective
towards the (R)-enantiomer [21,43,45]. A possible interaction between
the enantiomers in a racemic mixture, as seen for salbutamol, appar-
ently does not occur with atenolol [44,46]. A high degree of stereo-
selectivity was observed in the glucuronidation of atenolol, as 3.1-fold
more of the (S)-glucuronide conjugate was formed after incubation of
the racemate with UGT1A9 [48]. These clinical observations may
partially be explained by the higher intrinsic clearance of the (S)-en-
antiomer via OCT1 (including variants) and OCT2, but the almost 2-
fold difference in cell uptake via OCT2 is apparently not fully reflected
by the pharmacokinetic data.
Altogether, our in vitro data on stereospecificity in organic cation
transporter-mediated drug transport is in accordance with, and may
partially account for, stereospecificity in clinical pharmacokinetics,
especially with respect to formoterol, salbutamol, and atenolol. It is
notable that, for many racemic drugs, the pharmacokinetics were not
analysed with regard to stereospecificity, despite receptor interactions
being stereoselective in most cases. Here we showed that membrane
transport of several beta-(anti)adrenergic drugs can be stereospecific,
but it appears that stereoselectivity is more pronounced in bio-
transformation of some of the studied drugs. From a molecular per-
spective, the observed stereoselectivity in membrane transport may
indicate a relatively tight interaction between solute carriers and some
substrates. This could be explored in more detail using computational
molecular modelling as a follow-up to this study.
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A double‑flp‑in method for stable 
overexpression of two genes
ole Jensen1,4*, Salim Ansari1,4, Lukas Gebauer1,4, Simon F. Müller2, Kira A. A. T. Lowjaga2, 
Joachim Geyer2, Mladen V. Tzvetkov1,3 & Jürgen Brockmöller1
Overexpression of single genes in mammalian cells is widely used to investigate protein function in 
basic and applied biosciences and in drug research. A better understanding of interactions of two 
proteins is an important next step in the advancement of our understanding of complex biological 
systems. However, simultaneous and robust overexpression of two or more genes is challenging. The 
Flp-In system integrates a vector into cell lines at a specific genomic locus, but has not been used for 
integration of more than one gene. Here we present a modification of the Flp-In system that enables 
the simultaneous targeted integration of two genes. We describe the modification and generation of 
the vectors required and give the complete protocol for transfection and validation of correct genomic 
integration and expression. We also provide results on the stability and reproducibility, and we 
functionally validated this approach with a pharmacologically relevant combination of a membrane 
transporter facilitating drug uptake and an enzyme mediating drug metabolism.
The use of immortal cell lines has become an indispensable tool in basic and applied biomedical research in the 
last decades. In vitro experiments with cell lines are often used to generate new hypotheses, or to validate in vivo 
findings with the possibility to manipulate under well-defined  conditions1,2. In drug research, cell lines over-
expressing specific genes are an important screening tool. Overexpression can be achieved via numerous ways, 
with transient or stable expression of the gene of  interest3,4. However, many transgene-introducing techniques 
come along with obvious disadvantages: Reproducibility, efficiency, and anisogeneity are only a few of them. 
Stable transfection, based on non-viral site-specific recombination circumvents these  disadvantages5–8. This can 
be accomplished by the use of recombinases, such as Cre from the P1 bacteriophage or Flp from Saccharomyces 
cerevisiae. These enzymes can catalyze the recombination of two DNA strands at specific recognition sequences, 
making it possible to insert, excise, invert, or translocate DNA  segments9,10. The Flp-In system (Thermo Fisher 
Scientific, Darmstadt, Germany) uses the Flp recombinase to generate isogenic cell lines, in which the gene of 
interest integrates at a single well-defined locus within the host cell  genome11–15. One highlight of the Flp-In 
system is the fact that the promoter, which drives the expression of the resistance against the selection antibiotic 
hygromycin, is present upstream of the recombination site in the host cell genome. This ensures the expression 
of the resistance gene only in successfully transfected cells that carry and stably overexpress the gene of interest. 
Since the promoter and the locus of genomic integration are the same for all constructed cell lines, the expression 
level of the genes of interest and general isogeneity are well  comparable11.
The Flp-In system, so far, was not applicable when two or more genes of interest are to be overexpressed in a 
controlled manner, although that option actually exists. The Flp recombination target (FRT) site not only per-
sists after the integration of a vector, but even a second FRT site is introduced upon vector integration (Fig. 1a). 
Modifying the Flp-In vector with internal ribosomal entry sites (IRES) would be one option to integrate and 
overexpress several  genes16, but the expression efficiency has been shown to depend strongly on the distance 
between IRES element and translation start site. The expression of the genes is highly dependent on the order 
in the operon and requires a precise  design17,18. The simple transfection of two kinds of the same vector is also a 
feasible  approach19. However, without a second selection antibiotic resistance gene, there is no easy way to select 
cell clones successfully transfected with both vectors. Excessive and sophisticated validation would be needed to 
ensure the presence of both genes of interest and their expression levels.
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Our goal was to develop a simple and robust protocol to transfect two different genes in a modular concept 
(Fig. 1). To achieve this, we introduced a one-nucleotide deletion into the original pcDNA5/FRT vector, which 
was necessary for correct expression of the hygromycin resistance gene from the promoter of the second vector. 
The second vector did not only include the promoter to drive hygromycin expression after correct integration 
but also the gene for puromycin resistance. To exclude that the puromycin resistance was already expressed upon 
transient presence of the vector, we inserted one nucleotide between the translation start site and the coding 
sequence of the puromycin resistance gene, which leads to a frame shift and to early termination of translation. 
After successful integration in the correct order, the deletion and the insertion will neutralize themselves and 
expression of both resistance genes will ensure proper selection (Fig. 2). These vectors can be used for the easy 
and replicable transfection of two genes for multifarious applications to study interactive actions of almost any 
two proteins. As proof of concept, we show the stability of the double transfection with two pairs of fluorescent 
proteins, we compare expression levels of single- to double-transfected genes, and we provide a scientifically 
relevant example for the application of this method to study the interaction between cell uptake transport and 
metabolism of the anti-malarial prodrug proguanil (Fig. 1). The scope of this technique, however, is much broader 
Figure 1.  The principle and an application example of the Double-Flp-In technique. (a) The integration of 
two simultaneously transfected plasmids encoding two genes of interest can be achieved into a single Flp 
recombination target (FRT) site. (b) As a proof of concept, we transfected HEK293 cells with the coding 
sequences for the human organic cation transporter 1 (OCT1) and cytochrome P450 isoform 2C19 (CYP2C19). 
Together, these proteins will facilitate the uptake of the anti-malarial prodrug proguanil and the metabolism to 
its active metabolite cycloguanil. Protein icons of OCT1 and CYP2C19 and chemical structures were created 
using The PyMOL Molecular Graphics System, Version 1.3, Schrödinger, LLC, www.pymol .org.
Figure 2.  Illustration of the total construct and the reading frame shift introduced to ensure expression of 
both resistance genes only in case of successful double transfection. The reading frame shift introduced into 
the both FRT vectors leads to expression of both resistance genes only after successful stable integration (green 
ticks), and not before (red x). The introduction of an additional C between the start codon (ATG) and the FRT 
site is indicated. This allows reliable selection of double-transfected cell clones (sequence elements for bacterial 
expression are not shown) and expression of genes of interest cloned into the multiple cloning sites (MCS) from 
identical promoters. (PSV40 SV40 promoter, SV40 pA polyA signal of SV40, PCMV CMV promoter; bGH pA 
polyA signal of bovine growth hormone).
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and includes any combination of substance uptake and metabolism, substance metabolism and efflux, or any 
other interaction in intermediary metabolism or cell signaling.
Results
Below, we recapitulate the principles of our approach and explain some critical items in the generation of the 
stable double transfection. The system was then tested and validated by three gene pairs, a pair of two membrane 
bound fluorescently labeled transport proteins, a pair of two cytosolic fluorescent proteins used particularly to 
prove the stability of stable expression, and as a pharmacologically relevant application a pair of a membrane 
transporter (OCT1) and a drug-metabolizing enzyme (CYP2C19).
Strategy for the Double-Flp-In and the generation of the required vectors. To generate the Dou-
ble Flp-In system we took advantage from the fact that by the integration of a single plasmid in the classical 
Flp-In system, the FRT site is not destroyed, but is even duplicated. This enables the integration of at least one 
additional expression vector in one of the FRT sites.
Therefore, we engineered a second expression vector (pcDNA5/FRTpuro-fs) carrying a puromycin resistance 
gene. This additional expression vector was created based on the backbone of the existing pcDNA5/FRT vector 
by replacing the hygromycin with a puromycin resistance gene (Fig. S1). Additionally, a SV40 promoter region, 
as present in the host cell genome, was included in the vector to facilitate the expression of the hygromycin 
resistance gene after chromosomal integration of both vectors. To ensure that this promoter will not drive expres-
sion of the puromycin resistance gene in the non-integrated transient state, we generated a reading-frame shift 
by introducing a single base between the start codon ATG and the puromycin resistance coding sequence. In 
addition, a one-base deletion was introduced into the original pcDNA5/FRT vector, resulting in the pcDNA5/
FRThygro-fs plasmid (Fig. 2). This frame shift was necessary to restore the distance between the ATG from the 
pcDNA5/FRTpuro-fs and the hygromycin resistance coding sequence from the pcDNA5/FRThygro-fs. This enables 
the expression of the hygromycin resistance of the downstream plasmid by the SV40 promoter introduced by 
the upstream plasmid.
Transfection protocol optimization. Since the main difference between the transfection protocol for 
one vector as provided by the manufacturer and our approach is the second vector and the requirement of a 
second antibiotic, we had to titrate the antibiotics concentrations required to eliminate non-resistant (i.e. not 
correctly transfected) HEK293 cells by a simple checkerboard  approach20. The result was a slightly reduced 
concentration of hygromycin compared to the one typically used for single transfection of HEK293 cells in 
our laboratory for initial selection of cell clones (200 µg/mL instead of 300 µg/mL). During initial cultivation 
of cell clones, we also used a reduced hygromycin concentration of 50 µg/mL instead of typically 100 µg/mL. 
The concentration of puromycin was more difficult to obtain, because the HEK293 cells were highly sensitive to 
puromycin treatment. The final concentration used for the double transfection was 0.25 µg/mL during selection 
and 0.025 µg/mL during the cultivation period until complete validation of the cell clones.
Regarding the amounts of DNA used for transfection, initial experiments showed that an increased amount of 
transfected vector DNA, compared to the single transfection protocol, is not required and only leads to unwanted 
multiple integrations due to the surplus of vector DNA (data not shown). The ratio of 400 ng pcDNA5 vector(s) 
to 3.6 µg pOG44 (encoding the transient expression of the Flp recombinase) was maintained as stated in the 
original transfection protocol by the manufacturer. In case of double transfections, the plasmids were mixed 
and transfected in an equimolar ratio.
In a preliminary experiment, selection of double-transfected cells was performed with only hygromycin and 
22 out of 25 cell clones showed proper expression of both genes of interest (eGFP and tdTomato).
Double transient vs. double stable transfection. For the initial testing of the created plasmids, we 
double-transfected the cyan or the yellow fluorescent protein (CFP, YFP) tagged sodium/bile acid cotransporter 
(NTCP) into HEK293 cells and compared the transient to the stable transfection. The fluorescent cells were 
analyzed by microscopy (Fig. 3a). The stable transfection and clonal selection of cells provided a homogeneous 
signal with highly comparable signals per individual cell. Moreover, the cells were positive for both transfected 
fluorescent proteins. On the other side, transiently transfected cells were characterized by a limited efficiency as 
not all cells showed a fluorescence signal and by a high signal variability within the fluorescent cells, making it 
difficult to find microscopy settings for an average signal.
Stability of the genomic integration. The stability of double transfection was determined by flow 
cytometry and confocal microscopy. Cells validated by flow cytometry had been transfected with pcDNA5/
FRTpuro-fs::tdTomato and pcDNA5/FRThygro-fs::eGFP and double-positivity was compared to empty vector-
transfected cells (Fig. 3b). Results showed a stable expression and presence of both fluorescence proteins over 30 
passages, regardless of whether the selection antibiotics used for clonal selection was present in the cell culture 
medium or not. After 25 passages, 99.95% (± 0.03% SEM) of the cells cultivated in medium containing hygro-
mycin and puromycin, and 99.5% (± 0.03% SEM) of the cells cultivated in medium without selection antibiotics 
were double-positive (Fig. 3c). Similar results were obtained when the stability of the integration was analyzed 
in the cells double-transfected with CFP- and YFP-tagged NTCP. Here, the signals were analyzed by fluorescence 
microscopy. After 25 passages, the amount of double-positive cells was not significantly different (unpaired 
t-test, p > 0.05, GraphPad Prism version 5.01 for Windows, GraphPad Software, La Jolla, California, USA), in 
cells cultured with and without selection antibiotics (98.0% ± 1.2% SEM and 96.7% ± 1.8% SEM) (Fig. 3d). Alto-
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gether, although a very minor decline appeared to exist according to the nominal values (Fig. 3c,d), this decline 
was not significant.
Genomic validation. The integration of both vectors in the intended order was confirmed and different 
cases of multiple integrations were analyzed by PCR. The PCRs were established to detect all possible different 
arrangements of the two integrated vectors. For this, primers were designed binding at specific elements only 
Figure 3.  Microscopic and flow cytometric analyses of double-transfected cell lines overexpressing 
fluorophores. (a) Simultaneous co-transfection of the sodium/bile acid cotransporter (NTCP) tagged with 
cyan or yellow fluorescent protein (CFP, YFP) into HEK293 cells reveals an even expression in virtually all 
cells. Transient co-transfection of NTCP-CFP and NTCP-YFP illustrates the heterogeneity in strength and 
distribution of transient transfections, compared to the stably integrated double-transfection. (b) HEK293 cells 
showed consistent overexpression of tdTomato and eGFP during the early selection process by live-cell imaging. 
(c) Flow cytometric analysis of the integration of the genes encoding eGFP and tdTomato showed a high 
stability over 30 passages (mean ± SEM). (d) Stability of genomic integration of simultaneously transfected CFP- 
and YFP-tagged sodium/bile acid cotransporter (NTCP) was additionally confirmed by microscopic analysis 
(mean ± SEM). Figures (c) and (d) were created using GraphPad Prism version 5.01 for Windows, GraphPad 
Software, La Jolla, California, USA, www.graph pad.com.
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present in the FRT locus of the host cell line or in one of the two expression vectors. This led to two reactions 
confirming the successful integration of both vectors in the intended order and three reactions detecting all 
setups of multiple integrations (Fig. 4a). This genomic validation assay was planned in a way which allowed to 
perform four of the reactions simultaneously as part of a multiplex polymerase chain reaction since these four 
reactions share in total two forward and two reverse primers, and their amplicons differ sufficiently in length. 
This provides a suitable basis for initial screening of cell lines covering one integration PCR and all three multiple 
integration PCRs.
Next, we generated OCT1/CYP2C19 overexpressing cell lines in several combinations to perform functional 
studies later. For each cell line, a number of cell clones were screened by multiplex PCR. The result of this screen-
ing is shown in Fig. 4b for all cell clones used for transport experiments in this study. Considering the known 
limitations of multiplex PCR, we subsequently confirmed the results by performing single PCRs for each reaction 
and each cell line. Figure 4c shows the exemplary result of this single analysis for one of the analyzed clones which 
confirmed the findings of the multiplex reaction. Single PCRs for all other double-transfected cell clones used 
in this study are shown in Fig. S2. Sanger sequencing of the regions around the three FRT sites showed proper 
arrangement (Fig. S3), as indicated by PCR screening.
Quantification of gene expression. In a next step, we addressed the question of whether the integration 
of a second expression vector and the expression of a second gene of interest affects the expression of the first 
gene of interest and vice versa. For this, we analyzed the gene expression of selected cell clones, which had passed 
the genomic validation process. In particular, we compared the expression of OCT1 and CYP2C19 of single 
transfected cell lines to the double transfected ones and moreover analyzed whether the order of integration 
of both vectors affects the expression of the genes of interest (Fig. 4d). The OCT1 expression levels were highly 
similar among all analyzed cell lines. In the first place, the number of integrated vectors did not significantly 
affect the OCT1 expression (One-way ANOVA with post-hoc Tukey test) and secondly, the order of integra-
tion as shown by comparison of the OCT1/CYP2C19 (OCT1 in the pcDNA/FRTpuro and CYP2C19 in pcDNA/
FTRhygro) and the CYP2C19/OCT1 (CYP2C19 in the pcDNA/FRTpuro and OCT1 in pcDNA/FTRhygro) cell lines 
did also not alter the level of gene expression. The same findings were made for the expression of CYP2C19. 
Its relative expression in all double-transfected cell lines shows no significant difference in comparison to the 
CYP2C19 only transfected cell line and the order of integration did not affect its expression as well. Moreover, 
the basal expression of OCT1 and CYP2C19 genes was negligible (not detected) in empty vector-transfected cell 
lines (data not shown) and cell lines not overexpressing these genes.
Functional validation. For the functional validation of this novel overexpression system, we performed 
cellular uptake and metabolism experiments with the OCT1/CYP2C19 generated cell lines. For this, the uptake 
via OCT1 and the metabolic activation of proguanil to cycloguanil via CYP2C19 were analyzed (Fig. 5). Both, 
the transporter and the phase I enzyme were previously known to be involved in the uptake and metabolism of 
 proguanil21,22. Uptake of proguanil was remarkably increased in OCT1 overexpressing compared to non-over-
expressing cell lines. However, the uptake as indicated by the reduction of extracellular proguanil as well as the 
accumulation of intracellular proguanil was highly similar in all different OCT1 overexpressing cell lines. This 
could be regardless of whether the cells were single or double transfected, of the order of integration (OCT1/
CYP2C19 or CYP2C19/OCT1) and of whether the second expression vector was empty or carrying CYP2C19. 
Accumulation of cycloguanil was only observed in cell lines overexpressing CYP2C19. Nevertheless, it was 
highly increased in double-transfected cell lines co-overexpressing OCT1 as compared to cell lines overexpress-
ing CYP2C19 alone. Additionally, a time-dependent increase of extracellular cycloguanil was also observed as a 
result of passive diffusion or the presence of endogenous transporters facilitating the export of cycloguanil. Both, 
the intracellular accumulation as well as the extracellular increase of cycloguanil, were indistinguishable within 
the two OCT1 and CYP2C19 overexpressing cell lines, but also within the single CYP2C19 and CYP2C19/
mock-double transfected cell lines. Pharmacologically, these experiments demonstrate how remarkable a drug 
metabolic activity in a cell system is enhanced by combined overexpression of the relevant transport protein with 
the drug-metabolizing enzyme, compared to the enzyme alone.
Discussion
We established a robust transfection system for simultaneous overexpression of two different genes using sev-
eral modifications of the Flp-In  system5–8, and confirmed the long-term stability of gene expression even in the 
absence of selection antibiotics. We demonstrated that the integration of a second expression vector in the Flp-In 
locus is not only possible, but also that expression of two genes of interest does not affect each other’s expression, 
and expression levels are highly similar to single-overexpressing cells. Our protocol allows the generation and 
validation of isogenic cell lines within approximately four weeks. This system provides an ideal tool for studying 
the interaction of two proteins under well-defined conditions.
As one application from the area of pharmacogenomics pathway analysis, we demonstrated its value for 
understanding the distinct interactions between transporter mediated drug cell uptake and drug metabolism 
on the example of the uptake of proguanil and its metabolomic activation to cycloguanil. The obtained results 
were highly comparable to experiments performed with primary human  hepatocytes22, indicating our system 
might be suitable to partially replace drug metabolism analysis in primary human tissue. Moreover, only in the 
combination with the right transporter, the CYP2C19 overexpressing cells are highly efficient in biotransforma-
tion. Such systems may even be further developed for biosynthetic production purposes.
In previous publications, researchers showed the possibilities of multigene expression using the Flp-In sys-
tem by two succeeding  transfections19. This approach, however, is not just more laborious, since it requires two 
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Figure 4.  Validation of the double-Flp-In cell clones on genomic and transcriptional level. (a) Simultaneous 
integration of two vectors my lead to at least four unwanted combinations (red ‘x’) besides the intended one 
(green tick). (b) Screening of cell clones by multiplex PCR allowed verification of single integration of each 
vector (EV empty vector; primers as given in Table 1). (c) More precise single PCRs were used to validate 
correct integration for each cell clone, as shown here using one representative example. (d) OCT1 and CYP2C19 
gene expression analysis of double-Flp-In cell clones compared to single transfected cell lines. Results of n = 3 
independent experiments are shown. Gene expression was normalized to the OCT1 only or CYP2C19 only 
transfected cell lines, respectively. Figure (d) was created using GraphPad Prism version 5.01 for Windows, 
GraphPad Software, La Jolla, California, USA, www.graph pad.com. Protein icons of OCT1 and CYP2C19 were 
created using The PyMOL Molecular Graphics System, Version 1.3, Schrödinger, LLC, www.pymol .org.
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consecutive transfections, it also goes along with clear disadvantages, when a single vector backbone is used: 
the lack of specific selection antibiotics for each gene of interest and the lack of validation on genomic level (and 
the early exclusion of clones with multiple integrated vectors from the validation process). The new vectors with 
novel frame shift matches could be conveniently used by other scientists, who used the Flp-In system as one 
part of their strategy for generating multiple  transfectants23,24. These projects could profit from the simultaneous 
transfection of two Flp-In vectors, since the intermediate validation and screening procedure after conventional 
transfection could be skipped. In contrast to IRES-dependent expression of two genes of interest from a bicis-
tronic vector, there is no effect on the expression level in our  system18.
Depending on the purpose, the here presented method can easily be modified or refined. The Flp-mediated 
recombination could be complemented by other recombination enzymes using specific integration sites. Also, 
modification of the FRT site could modulate specificity of the location of vector  integration25. This means that 
several divergent genomic FRT sites could serve as target sites for analogously divergent FRT sites in vector, and 
recombination could be facilitated by the same enzyme at different sites simultaneously. The frame-dependent 
expression of the resistance gene only in the case of successful genomic integration is limited to two frames in 
the case of the FRT site—the third frame leads to a premature stop within the recombination site. Sequence 
Figure 5.  Transport and metabolism of proguanil via two simultaneously transfected genes. Overexpression 
of OCT1 facilitates the uptake of the anti-malarial prodrug proguanil, while overexpression of CYP2C19 
catalyzes the metabolism of proguanil to cycloguanil. Accumulation of cycloguanil was only present in cells 
overexpressing OCT1 as well as CYP2C19. Results of n = 3 independent experiments are shown. Figure was 
created using GraphPad Prism version 5.01 for Windows, GraphPad Software, La Jolla, California, USA, www.
graph pad.com. Protein icons of OCT1 and CYP2C19 were created using The PyMOL Molecular Graphics 
System, Version 1.3, Schrödinger, LLC, www.pymol .org.
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modifications or the use of other recombination enzymes with needs for different recombination sites could 
solve this issue potentially.
Limitations of the here presented method, such as the treatment with two antibiotics simultaneously, could 
apply to very sensitive cell lines. However, the use of only hygromycin could be sufficient to select double-trans-
fected cells, because the resistance gene is only expressed after integration downstream to the pcDNA5/FRTpuro-fs 
vector. In preliminary experiments, 22 out of 25 cell clones with fluorescent genes of interest showed integration 
of both vectors after selection with only hygromycin. This might be useful when adapting the here presented 
protocol to different cell systems. A general problem of stable integration by site-specific recombinases (SSRs) 
is the integration in pseudosites with high homology to the recombination target site. This off-target activity of 
SSRs, however, is lower than by other site-specific DNA integration  systems10.
Double transfections using the method shown here or possible further adoptions to triple or quadruple 
transfections may serve a scientifically very important bridging between the study of single genes and complex 
systems biology studies of a large number of genes. Overall we believe that this technique will be helpful in the 
near future to not only investigate the associations among pharmacogenes, but will be useful when studying gene 
interactions, and could be extended to three or more genes of interest.
Methods
Modification of the original vector pcDNA5/FRT. To match the introduced frame shift between the 
promoter and the FRT site, the original Flp-In vector pcDNA5/FRT (Thermo Fisher Scientific, Darmstadt, Ger-
many) was modified by deletion of one cytosine (C1590del) and termed pcDNA5/FRThygro-fs here. This modi-
fication was achieved by site-directed  mutagenesis26. For this, 1.0 µL (50 ng) of the pcDNA5/FRT vector was 
mixed with 5 µL Q-Solution (Qiagen, Hilden, Germany), 2.5 µL 10 × KOD buffer (KOD Hot Start DNA Poly-
merase Kit; Merck, Darmstadt, Germany), 2.5 µL dNTPs (2 mM each), 1 µL  MgSO4 (25 mM), 0.65 µL forward 
primer SDM_hygro_fwd (5′-GTA TAG GAA CTT CCT TGG CAA AAA GCC TGA ACT CAC C-3′), 0.65 µL reverse 
primer SDM_hygro_rev (5′-GGT GAG TTC AGG CTT TTT GCC AAG GAA GTT CCT ATA C-3′), 0.5 µL HotStart 
KOD Polymerase and 11.2 µL  H2O, and PCR was carried out at 95 °C for 3 min, followed by 20 cycles of 95 °C 
for 30 s, 63 °C for 45 s, and 72 °C for 4 min. The product was digested with DpnI. For this, 25 µL of the PCR 
product were mixed with 3 µL cut smart buffer (New England Biolabs, Ipswich, USA) and 1.5 µL DpnI (20 units/
mL; New England Biolabs) and incubated at 37 °C for 1 h. After this, further 1 µL DpnI was added and the mix-
ture was incubated at 37 °C for one more hour. The product was dialyzed and transformed into E.coli using an 
Electroporator Gene Pulser II (Bio-Rad Laboratories, Hercules, California, USA) for clonal amplification prior 
to sequence validation.
Generation of second vector (pcDNA5/FRTpuro). The second vector was built to include the same pro-
moter as in the Flp-In host cell line (from vector pcDNA5/lacZeo, Thermo Fisher Scientific) including the FRT 
site, the puromycin resistance gene, and the backbone of the regular pcDNA5/FRT vector. To distinguish the two 
vectors by PCR, we also introduced a unique sequence, at which primers could bind for the eventual validation. 
For cloning, the three different fragments were generated by PCR using hybrid primers to generate overlapping 
amplicons (Fig. S1). The fragments of the puromycin resistance gene and the SV40 promoter/FRT region were 
then fused by overlap-extension  PCR27 and recombined with the pcDNA5 backbone by sequence and ligation 
independent  cloning28–30.
To amplify the pcDNA5 backbone, 10 µL Q-solution (Qiagen, Hilden, Germany), 5 µL 10 × KOD buffer 
(KOD Hot Start DNA Polymerase Kit; Merck, Darmstadt, Germany), 5 µL dNTPs (2 mM each), 3 µL  MgSO4 
(25 mM), 1.5 µL forward primer PuroR_p5_fwd (5′-cacgaccccatgGGC TGG ATG ATC CTC CAG CG-3′), 1.5 µL 
reverse primer SV40/FRT_p5_rev (5′-gacacgtacgtacgtGGC GAA CGT GGC GAG AAA GG-3′), 1 µL HotStart 
KOD polymerase, 1.5 µL pcDNA5/FRT DNA (100 ng) and 21.5 µL  H2O were mixed and PCR was carried out at 
95 °C for 2 min, followed by 35 cycles of 95 °C for 30 s, 68.1 °C for 30 s, 72 °C for 5 min and completed at 72 °C 
for 10 min. The PCR product was DpnI digested to remove template DNA interfering with subsequent clon-
ing steps as described above. The PCR for the amplification of the SV40 promoter region and the FRT site was 
composed of 10 µL Q-solution, 5 µL 10 × KOD buffer, 5  µL dNTPs (2 mM each), 3  µL  MgSO4 (25 mM), 1.5 µL 
forward primer p5_SV40/FRT_fwd (5′-gccacgtacgtacgtGTC AGT TAG GGT GTG GAA AG-3′), 1.5 µL reverse 
primer PuroR_SV40/FRT_rev (5′-tcggtggccaagGAA GTT CCT ATA CTT TCT AGAG-3′), 1 µL HotStart KOD 
polymerase, 1.5 µL pcDNA5/lacZeo DNA (100 ng) and 21.5 µL  H2O and carried out at 95 °C for 2 min, followed 
by 35 cycles of 95 °C for 30 s, 64.9 °C for 30 s, 72 °C for 1 min and completed at 72 °C for 10 min. To amplify 
the puromycin resistance gene, 10 µL Q-solution, 5 µL 10 × KOD buffer, 5 µL dNTPs (2 mM each), 3 µL  MgSO4 
(25 mM), 1.5 µL forward primer SV40/FRT_PuroR_fwd (5′-ttccttggccACC GAG TAC AAG CCC ACG G-3′) 
, 1.5 µL reverse primer p5_PuroR_rev (5′-tcatccagccCAT GGG GTC GTG CGC TCC -3′) , 1 µL HotStart KOD 
polymerase, 1.5 µL of a puromycin resistance gene-containing vector (100 ng) and 21.5 µL  H2O were mixed and 
PCR was carried out at 95 °C for 2 min, followed by 35 cycles of 95 °C for 30 s, 68.1 °C for 30 s, 72 °C for 2 min 
and completed at 72 °C for 10 min.
For the recombination of the ‘SV40 promoter-FRT’ region and the puromycin resistance gene, overlap-
extension PCR composed of 10 µL Q-Solution, 5 µL 10 × KOD buffer, 5 µL dNTPs (2 mM each), 3 µL  MgSO4 
(25 mM), 5 µL purified PCR product of SV40/FRT PCR (60 ng/µL), 5 µL purified PCR product of puromycin 
resistance gene (109 ng/µL; equimolar ratio), 1 µL HotStart KOD polymerase and 17 µL  H2O was performed at 
95 °C for 2 min, followed by 35 cycles of 95 °C for 30 s, 50 °C for 45 s, 72 °C for 2 min and completed at 72 °C for 
10 min. Subsequently, 2 µL of the PCR product were mixed with 10 µL Q-Solution, 5 µL 10 × KOD buffer, 5 µL 
dNTPs (2 mM each), 3 µL  MgSO4 (25 mM), 1.3 µL forward primer p5_SV40/FRT_fwd (5′-gccacgtacgtacgt-
GTC AGT TAG GGT GTG GAA AG-3′), 1.3 µL reverse primer p5_PuroR_rev (5′-tcatccagccCAT GGG GTC GTG 
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CGC TCC -3′), 1 µL HotStart KOD polymerase and 22.4 µL  H2O and incubated at 95 °C for 2 min, followed by 
35 cycles of 95 °C for 30 s, 50 °C for 45 s, 72 °C for 3 min and completed at 72 °C for 10 min.
The final vector was recombined by sequence and ligation independent  cloning28–30. For this, 6 µL of the puri-
fied pcDNA5/FRT backbone (60 ng) were mixed with 1.44 µL purified product of the overlap-extension PCR 
(1:3 vector to insert molar ratio), 1 µL 10 × BSA (New England Biolabs, Ipswich, USA), 1 µL 10 × NEB Buffer 
2.1 (New England Biolabs), 0.56 µL  H2O and 0.5 µL T4 DNA polymerase (3 units/µL; New England Biolabs), 
incubated at 50 °C for 40 s and subsequently kept on ice for 10 min. After this, dialysis was performed and the 
dialyzed product was electroporated into One Shot TOP10 Electrocomp E. coli. Obtained bacterial clones were 
screened via colony PCR and correct assembly of the plasmid was confirmed by sequencing.
The created plasmid pcDNA5/FRTpuro was modified by site-directed mutagenesis to correct the FRT site, 
since the FRT site present in the provided pcDNA5/lacZeo differs in one nucleotide from the one present in 
the original pcDNA5/FRT vector, and to introduce a frame shift (C1757ins) matching the reading frame of 
the pcDNA5/FRThygro-fs vector. For this, 0.6 µL (50 ng) of the pcDNA5/FRTpuro vector were mixed with 5 µL 
Q-Solution, 2.5 µL 10 × KOD buffer, 2.5 µL dNTPs (2 mM each), 1 µL  MgSO4 (25 mM), 0.65 µL forward primer 
SDM_puro_fwd (5′-CATGG CAGA AGT TCCTA TTC CGA AGT TCC-3′), 0.65 µL reverse primer SDM_puro_rev 
(5′-AATAG GAAC TTC TGCCA TGG TAG CCT CC-3′), 0.5 µL HotStart KOD Polymerase and 11.2 µL  H2O and 
PCR was carried out at 95 °C for 3 min, followed by 20 cycles of 95 °C for 30 s, 58.1 °C for 45 s, 72 °C for 3 min 
and completed at 72 °C for 10 min. The product was DpnI digested as described above and transformed into 
E.coli prior to sequence validation. The obtained vector was termed pcDNA5/FRTpuro-fs hereafter.
Cloning CYP2C19 from human liver RNA. Human liver total RNA (TaKaRa Bio, Kusatsu, Japan) was 
used to clone CYP2C19. For this, 1 µL RNA (1 µg) was diluted by adding 16.75 µL RNase-free water, mixed with 
1 µL gene-specific primers (5′-GAG GAA AGA GAG CTG CAG GG-3′), incubated at 72 °C for 10 min and subse-
quently cooled down to room temperature. After this, 6 µL 5 × RT buffer (SuperScript II Reverse Transcriptase 
Kit; Thermo Fisher Scientific, Darmstadt, Germany), 3.5 µL DTT (0.1 M), 1 µL dNTPs (2 mM each), 0.5 µL 
RNase inhibitor (40 U/µL) and 0.25 µL SuperScript II Reverse Transcriptase (200 U/µL) were added and reverse 
transcription was carried out at 42 °C for 1 h before temperature was raised to 75 °C for 15 min. Synthesized 
cDNA was amplified with primers containing restriction sites for eventual cloning with HindIII and EcoRV (see 
Table 1). The PCR for the amplification was composed of 10 µL Q-solution, 5 µL 10 × KOD buffer, 5 µL dNTPs 
(2 mM each), 2 µL  MgSO4 (25 mM), 1.3 µL forward primer CYP2C19_HindIII_fwd (5′-AAG AGG AGaagct-
tACC ATG GAT CCT TTT GTG GTC CTT G-3′), 1.3 µL reverse primer CYP2C19_EcoRV_rev (5′-CAT CTG Tga-
tatcTCA GAC AGG AAT GAA GCA CAGC-3′), 1 µL HotStart KOD polymerase, 2.0 µL cDNA template and 22.4 
µL  H2O and carried out at 95 °C for 3 min, followed by 35 cycles of 95 °C for 30 s, 61 °C for 30 s, 72 °C for 
2:30 min and completed at 72 °C for 10 min. After amplification, the CYP2C19 was subcloned by TOPO cloning 
using the TOPO XL PCR Cloning Kit (Thermo Fisher Scientific, Darmstadt, Germany) following the instruc-
tions of the manufacturer. Sequencing revealed two single nucleotide polymorphisms: c.99C>T (rs17885098; 
synonymous) and c.991A>G (rs3758581, p.ile331val). Both polymorphisms define the *1B variant of CYP2C19, 
which is not associated with changes in its in vitro catalytic  activity31 and additionally the most abundant vari-
ant in the global  population32–34. It was therefore used for further cloning into the expression vectors and for 
performing transport and metabolism experiments.
Transfection protocol. Generally, cell lines used in this study were cultivated in DMEM culture medium 
(Thermo Fisher Scientific, Darmstadt, Germany) which was supplemented with 10% fetal calf serum (FCS; 
Thermo Fisher Scientific, Darmstadt, Germany) and penicillin/streptomycin (100 units/mL, 100 µg/mL; Thermo 
Fisher Scientific, Darmstadt, Germany) unless explicitly described differently. Cells were cultured at 37 °C in a 
humidified atmosphere (5%  CO2, 95% relative humidity). All experiments were carried in HEK293 T-REx cells 
(Thermo Fisher Scientific, Darmstadt, Germany).
For transfection of HEK293 T-REx cells, one million cells were plated for each transfection in a 6-well plate 
24 h in advance. On the day of transfection, for double transfections, 200 ng of each expression plasmid in 
midi-prep quality were mixed with 3.6 µg pOG44 encoding the Flp recombinase in 100 µL DMEM. For single 
transfections, 400 ng of expression plasmid was mixed with 3.6 µg pOG44 encoding the Flp recombinase in 
100 µL DMEM. Additionally, 12 µL FuGene 6 transfection reagent (Promega Corporation, Walldorf, Germany), 
were added to 100 µL DMEM. After an incubation period of 5 min at room temperature, both solutions were 
mixed by repetitive pipetting and incubated for another 15 min at room temperature. In the meantime, the cells 
were washed once with 2 mL DMEM with 10% FCS and 1.8 mL fresh DMEM with 10% FCS were added to 
the cells. After incubation, the 200 µL DNA-FuGene 6 was pipetted dropwise onto the cells. After 24 h, the cell 
culture medium was replaced by DMEM with 10% FCS and penicillin–streptomycin. On the next day (48 h post 
transfection), cells were transferred to a 100 mm petri dish. After 24 h, the selection was performed by adding 
hygromycin B (final concentration 200 µg/mL; Thermo Fisher Scientific, Darmstadt, Germany) and puromycin 
(final concentration 0.25 µg/mL; Thermo Fisher Scientific, Darmstadt, Germany). Five days later, the supernatant 
was replaced by fresh cell culture medium containing hygromycin and puromycin. Around ten days after selec-
tion started, single colonies were picked. For this, cells were washed once with culture medium to remove dead 
cells and finally the medium was completely removed. Single colonies were resuspended in 2 µL medium and 
transferred to a 24-well-plate, where 1 mL culture medium with a reduced concentration of the selection antibiot-
ics (hygromycin: 50 µg/mL, puromycin: 0.025 µg/mL) had been placed in advance. After reaching a confluence 
of 70–80%, cells were transferred to a 6 well plate and later to a T25 culture flask. When cells were passaged the 
first time, 40% of cells were used to prepare cell pellets for DNA and RNA extraction each, to allow validation 
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of generated cell lines on genomic as well as on transcriptional level. Transfections were usually carried out in 
duplicates to ensure a sufficient number of clones to analyze.
The same protocol was independently performed in the Institute of Pharmacology and Toxicology at the 
Justus Liebig University in Giessen to stably transfect two versions of the sodium/bile acid transporter (NTCP) 
tagged with yellow or cyan fluorescent protein (NTCP-YFP, NTCP-CFP).
Validation of correct integration by PCR. The stable, genomic integration of both plasmids was vali-
dated by PCR. For this, the genomic DNA of 2 × 106 cells was isolated using the QIAGEN DNeasy Blood & 
Table 1.  Primers used for PCR. The 5′-hybrid part of primers used for generation of overlapping amplicons 
for creation of the pcDNA5/FRTpuro vector is shown by nucleotides in small capital letters. The unique 
sequence introduced into the generated vector is underscored. The newly introduced base into the pcDNA5/
FRTpuro vector for frame shift generation is marked in bold, the nucleotide substitution for the correction of the 
FRT site is highlighted by an italic, bold letter. The position of the single nucleotide deletion introduced into 
the pcDNA5/FRThygro vector is shown by a hyphen. Endonuclease restriction sites are indicated by lower case 
letters.
Primers used for generation of pcDNA5/FRTpuro vector
Fragment Primer Sequene (5′–3′) Amplicon size (bp)
pcDNA5 backbone
PuroR_p5_fwd cacgaccccatgGGC TGG ATG ATC CTC CAG CG
3,834
SV40/FRT_p5_rev gacacgtacgtacgtGGC GAA CGT GGC GAG AAA GG
Puromycin resistance
SV40/FRT_PuroR_fwd ttccttggccACC GAG TAC AAG CCC ACG G
669
p5_PuroR_rev tcatccagccCAT GGG GTC GTG CGC TCC 
SV40 promotor-FRT region
p5_SV40/FRT_fwd gccacgtacgtacgtGTC AGT TAG GGT GTG GAA AG
395
PuroR_SV40/FRT_rev tcggtggccaagGAA GTT CCT ATA CTT TCT AGAG 
Primers used for site-directed mutagenesis
Vector Primer Sequence (5′–3′) Amplicon size (bp)
pcDNA5/FRThygro
SDM_hygro_fwd GTA TAG GAA CTT CCT TGG C-AAA AAG CCT GAA CTC ACC 
N/A
SDM_hygro_rev GGT GAG TTC AGG CTT TTT -GCC AAG GAA GTT CCT ATA C
pcDNA5/FRTpuro
SDM_puro_fwd CATGG CAGA AGT TCCTA TTC CGA AGT TCC 
N/A
SDM_puro_rev AATAG GAAC TTC TGCCA TGG TAG CCT CC
Primers used for cloning of CYP2C19
Reaction Primer Sequence (5′–3′) Amplicon size (bp)
Reverse transcription CYP2C19_GSP_rev GAG GAA AGA GAG CTG CAG GG N/A
Introduction of restriction sites
CYP2C19_HindIII_fwd AAG AGG AGaagcttACC ATG GAT CCT TTT GTG GTC CTT G 1516
CYP2C19_EcoRV_rev CAT CTG TgatatcTCA GAC AGG AAT GAA GCA CAGC 
Primers used for Validation PCRs
Reaction Primer Sequence (5′–3′) Amplicon size (bp)
Integration PCR 1
PSV40 AGC TGT GGA ATG TGT GTC AGT TAG G 559
Ppuro_r CGA CGC GCG TGA GGA AGA GTT CTT G
Integration PCR 2
Puni_f CGT TCG CCA CGT ACG TAC GTG TCA G 489
Phyr_r CTT CGC CCT CCG AGA GCT GCA TCA G
Multiple Integration PCR A
Puni_f CGT TCG CCA CGT ACG TAC GTG TCA G 564
Ppuro_r CGA CGC GCG TGA GGA AGA GTT CTT G
Multiple Integration PCR B
PFRT_f AAT CGG GGG CTC CCT TTA GGG TTC C 313
Ppuro_r CGA CGC GCG TGA GGA AGA GTT CTT G
Multiple Integration PCR C
PFRT_f AAT CGG GGG CTC CCT TTA GGG TTC C 238
Phyr_r CTT CGC CCT CCG AGA GCT GCA TCA G
Primers used for quantitative RT-PCR
Gene Primer Sequence (5′-3′) Amplicon size (bp)
CYP2C19
PCYP2C19_f CCT GAT CAA AAT GGA GAA GGA AAA G 99
PCYP2C19_r TCT GTC CCA GCT CCA AGT AAG 
HPRT1
PHPRT1_f TGA CAC TGG CAA AAC AAT GCA 94
PHPRT1_r GGT CCT TTT CAC CAG CAA GCT 
OCT1
POCT1_f TGT CAC CGA AAA GCT GAG CC 96
POCT1_r TCC GTG AAC CAC AGG TAC ATC 
11
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:14018  | https://doi.org/10.1038/s41598-020-71051-5
www.nature.com/scientificreports/
Tissue Kit (Qiagen, Hilden, Germany) in a QIACube robot (Qiagen) following the manufacturer’s protocol. The 
isolated DNA was analyzed by multiplex PCR using the QIAGen Multiplex PCR Kit (Qiagen). This reaction 
covered the Integration PCR 2 as well as the Multiple Integration PCRs A-C (for detailed primer information 
see Table 1). Multiplex PCR was composed of 5 µL 2 × QIAGEN Multiplex PCR Master mix, 2 µL Q-Solution, 
1 µL 10 × primer mix (2 µM each), 1 µL genomic DNA (100 ng) and 1 µL  H2O. PCR was carried out at 95 °C for 
15 min, followed by 35 cycles of 95 °C for 30 s, 62.7 °C for 90 s, 72 °C for 90 s and completed at 72 °C for 10 min. 
As a positive control, the genomic DNA of a cell clone validated for all types of multiple integrations was used. 
Cell clones passing the multiplex PCR screening were validated again by single PCRs (Integration PCRs 1 and 
2, Multiple Integration PCRs A-C) composed of 5 µL 2 × QIAGEN Multiplex PCR Master mix, 2 µL Q-Solution, 
0.25 µL forward primer (10 µM), 0.25 µL reverse primer (10 µM), 1 µL genomic DNA (100 ng) and 1.5 µL  ddH2O 
using the same thermocycler conditions.
Sanger sequencing was performed on the products including the FRT sites. For the third FRT site, the primers 
 PFRT_f and  PLacZ (5′-CCT TCC TGT AGC CAG CTT TCA TCA A-3′) under the same conditions as mentioned for 
single PCRs above. The resulting amplicons were separated on a 0.8% agarose gel, cut out and extracted using 
the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). For sanger sequencing, 100 ng DNA were pre-
mixed with 30 pmol of one of the primers used for amplification and sent to external sequencing by Microsynth 
Seqlab, Göttingen.
Tracking of eGFP/tdTomato double-transfected cells by flow cytometry. The stability of stable 
transfection was tracked by analyzing fluorescence signals of eGFP/tdTomato double-transfected cell lines over 
30 passages. Two independently generated cell lines were cultured in parallel in DMEM cell culture medium 
with or without the culturing concentrations of hygromycin (50 µg/mL) and puromycin (0.025 µg/mL). Every 
second passage, cells were analyzed using a LSR II (BD Bioscience, Heidelberg, Germany) flow cytometer and 
the software BD FACSDiva (Version 6.1.3, BD Bioscience). Fluorescence intensities of green channel (laser exci-
tation wavelength 488 nm) and red channel (laser excitation wavelength 561 nm) were plotted to determine 
double-positive cells. Thresholds for classifying cells as positive were set by comparing the fluorophore express-
ing cells to a mock-transfected control cell line.
Expression analyses. The RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) was used according to 
the manufacturer’s instructions for total RNA isolation. Briefly, 1 to 2 × 106 cells were harvested by centrif-
ugation at 500×g for 5  min at RT. The pellet was dissolved in 350  µL of RLT buffer supplemented with 1% 
β-mercaptoethanol (v/v). The automatic isolation was performed using a QIAcube (Qiagen, Hilden, Germany), 
in which the genomic DNA eliminator spin column removed the genomic DNA and total RNA was eluted in 
50 µL of RNAse free  ddH2O.
The cDNA synthesis from isolated RNA was performed using the SuperScript II Reverse Transcriptase Kit 
(Thermo Fisher Scientific, Darmstadt, Germany). Three µg RNA was diluted in 17.75 µL of RNAse free  ddH2O. 
Primer annealing was initiated with the addition of 1 µL anchored-dT primer (10 µM) and incubation at 70 °C 
for 10 min. To initiate cDNA synthesis, 11.25 µL of a reverse transcription reaction mix [6 µl 5 × Superscript RT 
buffer, 3.5 µL DTT (0.1 M), 1 µL dNTPs (10 mM), 0.5 µL RNase Inhibitor P/N (40 U/µL), 0.25 µL SuperScript 
II Reverse Transcriptase (200 U/µL)] were added and incubated at 42 °C for one hour. Afterward, enzyme dena-
turation was done by increasing the temperature to 75 °C for 15 min. To this 30 µL synthesized cDNA, 70 µL 
of RNAse free  ddH2O were added and concentration was further adjusted to 3 ng/µL cDNA by 1:10 dilution.
HOT FIREPol EvaGreen qPCR Mix Plus (ROX) kit (Solis BioDyne, Tartu, Estonia) was used to perform the 
real-time qPCR. Briefly, the reaction mixture constituted 2 µL 5 × EvaGreen qPCR Mix, 5.6 µL  ddH2O, 0.4 µL 
primer mix (10 µM each; HPRT1: forward (5′-TGA CAC TGG CAA AAC AAT GCA-3′), reverse (5′-GGT CCT TTT 
CAC CAG CAA GCT-3′); OCT1: forward (5′-TGT CAC CGA AAA GCT GAG CC-3′), reverse (5′-TCC GTG AAC 
CAC AGG TAC ATC-3′), CYP2C19: forward (5′-CCT GAT CAA AAT GGA GAA GGA AAA G-3′), reverse (5′-TCT 
GTC CCA GCT CCA AGT AAG-3′)), 2 µL cDNA (6 ng total). Standard curve analysis for each primer pair was 
performed to check the primer efficiency and amplification of a single specific amplicon. To do so, five concentra-
tions of a cDNA pool in a 1:5 dilution series were distributed in a 384 well-plate and amplification was performed 
in TaqMan 7900HT (Applied Biosystems, Darmstadt, Germany) machine. SDS 1.2 software (Applied Biosystems, 
Darmstadt, Germany) was used to identify the Cycle threshold (Ct) value. The Primer efficiency was well within 
the accepted range, namely 107% (HPRT1), 101% (OCT1), and 99% (CYP2C19)35. Subsequently, expression 
levels of OCT1 and CYP2C19 genes, along with the housekeeping gene HPRT1, were measured in technical and 
biological triplicate manner. The ΔΔCt method was used for expression  analysis36. Relative expression against 
single transfected OCT1 and CYP2C19 cell lines were calculated based on this equation:
Transport experiments. Functional validation of the stably integrated genes was performed via trans-
port and metabolism of proguanil. Two days ahead of the transport experiment, 600,000 cells were plated in 
poly-d-lysine pre-coated 12-well-plates. On the day of experiment, cells were washed once with 2 mL 37 °C 
pre-warmed Hanks buffered saline solution (Thermo Fisher Scientific, Darmstadt, Germany) containing 10 mM 
HEPES (Sigma-Aldrich, Taufkirchen, Germany; from here on named HBSS+) followed by incubation with 
HBSS+ containing 1 μM Proguanil (Sigma-Aldrich, Taufkirchen, Germany). After 2, 5, 15, 30 and 60 min, the 
incubation was stopped by collecting the supernatant and cells were immediately washed twice with 1 mL ice-
cold HBSS+ and cells were lysed by adding 500 μL lysis buffer [acetonitrile:water 4:1 (v/v)] containing 10 ng/μL 
Relative expression = 2−[(Ct experimental− Ct housekeeping experimental)− (Ct control− Ct housekeeping control)] = 2−[��Ct]
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proguanil-d6 (Toronto Research Chemicals, North York, Canada) and 10 ng/μL desvenlafaxine (Sigma-Aldrich, 
Taufkirchen, Germany) as an internal standard for mass spectrometry analysis. For sample preparation, cell 
lysates were centrifuged in a desktop centrifuge at maximum speed for 15 min, 400 μL were transferred into a 
collection plate, evaporated at 40 °C under nitrogen flow and the dry residues were dissolved in 250 μL 0.1% 
formic acid. For the processing of cell supernatant, samples were centrifuged at 400×g for 5 min. After this, 
400 μL was transferred to a new reaction tube and 800 μL of precipitation reagent [acetonitrile:methanol 10:1 
(v/v) containing the same internal standards as described above] were added and the mixture was incubated for 
15 min on a rotation shaker. Precipitated protein was pelleted by centrifugation at full-speed in a desktop centri-
fuge for 15 min, 800 μL of the supernatant was used for evaporation and dry residues were dissolved in 250 μL 
0.1% formic acid for analysis as well.
LC–MS/MS determination of proguanil transport and metabolism. Concentrations of proguanil 
and cycloguanil were quantified by high-performance liquid chromatography coupled to mass spectrometry. 
For sample separation, we used a Shimadzu Nexera 2 UHPLC system containing an auto-sampler SIL-30AC, 
a communications bus module CBM-20A, a liquid chromatograph LC-30AD, a column oven CTO-20AC and 
a Brownlee SPP RP-Amide column (4.6 × 100 mm inner dimension with 2.7 μm particle size) with a C18 pre-
column. For chromatography, an aqueous mobile phase containing 20% organic additive (acetonitrile:methanol 
6:1 (v/v)) was used with a flow gradient starting with 0.3 mL/min for the first 4.5 min, increased to 0.7 mL/min 
at 4.6 min and back to 0.3 mL/min from 9.0 to 9.1 min, which was left for another two minutes to reconstitute 
the original conditions for the next measurement. The HPLC system was coupled with an API 4000 tandem 
mass spectrometer (AB SCIEX, Darmstadt, Germany), which enabled the detection of substrates via specific LC 
retention times and mass transitions in MRM mode with parameters given in Table S1. The quantification was 
performed by integration of the peak areas using the Analyst software (Version 1.6.2, AB SCIEX, Darmstadt, 
Germany). Concentrations of proguanil and cycloguanil (Santa Cruz Biotechnology, Heidelberg, Germany) 
were determined by simultaneous measurement of a standard curve with known concentrations. To calculate 
the net uptake of proguanil, the measurement of an empty vector-transfected cell line was subtracted from the 
other cell lines to take passive diffusion and endogenous transporters into account.
Total protein quantification. Results of cellular transport experiments were normalized to the total 
amount of protein per well to compensate differences in cell density. For this, the total protein of one well per 
cell line in each transport experiment was quantified using a BCA assay. Cells were lysed by incubation with 
500 μL RIPA buffer for 10 min. Five microliter of each sample were incubated after adding 200 μL bicinchoninic 
acid with 0.008% copper sulfate at 37 °C for 30 min. Subsequently, the absorbance at a wavelength of 570 nm was 
measured using a Tecan Ultra microplate reader (Tecan Group, Männedorf, Switzerland). The protein concentra-
tion was quantified by comparison to a standard curve using bovine serum albumin.
Tracking of double-transfected cells by microscopy. HEK293-Flp-In cells stably transfected by our 
Double-Flp-In Method with NTCP-CFP and NTCP-YFP, a classical Foerster Resonance Energy Transfer (FRET) 
pair, were seeded onto IBIDI chamber-slides to reach confluency at the day of microscopy. For comparison 
HEK293-MSR cells were seeded like above and were transiently transfected with Lipofectamine 2000 (Thermo 
Fisher Scientific, Darmstadt, Germany) with an equimolar number of premixed plasmids of pcDNA5 vectors 
coding for NTCP-CFP or NTCP-YFP both under the control of the identical CMV-promoter, which is also 
applied by the Double-Flp-In Method. After 48 h of standard incubation, slides were washed twice with PBS 
and transferred to microscopy at room temperature covered in PBS. Images were taken with a Leica DMI6000 
B inverted fluorescent microscope at 40× objective magnification. For qualitative analysis and comparison of 
expression levels and patterns of the fluorescent proteins CFP and YFP channels were adjusted to yield similar 
signal intensities. Phase contrast channel was applied to demonstrate the confluency of the cell layer and trans-
fection rates. Staining of the cell nuclei and the fixation of the cells was deliberately avoided to not interfere with 
CFP and YFP signals.
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Figure S1: Illustration of vector creation. The newly generated vector pcDNA5/FRTpuro was 
created by PCR amplification with primers including overhangs from two of the vectors that 
belong to the Flp-In™ system, pcDNA5/FRT and pFRT/lacZeo. The puromycin resistance 
cassette was cloned from a third puromycin resistance-containing vector by PCR amplification 
and sequence and ligation-independent cloning (SLIC). 
 
 
Figure S2: Validation of used cell clones by PCR. In addition to the initial screening by 
multiplex PCR (see Figure 4), the finally employed cell clones (OCT1/EV, CYP2C19/OCT1, 
CYP2C19/EV) were validated by single PCRs. 
 
 
Figure S3: Sequence validation of the three FRT sites including flanking regions. Sanger 
sequencing was performed on the cell clone OCT1/CYP2C19 to validate correct integration on 
nucleotide level. Sequences of the FRT sites are highlighted in bold italic, while other 
functional elements are indicated in their respective color, as shown in Figure 2. 
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Variability and Heritability of Thiamine 
Pharmacokinetics With Focus on OCT1 Effects 
on Membrane Transport and Pharmacokinetics 
in Humans
Ole Jensen1,* , Johannes Matthaei1, Felix Blome1, Matthias Schwab2,3,4 , Mladen V. Tzvetkov1,5 and 
Jürgen Brockmöller1
Thiamine is substrate of the hepatic uptake transporter organic cation transporter 1 (OCT1), and pathological lipid 
metabolism was associated with OCT1-dependent thiamine transport. However, it is unknown whether clinical 
pharmacokinetics of thiamine is modulated by OCT1 genotype. We analyzed thiamine transport in vitro, thiamine 
blood concentrations after high-dose and low-dose (nutritional) intake, and heritability of thiamine and thiamine-
phosphate blood concentrations. The variant OCT1*2 had reduced and OCT1*3 to OCT1*6 had deficient thiamine 
uptake activity. However, pharmacokinetics of thiamine did not differ depending on OCT1 genotype. Further studies 
in primary human hepatocytes indicated that several cation transporters, including OCT1, OCT3, and THTR-2, 
contribute to hepatic uptake of thiamine. As much as 54% of the variation in thiamine and 75% in variation of 
thiamine monophosphate plasma concentrations was determined by heritable factors. Apparently, thiamine is not 
useful as a probe drug for OCT1 activity, but the high heritability, particularly of thiamine monophosphate, may 
stimulate further genomic research.
The organic cation transporter 1 (OCT1) mediates hepatic up-
take of typically cationic substances with a molecular weight 
below 400 Dalton.1–4 In humans, OCT1 shows strong expression 
in the sinusoidal membrane of hepatocytes5 and only minor, if 
any, expression in other organs.6,7 OCT1 can be relevant for the 
hepatic uptake and pharmacokinetics of numerous drugs, includ-
ing metformin, morphine, O-desmethyltramadol, sumatriptan, 
fenoterol, trospium, and ranitidine.3,8–14 Beyond that, OCT1 may 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Human organic cation transporter 1 (OCT1) can mediate 
cell uptake of thiamine and OCT1-genotype-dependent differ-
ences in hepatic metabolism may be caused by OCT1-mediated 
thiamine transport.
WHAT QUESTION DID THIS STUDY ADDRESS?
 Do human thiamine blood concentrations differ depend-
ing on the OCT1 genotype? Can thiamine blood concentra-
tions serve as a biomarker for in vivo OCT1 activity? How much 
of the variation of thiamine blood concentrations is heritable?
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
 Thiamine pharmacokinetics does not depend on OCT1 
genotypes but variation in thiamine plasma concentrations 
is determined by heritable factors. Combined clinical and 
in vitro data indicate that hepatic thiamine uptake is mediated 
by multiple transporters with a minor contribution of OCT1. 
Translation from murine OCT models to humans may be 
difficult.
HOW MIGHT THIS CHANGE CLINICAL PHARMA- 
COLOGY OR TRANSLATIONAL SCIENCE?
 Thiamine is not suitable as a probe drug for OCT1 activ-
ity. Associations of cardiometabolic phenotypes with OCT1 
genotype may be mediated by mechanisms other than OCT1-
mediated thiamine transport. Apparently, thiamine pharma-
cokinetics is modulated by genomic variation but the underlying 
genes are not yet identified.
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also be relevant for hepatic uptake of numerous naturally occur-
ring cations, including dopamine, epinephrine, serotonin, tyra-
mine, and thiamine.15 OCT1 activity is highly variable between 
individuals due to numerous naturally occurring synonymous and 
nonsynonymous variants. Five alleles are rather common in the 
European population (Figure 1b) and cause deficient or strongly 
reduced transport activity.16,17 Activity of OCT1*2 is substrate 
dependent and there is some remaining but low activity of *3 and 
*4, whereas proteins coded by alleles *5 and *6 have no activity 
at all. Thus, depending on the substrate, between 2% and 9% of 
Europeans are deficient in OCT1-mediated transport.
Compared with other solute carriers and ABC transporters, 
OCT1 has a very high hepatic expression12,18 suggesting a phys-
iological role of OCT1, but only a few endogenous substrates are 
known. Recent data demonstrate a role of OCT1 in membrane 
transport of thiamine (vitamin B1).15 In cell culture, thiamine up-
take was inhibited by structurally unrelated organic cations like 
1-methyl-4-phenylpyridinium (MPP+) (an OCT1 model substrate 
and inhibitor) and by serotonin and other OCT inhibitors as well. 
Human OCT1 is a high capacity but low affinity transporter for thi-
amine. Transgenic mice expressing human OCT1 showed enlarged 
livers and hepatic steatosis upon high-fat diets, whereas in knock-
out mice, the lack of OCT1 resulted in decreased hepatic concentra-
tions of thiamine and the active metabolite thiamine diphosphate.15 
Most interestingly, in this model OCT1-mediated thiamine uptake 
correlated with hepatic steatosis.19 Recent human genomewide asso-
ciation study data indicate a possible correlation between metabolic 
phenotypes and OCT1 genotype in humans as well.20 Beyond that 
and because of its very low toxicity, thiamine might be an excellent in 
vivo probe drug for human OCT1 activity, if one could show a cor-
relation between thiamine pharmacokinetics and OCT1 genotype.
Here, we wanted to further elucidate the role of OCT1 and 
its naturally occurring variants for thiamine disposition in hu-
mans. Therefore, we first compared thiamine cellular uptake via 
OCT1 with uptake via other cation transporters, including the 
thiamine transporters thiamine transporter 1 (THTR-1) and thi-
amine transporter 2 (THTR-2) using overexpressing cell lines and 
human hepatocytes. We then analyzed the effects of OCT1 and 
its variants on clinical pharmacokinetics of high-dose thiamine 
and low-dose thiamine in humans. In this clinical study, we took 
advantage of the common low or zero-activity variants of OCT1 
to elucidate the quantitative contribution of OCT1 deficiency to 
thiamine pharmacokinetics in humans. Furthermore, we analyzed 
the overall heritability of thiamine and thiamine monophosphate 
plasma concentrations in humans using the repeated measurements 
approach and the twin study design.
RESULTS
Thiamine uptake via OCT1 and effects of common 
polymorphisms in human OCT1
First, we confirmed the high-capacity thiamine transport by 
wild-type OCT1*1. At 15  µM thiamine, cells expressing the 
variant OCT1*2 (a variant found almost worldwide) showed 
only about 50% of the uptake compared with the wild-type al-
lele (Figure 1a,b). Cells expressing variants *3 and *4 had only 
6% of the transport capacity of OCT1*1. The alleles OCT1*7 
and OCT1*8, which are more common in African populations, 
showed 111% and 132%, respectively, of the wild-type activity. 
The intrinsic clearance by the common variant OCT1*2 was 
about 60% of that of OCT1*1 but uptake via OCT1*3 and 
OCT1*4 was so small and not saturating that no reliable trans-
port kinetic constants could be estimated (Table 1). OCT1*5 
and OCT1*6 (known as nonfunctional) did not produce any 
uptake above the control. The variants OCT1*7 and OCT1*8 
showed similar or insignificantly increased maximum transport 
capacity, compared with the wild-type allele. Affinity was in-
creased for the OCT1*7 variant compared with the wild-type 
allele (P < 0.05, Student t-test, no adjustment for multiple test-
ing; Figure 1a,d, Table 1).
Pharmacokinetics of thiamine and its phosphate esters 
after a high dose of 200 mg
As a high capacity thiamine transporter, OCT1 should be most 
relevant at very high doses and high extracellular concentrations. 
To confirm that clinically, we administered thiamine orally to 
18 healthy volunteers preselected according to their OCT1 
genotype. Both groups, those with low activity or deficiency of 
OCT1 and those with high OCT1 activity, had a comparable 
sex proportion (4 women and 5 men each in both groups), sim-
ilar age (mean 25.6 vs. 25.2 years) and similar body mass index 
(22.8 vs. 22.1 kg/m2). Per study protocol, we classified OCT1 al-
leles *2 to *6 as inactive and all homozygous and compound-ho-
mozygous carriers of alleles *2 to *6 as inactive. Alleles *6, *7, 
and *8 were not found among the volunteers screened for the 
present study. As illustrated in Figure 2, the concentration time 
curves after the end of the absorption phase tended to be higher 
in carriers of zero OCT1 activity alleles. However, none of the 
pharmacokinetic parameters differed statistically significantly 
between the groups with high vs. low OCT1 activity (Table 2). 
Pharmacokinetic parameters for thiamine monophosphate and 
thiamine diphosphate did also not significantly differ between 
the subgroups defined by OCT1 genotype. Because more de-
tailed transport kinetics measurements revealed that OCT1*2 
still retained some transport activity (Table 1), the plasma and 
whole blood thiamine area under the curves (AUCs) were an-
alyzed depending on the OCT1 in vitro activity score, which 
was calculated based on an additive model of inheritance using 
the activity score from transport experiments (Figure 1a). The 
in vitro activity score was assigned per allele, relative to wild-type 
OCT1*1. Alleles OCT1*2 was classified as 0.51, OCT1*3 and 
OCT1*4 as 0.07, and OCT1*5 and OCT1*6 as zero. However, 
also using this classification, there was not even a trend of in-
creasing plasma or whole blood thiamine AUCs with increasing 
genotype-predicted OCT1 activity (Figure 3).
Effect of OCT1 deficiency on thiamine trough concentrations
We further tested whether morning trough thiamine blood 
concentrations after overnight fasting may be influenced by the 
OCT1 genotype, both after low-dose nutritional thiamine in-
take and 24 hours after 200 mg high-dose thiamine. At that time, 
thiamine and thiamine monophosphate plasma concentrations 
were still significantly above those concentrations measured with 
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nutritional thiamine intake only. However, none of the concen-
trations differed significantly between the OCT1 active and de-
ficient genotypes (Table S1). Similarly, thiamine monophosphate 
blood concentrations did also not differ between OCT1 geno-
types (Table  S1). Single values are illustrated in relation to the 
two classifications of OCT1 genotypes in Figure 3, but none of 
the differences were significant according to one-way analysis of 
variance.
Thiamine uptake by other solute carriers
The lack of significant differences in thiamine pharmacokinetics 
between active and deficient OCT1 genotypes was unexpected. 
To further clarify the reasons for that, we first characterized 
the uptake of thiamine via OCT1 in comparison to its known 
high-affinity transporters THTR-1 and THTR-2 (Figure  1e). 
The two thiamine transporters THTR-1 and THTR-2 exhib-
ited high-affinity transport with limited capacity (Table 1). The 
Figure 1 Thiamine uptake by wild-type and variant organic cation transporter (OCT)1 and by other organic cation transporters. At 15 µM 
thiamine, uptake was significantly reduced in variants *2 to *6 compared with wild-type OCT1*1 (P < 0.05 (a)). Thiamine uptake with variants 
*5 and *6 not statistically significantly different from the empty vector (pcDNA5). Common haplotypes result from combinations of six amino 
acid substitutions and the methionine420 deletion (b). Thiamine transport was analyzed under the same conditions in cells overexpressing 
THTR-1 and THTR-2 (e), as well as MATE1 and MATE2-K (f). (c–f) In these panels, carrier-mediated uptake is illustrated, that is the difference 
between uptake measured in the respective transfected cell lines minus the uptake into HEK cells transfected with the empty plasmid.
ARTICLE
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 107 NUMBER 3 | MARCH 2020 631
organic cation transporter 3 (OCT3), which is also expressed in 
the liver, showed a higher affinity but lower capacity compared to 
OCT1 (Table 1). However, compared with the high-affinity thia-
mine transporters, OCT3 also had low affinity.
Primary human hepatocytes in combination with inhibitors 
of the transporters are more suitable to estimate the relative con-
tribution of the specific transporters to overall cellular uptake. 
Therefore, we analyzed the inhibitory potency of the relatively 
OCT1-specific inhibitors dextrorphan and desipramine, and 
the relatively THTR-2-specific inhibitor amprolium together 
with an unspecific inhibitor of cation transporters, MPP+. 
Concentrations leading to at least 90% reduction in transport 
activity in human embryonic kidney 293 cells (HEK293) cells 
overexpressing OCT1 or THTR-2 were used to inhibit thia-
mine uptake in hepatocytes (50 µM dextrorphan; 100 µM desip-
ramine; 100 µM amprolium; and 1 mM MPP+; Figure 4). By 
using low and high thiamine concentrations, we modeled trough 
concentrations from our clinical study and estimated maximum 
concentrations in the portal vein according to Ito et al.21 We 
could indeed show a bigger impact of OCT1 on cellular uptake 
of thiamine if thiamine concentration was high (40 µM) com-
pared with low thiamine (0.15 µM). Inhibition of the thiamine 
transporter THTR-2 resulted only in a moderate reduction of 
cellular uptake.
Altogether, these experiments indicate that thiamine hepa-
tocellular uptake may be mediated by multiple transporters. 
OCT1-mediated thiamine transport could be relevant at very high 
concentrations only, whereas at typical thiamine blood concentra-
tions other transporters are responsible for thiamine uptake into 
the liver. Quantitative expression data in different tissues confirmed 
the almost exclusive hepatic expression of OCT1 (Figure S2). In 
contrast, THTR-1 and THTR-2 were expressed at low to moder-
ate levels in other tissues, as well as in HEK293 cells. The very high 
hepatic expression of OCT1 may not compensate for the more than 
1,000-fold higher affinity of thiamine transporters (Figure S2).
Heritability of morning fasting thiamine plasma 
concentrations
To explore overall heritability in thiamine membrane trans-
port and metabolism, we used two independent samples and ap-
proaches, first, data from repeated measurements and, second, 
data from a study in monozygotic and dizygotic twins. In the first 
study, on average four samples were drawn per person (n  =  40) 
with a time interval of at least 1  week between the samplings. 
From those data we estimated the genetic component by the ap-
proach suggested by Kalow et al.22 Mean SD of thiamine concen-
tration within the same subjects was 0.194 and mean SD between 
the subjects was 0.220. From that, a genetic component of 0.226 
was calculated, thus, only 22.6% of the variation may be due to 
heritable factors. However, heritability might be much higher for 
thiamine monophosphate. With mean within and between SDs 
of 0.321 and 0.670, the genetic component was 0.770, thus, up to 
77% of the variation in thiamine monophosphate concentrations 
may be due to heritable factors.
In the second study, to further investigate the heritability of thi-
amine in the blood, we determined basal plasma thiamine and thi-
amine monophosphate concentrations in 86 monozygotic and 28 
dizygotic twins. All were healthy and had taken no drugs. Further 
details about the study have been described earlier.23 In the twin 
study, variation could be attributed to additive genetic effects, 
dominant genetic effects, common environmental effects, and 
unique environmental effects. As summarized in Table S2, varia-
tion in thiamine and thiamine monophosphate plasma concentra-
tions could be described best by a model including additive genetic 
and unique environmental effects. Thus, according to this analysis, 
broad heritability of plasma thiamine was 54% (95% confidence 
Table 1 Thiamine transport kinetic constants (mean ± SEM) studied in HEK cells
Transporter Km (µM) Vmax (pmol/mg protein/minute) Clint (Vmax/Km) (µL/mg protein/minute)
OCT1*1 1,997 ± 174 5,750 ± 388 3.0 ± 0.1
OCT1*2 2,729 ± 1,228 3,761 ± 964 2.1 ± 0.4
OCT1*3 —a —a —a
OCT1*4 —a —a —a
OCT1*5 —a,b —a,b —a,b
OCT1*6 —a,b —a,b —a,b
OCT1*7 1,348 ± 201 4,293 ± 704 2.9 ± 0.5
OCT1*8 1,577 ± 390 6,747 ± 1,061 4.8 ± 1.2
OCT2 163 ± 20 1,336 ± 93 8.4 ± 0.6
OCT3 443 ± 158 2,840 ± 616 8.2 ± 1.7
MATE1 44.7 ± 8.5 1,496 ± 205 38.9 ± 9.1
MATE2-K 5.2 ± 1.3 245 ± 38 50.5 ± 5.7
THTR-1 1.2 ± 0.2 16.6 ± 1.6 15.1 ± 2.5
THTR-2 1.2 ± 0.1 43.4 ± 4.2 37.1 ± 2.1
HEK, human embryonic kidney; Km, Michaelis constant; MATE1, multidrug and toxin extrusion protein 1; MATE2-K, multidrug and toxin extrusion protein 2-K; 
THTR-1, thiamine transporter 1; THTR-2 , thiamin transporter 2; OCT, organic cation transporter; Vmax, maximal rate of metabolism.
aNo saturating transport observed and therefore Km and Vmax could not be determined. 
bVariants OCT1*5 and OCT1*6 are known to result in complete transport 
deficiency.
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Figure 2 Pharmacokinetics of thiamine and its phosphate esters in human plasma and in whole blood after 200 mg thiamine orally. As defined 
in the study protocol, carriers of two organic cation transporter (OCT)1 active alleles were exclusively carriers of OCT1*1, thus allele OCT1*2 was 
classified as inactive. Carriers of two inactive alleles had homozygous or compound homozygous genotypes with alleles *2, *3, *4, and *5. As 
known, thiamine diphosphate is not found in relevant concentrations in plasma. AUC, area under the curve; Cmax, peak plasma concentration.
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Table 2 Pharmacokinetics of high-dose thiamine in human plasma and whole blood
 
Plasma Whole blood
Number of active OCT1 alleles Number of active OCT1 alleles
Zero (n = 9) Two (n = 9) Zero (n = 9) Two (n = 9)
Thiamine
AUC (minute µg/mL) 11.2 ± 1.0 10.4 ± 1.1 6.1 ± 0.7 5.6 ± 0.5
Clearance/F (L/minute) 8.1 ± 0.8 10.0 ± 1.3 13.4 ± 2.1 15.1 ± 1.5
Cmax (ng/mL) 21.2 ± 2.6 23.0 ± 5.8 10.6 ± 1.7 10.1 ± 2.4
Tmax (hour) 2.2 ± 0.5 1.4 ± 0.3 2.2 ± 0.6 1.9 ± 0.3
Half-life (hour) 41.3 ± 10.0 35.5 ± 9.3 45.0 ± 11.1 40.0 ± 4.6
VZ/F (L) 24,546 ± 3,855 24,526 ± 2,378 41,215 ± 5,250 48,754 ± 3,108
C24h (ng/mL) 4.9 ± 0.2 4.5 ± 0.2 2.9 ± 0.2 2.6 ± 0.1
Thiamine monophosphate
AUC (minute µg/mL) 5.2 ± 0.4 4.6 ± 0.4 5.5 ± 0.5 5.0 ± 0.3
Cmax (ng/mL) 5.2 ± 0.4 5.1 ± 0.4 5.0 ± 0.6 5.1 ± 0.3
Tmax (hour) 3.0 ± 0.9 4.6 ± 2.6 3.1 ± 0.8 2.8 ± 0.8
Thiamine diphosphate
AUC (minute µg/mL) — — 113.5 ± 7.5 111.2 ± 4.5
Cmax (ng/mL) — — 86.7 ± 6.6 83.4 ± 2.7
Tmax (hour) — — 11.0 ± 3.5 6.3 ± 2.4
All data provided as arithmetic means ± SEM.
AUC, area under the curve; C24h, 24-hour drug concentration; Cmax, peak plasma concentration; OCT, organic cation transporter; Tmax, time of maximum plasma 
concentration; Vz/F, volume of distribution based on the terminal phase.
Figure 3 Plasma thiamine trough concentrations and area under the curve (AUC) in relation to organic cation transporter (OCT)1 genotypes 
and correlation of plasma thiamine and thiamine monophosphate concentrations in monozygotic (MZ) and dizygotic (DZ) twins. Plasma 
thiamine trough concentrations in healthy volunteers grouped by their OCT1 genotypes showed no significant differences. Classification 
according to the number of active OCT1 alleles ((a); classifying OCT1*2 as active) or by their in vitro activity score (b) also revealed no 
statistically significant differences (one-way analysis of variance). (c) In addition, the plasma thiamine AUC showed no dependency on the 
in vitro OCT1 activity score. (d, e) These panels show correlations of thiamine and thiamine monophosphate in MZ and DZ twins. The higher 
correlation in MZ twins (100% genotypes identical) compared with DZ twins (50% genotypes identical) indicates heritability. A detailed analysis 
using structural equation modeling is provided in Table S2. Green, yellow, and red dots refer to carriers of two, one, and zero active alleles. DZ 
twins having different genotypes are indicated by the respective semicircles.
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interval (CI) 0.34–0.75), whereas 46% (95% CI 0.25–0.66) was 
due to random environmental effects. Broad heritability of thia-
mine monophosphate was 75% (95% CI 0.62–0.88), whereas 25% 
(95% CI 0.12–0.38) was due to environmental effects. Estimates of 
heritability in thiamine monophosphate corresponded particularly 
well with the estimate of a genetic component of 0.77 in the other 
independent study.
DISCUSSION
Our data confirm earlier findings in mice and human cell cul-
ture showing that OCT1 unequivocally can serve as a thiamine 
uptake transporter. However, in humans, the pharmacokinet-
ics of thiamine and its phosphate esters were modulated only 
to a minor extent by naturally existing loss-of-function OCT1 
variants. When considering the huge liver concentrations ob-
served after injection of 11C thiamine in rats,24 it was partic-
ularly surprising that even peak plasma concentration (Cmax) 
of thiamine was not significantly different between the OCT1 
genotypes (Figure  2). In humans, parallel uptake via the thi-
amine transporters THTR-1 and THTR-2 may partially ex-
plain why there was no significant effect of OCT1 genotypes 
on blood and plasma thiamine concentrations. Chemical in-
hibition of THTR-1 and OCT1 reduced cellular uptake only 
moderately, indicating that even other uptake transporters may 
exist, one of which may be OCT3 (Figure 5).
Analysis of thiamine plasma concentrations in two indepen-
dent study samples clearly indicated that a relevant fraction of 
variation in thiamine concentrations was due to heritable factors. 
Figure 4 Inhibitor specificity and inhibitor effects on thiamine uptake in primary human hepatocytes. Inhibition of thiamine uptake with 
increasing concentrations of desipramine, dextrorphan, MPP+, and amprolium for organic cation transporter (OCT)1 and THTR-2. Red lines 
indicate concentrations used for experiments in primary human hepatocytes (a–d). Thiamine uptake into human hepatocytes was performed 
at low and high concentrations and revealed inhibitor-specific reduction (e, f). As seen, inhibitor concentrations resulting in < 20% uptake 
in the transfected cells resulted only in moderate inhibition of uptake in primary hepatocytes, indicating that still other transporters may be 
involved. MPP+, 1-methyl-4-phenylpyridinium; THTR-2, thiamine transporter 2.
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Considering that low-dose nutritional thiamine intake was not 
specifically defined except for excluding any vitamin supplements, 
the intraindividual constancy and heritability in thiamine pharma-
cokinetics was most likely even underestimated. However, again, 
the existing interindividual variation could not be explained by 
the well-defined OCT1 variants (Figure 3). Interestingly, herita-
bility of thiamine monophosphate was much higher than that of 
free thiamine, possibly indicating heritability in other enzymes and 
transporters in the thiamine cycle.25 The significant heritability in 
the variation of thiamine monophosphate is particularly notable 
considering that the phosphate esters serve important functions in 
the intermediate-term thiamine storage.
Thiamine might have been an ideal probe drug to test in vivo 
human OCT1 activity, but in contrast to expectations from in 
vitro data (Table 1)15 and Oct1 knockout mice,20 thiamine blood 
and plasma concentrations did not reflect individual OCT1 geno-
types. In addition, the thiamine phosphate esters did not correlate 
with the loss-of-function OCT1 genotypes. Apparently, it is not 
always possible to predict from in vitro experiments or from genet-
ically modified mice whether or not human pharmacokinetics of 
an OCT1 substrate is dependent on OCT1 genotypes. Similar as 
with thiamine, also pharmacokinetics of some other prototypical 
substrates of OCT1 like metformin or proguanil did not depend 
in a significant fashion on OCT1 genotypes,26,27 although intra-
hepatic metformin concentrations and pharmacodynamics did 
depend on OCT1 genotypes.28,29 In the case of thiamine, several 
other organs also contribute to storage of thiamine and its phos-
phate esters even more than the liver.30 Particularly the relatively 
high muscle, heart, kidney, or lung thiamine concentrations are not 
expected to depend on OCT1 genotypes because there is only neg-
ligible OCT1 expression outside the liver (Figure S2). In contrast, 
some other substances, including sumatriptan and fenoterol, did 
differ depending on OCT1 genotype most likely to be explained 
by a more selective accumulation of these two drugs in the human 
liver with only small accumulation in other organs.
At low concentrations, thiamine cell uptake should be 
mostly mediated by the high affinity transporters THTR-1 and 
THTR-2.31,32 In our experiments using primary human hepato-
cytes, this was reflected by an almost negligible effect of OCT1 
inhibitors with 0.15 µM thiamine but a clearly detectable effect 
of OCT1 inhibitors at 40 µM (Figure 4). However, in both con-
ditions, inhibitors reduced the hepatocellular thiamine uptake 
only moderately, at least much less than that observed in the HEK 
cells transfected with OCT1. One interpretation of that may be 
the existence of other thiamine transporters, such as THTR-1 or 
solute carrier 35F3,33 but also OCT3 may contribute to hepatic 
uptake of thiamine. Intrinsic thiamine clearance mediated by 
OCT3 was higher than that mediated by OCT1 so that even in 
the situation that OCT3 is expressed at a 10-fold lower concen-
tration than OCT1 in the human liver, OCT3 may nevertheless 
contribute in a relevant manner to hepatic uptake of thiamine.
There seems to be an exciting association between OCT1 activ-
ity and OCT1 genotypes and hepatic lipid metabolism in mice and 
also in humans.15,19,20 However, whether or not this is solely medi-
ated by thiamine may be questionable. Considering that the relevant 
thiamine diphosphate ester concentrations in the cells are between 
10-fold and 100-fold higher than those of free thiamine30 (Table 2), 
phosphorylation and dephosphorylation, but also possibly trans-
port of the phosphate esters, may play an even bigger role than hepa-
tocellular uptake for the intrahepatic thiamine concentrations.
As indicated by our experiments with primary hepatocytes 
(Figure 4), OCT1 inhibition led to an about twofold reduction 
of hepatic uptake. Assuming a similar effect caused by OCT1 defi-
ciency, reduced uptake probably could be more than compensated 
by providing much higher doses of thiamine. Although our experi-
ments do not contribute to the question whether or not high intra-
hepatic thiamine concentrations result in metabolic disturbances, 
other quite ancient data on 70 humans who received a > 50-fold 
excess of thiamine compared with recommended nutritional 
intake over a period of 3 years did not result in major toxicity.34 
Nevertheless, it might be interesting to repeat such experiments 
now with more refined biomarkers of liver toxicity and lipid me-
tabolism. Our experiments do not support, but also do not exclude, 
relevance of OCT1 for hepatic thiamine-related metabolism 
Figure 5 Pathways of thiamine in high and low dose. A moderately bigger impact of organic cation transporter (OCT)1 for hepatic thiamine 
uptake with high extracellular thiamine compared with low extracellular thiamine was concluded from the in vitro experiments with primary 
human hepatocytes, but was not reflected by the thiamine blood concentrations measured in healthy volunteers, where even peak plasma 
concentration was not different depending on OCT1 genotype (Figure 2). ATP, adenosine triphosphate; AMP, adenosine monophosphate; TPK, 
thiamine pyrophosphokinase; THTR-2, thiamine transporter 2.
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under more challenging conditions, such as starvation, or alcoholic 
and nonalcoholic steatosis and hepatitis. Even if the contribution 
of OCT1 to hepatic thiamine uptake is moderate only, in the long 
term it may be relevant. According to the simple principle of ad-
ditivity of partial clearances, a higher or lower hepatic uptake in 
humans with high or low/deficient OCT1 activity should usually 
not be compensated by other transporters but results in higher or 
lower thiamine concentrations.
Next steps in human clinical research might include more de-
tailed analyses of OCT1 genotypes on hepatic metabolism in 
thiamine deficiency and thiamine oversupply with and without 
optimal conditions for thiamine phosphorylation and thiamine re-
quirements. Conditions of malnutrition with thiamine deficiency 
are not infrequent35 and the roles of specific hepatic transporters 
and intracellular phosphorylation are still not completely under-
stood. In addition, the source of thiamine monophosphate in 
human plasma may deserve further investigation, it is conceivable 
that this is already formed in the gut wall and released from the en-
terocytes, but it may also be released from erythrocytes and other 
cells. Although the clinical studies were not sufficiently powered 
to study the effects of OCT2 polymorphisms for renal secretion, 
THTR-2 or SLC5F3,33 polymorphisms, this may be an interesting 
topic for further research.
In conclusion, thiamine plasma concentrations under high-dose 
and low-dose exposures did not indicate a major impact of OCT1 
for human thiamine pharmacokinetics but can also not exclude 
moderate and, in the long term, relevant OCT1 genotype-de-
pendent differences in hepatic thiamine-dependent metabolism. 
Apparently, genomic variation is most relevant for thiamine phar-
macokinetics but many underlying genes are not yet known.
MATERIALS AND METHODS
In vitro uptake of thiamine
Thiamine uptake was characterized in all the HEK293 cells stably trans-
fected to overexpress the cation transporters included in the present 
study. In addition, thiamine uptake was studied in cryopreserved human 
hepatocytes (Gibco; Thermo Fisher Scientific, Darmstadt, Germany) 
from donors with active OCT1 alleles (donor a: OCT1*1/OCT1*1; 
donor b: OCT1*1/OCT1*2). Thiamine uptake in HEK293 cells or he-
patocytes was performed for 2 minutes at 37°C and pH 7.4 after a pre-
ceding fasting period. Cell lysates were reconstituted and thiamine and 
its phosphate esters were quantified after oxidation to the fluorescent 
thiochrome with K3[Fe(CN)6]. High-performance liquid chromatogra-
phy (HPLC) was performed on an XBridge C18 column (2.1 × 50 mm, 
3.5 µm, Waters) and gradient elution. The detailed description of the ex-
perimental procedures and thiamine quantification can be found in the 
Supplementary Material.
OCT1 genotyping
Genotyping for OCT1 was performed on DNA extracted from blood 
samples via automated solid-phase extraction (EZ1 DNA Blood Kit; 
Qiagen, Hilden, Germany). Genotyping was described in detail else-
where.36 Briefly, a single-base primer extension assay was performed to 
genotype following common genetic variants: Ser14Phe (rs34447885), 
Arg61Cys (rs12208357), Cys88Arg (rs55918055), Pro117Leu 
(rs200684404), Ser189Leu (rs34104736), Gly401Ser (rs34130495), 
Met420del (rs202220802), and Gly465Arg (rs34059508). Almost all 
samples included in the study were genotyped in duplicate, with 100% 
concordant results.
Clinical studies
A high dose of 200  mg thiamine was administered to 18 unrelated 
healthy male and female volunteers with European ancestry. The par-
ticipating volunteers were selected from a database of healthy volunteers 
according to their OCT1 genotype (9 carriers of 2 wild type alleles and 9 
homozygous or compound heterozygous carriers of alleles *2, *3, and *4). 
Health was verified by medical history, common clinical biochemistry 
and hematology tests, and by a clinical examination, including echocar-
diogram recording. After overnight fasting, each volunteer took a single 
oral dose of 200 mg thiamine (Ratiopharm, Neu-Ulm, Germany). Intake 
of any vitamin supplements was forbidden for 7 days prior to the study 
day and also intake of any drugs except for oral contraceptives for 2 weeks 
prior to the study day was an exclusion criterion. Plasma and whole blood 
concentrations of thiamine were measured predose, and 15, 30, 45, 60, 
90, 120, 180, 210, 240, 270, 300, 360, 480, 600, and 1,440 minutes after 
administration.
In another series of experiments, thiamine and thiamine monophos-
phate plasma concentrations were analyzed at the morning after overnight 
fasting in each subject on 3–5 separate occasions with intervals of at least 
1 week. The aim of this study was to compare intraindividual vs. interin-
dividual variation.37
In a third study, thiamine was analyzed in 28 dizygotic and 86 mono-
zygotic twins to assess the overall heritability of thiamine blood concen-
trations. All participants were healthy men and women younger than 
55  years. Details of that study have been described earlier.23 All partici-
pants had given written informed consent and the clinical studies were 
approved by the ethics committee of the University Medical Center 
Göttingen. The thiamine pharmacokinetics study was registered at 
ClinicalTrials.gov (NCT02054299) and in the European Clinical Trials 
Database (EudraCT 2012-003546-33).
Thiamine blood concentration analyses
Plasma and whole blood concentrations of thiamine, thiamine mono-
phosphate, and thiamine diphosphate were quantified with HPLC and 
fluorescence detection after oxidation to the respective thiochromes using 
potassium ferricyanide. Calibrators, thiamine, thiamine monophosphate, 
and thiamine diphosphate, were from Sigma. In brief, 300  µL plasma 
samples were mixed with 300  µL 10% trichloroacetic acid, thoroughly 
mixed, incubated on ice for 15 minutes, and centrifuged at 13,000 rpm 
for 15  minutes. Four hundred µL of the supernatant were washed with 
1.5  mL water-saturated methyl-butyl-ether and 240  µL of the aqueous 
phase were mixed with 60 µL methanol and 150 µL derivatization reagent 
(0.6 mM potassium ferricyanide in 15% NaOH). Then, 10 µL of the re-
action mixture were injected into the HPLC system. For chromatography, 
an X-Bridge C18 column (2.1 × 50 mm, 3.5 µm, Waters) was used with 
gradient elution. Plasma calibration range was 1–30 ng/mL for thiamine 
and 16 ng/mL for the thiamine phosphates, the whole blood calibration 
range was 0.5–25 ng for thiamine, 1–10 ng/mL for thiamine monophos-
phate, and 1–40 ng/mL for thiamine diphosphate.
Pharmacokinetic data analysis
Noncompartmental pharmacokinetic parameters were estimated with 
Phoenix WinNonlin version 6.3 (Certara USA, Princeton, NJ). The 
AUC was the predefined primary parameter and was calculated with the 
linear/log trapezoidal rule from time of thiamine administration and 
extrapolated to infinity based on the last predicted concentrations. The 
time of maximum concentration (Tmax) and the corresponding concen-
tration (Cmax) were given as measured.
Statistical analyses
Primary parameters were plasma AUC of thiamine. For the pharmaco-
kinetic study, the number of volunteers per genotype was calculated to 
give 80% power to identify a presumed 50% increase in the area under 
the time-concentration curve in the poor compared with the extensive 
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OCT1 transporters. The Student t-test was used with a type-I (alpha) 
error of 5% and assuming 35% SD of AUC in both groups based on 
published data.38 Comparison of intraindividual vs. interindividual 
variation may provide important hints on possible heritability. Repeated 
analysis in each subject was used to calculate the genetic component, as 
described by Kalow et al.22,37 Variance within (Vw) the subjects and vari-
ance between (Vb) the subjects were calculated and repeated genetic com-
ponent was calculated as (Vb − Vw)/Vb. This metric is often interpreted 
as an indicator of heritability but would also reflect individually constant 
environmental factors.
To unambiguously differentiate between individually constant ac-
quired factors vs. heritable factors, we analyzed thiamine and thiamin 
monophosphate concentrations in blood samples of monozygotic and 
dizygotic twins. Using monovariate structural equation modeling, we 
compared models with additive and dominant genetic factors, common 
environmental factors, and unique environmental factors. For structural 
equation analysis, the mets package in R was used.39
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Supplementary Methods
Crea�on and valida�on of cell lines
Thiamine cellular uptake was analyzed in HEK293 cells overexpressing wild-type OCT1 and its
common variants or OCT2, OCT3, MATE1, MATE2-K, and the thiamine transporters THTR-1 or THTR-
2, and in cryopreserved primary human hepatocytes. Genera�on and valida�on of the of cell lines
overexpressing OCT1 isoforms was described elsewhere 1, 2. Gene constructs of thiamine transporters
THTR-1 and THTR-2 were generated via reverse transcrip�on from HEK293 cell RNA via gene specific
primers (SLC19A2: ATCCAGGCAGTTGCTGTGC; SLC19A3: ACTTTGAAAGCCACTGTTGCG). The cDNA thus
obtained was cloned into pCR-XL-TOPO vectors (Invitrogen, Thermo Fisher Scien�fic) and wild-type
sequence was confirmed by Sanger sequencing. Gene sequences were amplified via PCR (KOD Hot
Start DNA Polymerase Kit, Merck Millipore) with primers introducing restric�on sites for HindIII and
EcoRV and subsequently cloned into the pcDNA5.1 plasmid. The obtained constructs were integrated
into HEK293 T-REx™ cells using the Flp-In™ system (Invitrogen) following to the manufacturer’s
protocol. Briefly, each transfec�on was conducted on 1 × 106 cells, which were plated per well in a 6-
well plate 24 hours before. Four hundred ng of the pcDNA5.1::THTR-1 or pcDNA5.1::THTR-2 plasmid
were co-transfected with 3.6 µg of the helper plasmid pOG44 using 12 µL FuGene6 transfection
reagent. Cells were incubated for 24 hours and on the next day the supernatant medium was
replaced by DMEM supplemented with 10% FCS, penicillin (50 U/mL) and streptomycin (50 µg/mL).
Forty-eight hours a�er transfec�on, cells were transferred from the 6-well plate to a 100 mm Petri
dish in 20 mL cell culture medium. Cells were then incubated overnight to ensure a�achment. Next
day, 120 μL hygromycin B (50 mg/mL) were added to the cell medium (final concentra�on: 300
μg/mL). The medium was renewed 4 days later again with fresh DMEM supplemented with 10% FCS,
penicillin, streptomycin and hygromycin B (300 μg/mL). Approximately 10 days a�er the ini�al
hygromycin B treatment colonies deriving from single cells appeared. Single colonies were selected
and transferred to 12-well plates and cultured in 2 mL DMEM supplemented with 10% FCS, penicillin,
streptomycin and hygromycin B (100 μg/mL). As the cells reached a confluence of about 70 to 80%,
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they were transferred into a 6-well plate and further cul�vated in DMEM supplemented with 10%
FCS, penicillin, streptomycin and hygromycin B (100 μg/mL). Upon confluence of 70 to 80%, cells
were transferred to a T25 (Sarstedt) cell culture flask with a ven�lated cap.
Correct integra�on of transfected plasmids was validated by three independent PCR reac�ons (Fig.
S1 A). For this, genomic DNA was extracted from pellets of cultured cells using the DNeasy Blood &
Tissue Kit (Qiagen) with the QIACube robot. An Integra�on PCR (Fwd. primer:
AGCTGTGGAATGTGTGTCAGTTAGG; Rev. primer: ACGCCCTCCTACATCGAAGCTGAAA; 518 bp
amplicon) was used to detect the integra�on of the vector into the host cell genome in general by
amplifica�on of the hygromycin B resistance gene provided by pcDNA5. A second PCR (Multiple
Integra�on PCR; Fwd: AATCGGGGGCTCCCTTTAGGGTTCC; Rev: CTTCGCCCTCCGAGAGCTGCATCAG;
238 bp amplicon) was carried out to exclude mul�ple vector integra�on. The outcome of this PCR
should be nega�ve when only a single vector integrated into the FRT site, but mul�ple, subsequent
integra�ons will lead to amplifica�on of a PCR product. A third PCR was performed to amplify and
thereby detect the gene of interest (GOI PCR; Fwd: CCATGGTGATGCGGTTTTGGCAGTA; Rev:
CCTTCCTGTAGCCAGCTTTCATCAA; 2965 (THTR-1) / 2962 (THTR-2) / 3137 (OCT1) bp amplicon). Gene-
unspecific primers were used to bind in the CMV promoter and LacZ-Zeocin region, both neighboring
the inserted gene, and the correct size of the insert was validated on an agarose gel (Fig. S1 B).
In cell clones, which passed the PCR valida�on process, overexpression of the gene of interest was
validated via quan�ta�ve RT-PCR using TaqMan™ assays (SLC22A1: Hs00427550_m1; SLC19A2:
Hs00949693_m1; SLC19A3: Hs00228858_m1 ; TBP: 4326322E; Thermo Fisher Scien�fic). For this
purpose, RNA from cultured cells was extracted using the RNeasy Plus Mini Kit (Qiagen) with the
QIACube robot according to the manufacturer’s instruc�ons. Normaliza�on of expression of different
transporter genes was performed with the help of plasmids carrying one gene copy per plasmid
molecule. The molecular weight of each plasmid was approximated via its length, and from measured
concentra�ons, standard curves with known plasmid quan��es were create. Through this, the
number copies of transcripts in unknown samples could be determined and compared (Fig. S1 C).
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Finally, stably transfected cells were func�onally validated via thiamine transport in concentra�on-
dependent uptake experiments (Fig. S1 D). OCT1 variant cell lines had been validated with numerous
other substrates known to be transported by wild-type OCT1 and some of its common naturally
occurring variants 2.
Uptake experiments
Concentra�on-dependent uptake was analyzed in HEK293 cells overexpressing OCT1, THTR-1 or
THTR-2 at varying thiamine concentra�ons. For this purpose, 12-well plates were pre-coated with
poly-D-lysine and 6 × 105 cells were plated 48 hours ahead of each uptake measurement per well to
reach 95 to 100% confluency on the day of the experiment. Human hepatocytes (Gibco, Thermo
Fisher Scien�fic) were thawed and processed rapidly according to the manufacturer’s protocol. One
hundred thousand hepatocytes were plated per well of a collagen-pre-coated 24-well plate (Gibco,
Thermo Fisher Scien�fic) and let adhere for 4 hours before further use in uptake experiments. In
order to reduce intracellular thiamine concentra�ons, HEK293 cells were incubated for 30 minutes in
HBSS+ before each uptake experiment. The op�mized pla�ng medium of hepatocytes was replaced
by thiamine-free DMEM (Gibco, Thermo Fisher Scien�fic) a�er 2 hours.
Uptake in HEK293 cells or hepatocytes was performed for two minutes at 37 °C and pH 7.4, and
stopped with ice-cold HBSS supplemented with 10 mM HEPES. Cells were lyzed with 80% acetonitrile
and the lysate was evaporated under nitrogen flow at 40 °C un�l dry. Standard curve samples for
transport experiments were prepared simultaneously in 100% MeOH to minimize evapora�on �me.
The dry lysates of unknown as well as standard were recons�tuted in 200 µL 20% methanol and
100 µL 0.6 mM K3[Fe(CN)6] in 15% NaOH were added and the intracellularly accumulated thiamine
was quan�fied via HPLC with fluorescence detec�on.
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Thiamine quan�fica�on
Thiamine was quan�fied via HPLC-coupled fluorescence detec�on of pre-column deriva�zed
samples. The Nexera 2 HPLC system (Shimadzu) was used with the SIL 30-AC autosampler to process
samples from a 96 deep well plate. Substance separa�on was achieved with a XBridge™ C18 column
(2.1 x 50 mm, 3.5 µm, Waters) and a Phenomonex C18 pre-column and gradient elu�on. Mobile
phase A (25 mM Na2HPO4, pH 7) and B (60% 25 mM Na2HPO4, pH 7, 40% MeOH) were used at a
constant flow of 0.5 mL/min with following gradient: 0% mobile phase B at 0 min, 30% B at 1 min,
30% B at 1.5 min, 100% B at 3 min, 0% B at 3.1 min, and 0% B at 8 min to restore ini�al condi�ons.
Fluorescence of deriva�zed thiamine (reten�on �me 6.22 min), thiamine-P (RT 5.19 min) and
thiamine-PP (RT 4.74 min) were detected with 375 nm excita�on and 435 nm emission wavelengths.
Legends to supplementary Figures and Tables
Figure S1: PCRs valida�ng integra�on of THTR-1 or THTR-2 by the Flp-In™ system. The schema�c
depic�on of the three conducted valida�on PCRs (A) and results of these PCRs for two newly
generated cell clones overexpressing THTR-1 or THTR-2 (B) are shown. Absolute quan�fica�on
reveals strong differences in expression levels of OCT1, THTR-1 and THTR-2 in HEK293 cells a�er
stable transfec�on (C). Func�on of thiamine transporter was verified with thiamine uptake
experiment (D). Thiamine uptake was calculated as the difference between uptake measured in the
respec�ve transfected cell lines minus the uptake into HEK cells transfected with the empty plasmid.
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Fig. S2: Expression of OCT1, THTR-1 and THTR-2 in 20 �ssues and HEK293 cells. Expression analysis
revealed high OCT1 mRNA levels in the liver, compared to THTR-1 and THTR-2. In contrast to OCT1,
both thiamine transporters were low to moderately expressed in other �ssues, and HEK293 cells.
Table S1: Plasma trough concentra�ons a�er low (nutri�onal) doses and high 200 mg dose of
thiamine. Thiamine morning trough levels measured a�er usual nutri�onal intake and at least 10
hours overnight fas�ng (low dose) and 24 hours a�er 200 mg thiamine orally. Depending on assay
condi�ons in cell culture, OCT1*2 has about 30 to 50% of the normal transport ac�vity conferred by
wild-type OCT1*1, thus, both classifica�ons may be jus�fied. Further differen�a�on is given in Fig. 3.
Table S2: Heritable and acquired determinants of thiamine and thiamine monophosphate plasma
concentra�ons. Es�mates and of addi�ve gene�c effects (A), dominant gene�c effects (D), shared
environmental effects (C) and unshared environmental effects (E) are presented under different
gene�c models. Both, for thiamine and thiamine monosphate the best model according to the
Akaike criterion (AIC) was the model with addi�ve gene�c effects and environmental effects (AE).
Thus, according to this analysis, broad heritability of plasma thiamine was 54% and broad heritability
of thiamine monophosphate was 0.75, which is quite high considering that nutri�onal intake was not
standardized.
(1) Saadatmand, A.R., Tadjerpisheh, S., Brockmöller, J. & Tzvetkov, M.V. The prototypic
pharmacogene�c drug debrisoquine is a substrate of the gene�cally polymorphic organic
ca�on transporter OCT1. Biochemical Pharmacology 83, 1427–34 (2012).
(2) Seitz, T. et al. Global gene�c analyses reveal strong inter-ethnic variability in the loss of
ac�vity of the organic ca�on transporter OCT1. Genome Med 7, 56 (2015).
Figure S1. PCRs validating integration of THTR-1 or THTR-2 by the Flp-In system. THTR-1, thiamine
transporter 1; THTR-2, thiamine transporter 2.
Figure S2. Expression of OCT 1, THTR-1, and THTR-2 in 20 tissues and HEK293 cells. HEK293, human
embryonic kidney 293 cells; OCT 1, organic cation transporter 1; THTR-1, thiamine transporter 1; THTR-
2, thiamine transporter 2.
Table S1: Plasma trough concentra�ons a�er low (nutri�onal) doses and a high 200 mg dose of
thiamine
Genotype classifica�on assuming that OCT1 allele *2 is deficient#
Thiamine trough concentra�ons in plasma [ng/ml]
No. of ac�ve OCT1 alleles 2 1 0
Low doses (n = 152) 0.92 (0.32 – 2.50) 0.90 (0.43 – 1.80) 0.92 (0.39 – 1.47)
200 mg dose (n=18) 4.49 (3.03 – 5.25) - 2.51 (1.43 – 4.32)
Thiamine monophosphate in plasma
No. of ac�ve OCT1 alleles 2 1 0
Low doses 1.65 (0.55 – 5.20) 1.51 (0.73 – 2.60) 1.73 (1.00 – 3.13)
200 mg dose 2.51 (1.43 – 4.32) - 3.07 (1.66 – 4.15)
Genotype classifica�on assuming that OCT1 allele *2 is ac�ve
Thiamine in plasma [ng/ml]
No. of active OCT1 alleles 2 1 0
Low doses (n = 152) 0.91 (0.32 – 2.50) 0.91 (0.47 – 1.80) 0.94 (0.39 – 1.47)
200 mg dose (n=18) 4.53 (3.03 – 5.45) 4.97 (4.59 – 5.36) 5.01 (4.28 – 5.57)
Thiamine monophosphate in plasma [ng/ml]
No. of active OCT1 alleles 2 1 0
Low doses 1.62 (0.55 – 5.20) 1.61 (0.90 – 2.60) 1.71 (1.00 – 3.13)
200 mg dose 2.53 (1.43 – 4.32) 3.51 (2.90 – 4.11) 3.22 (2.19 – 4.15)
Thiamine morning trough levels measured after usual nutri�onal intake and at least 10 hours
overnight fasting (low dose) and 24 hours after 200 mg thiamine orally. Depending on assay
condi�ons in cell culture, OCT1*2 has about 30 to 50% of the normal transport ac�vity conferred by
wild-type OCT1*1, thus, both classifica�ons may be jus�fied. Further differen�ation is given in Fig. 3.
All data provided as mean and range (minimum – maximum)
Table S2:
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(0.62 – 0.88) - -
0.25
(0.12 – 0.38) 79.57 0.005
CE - -
0.63
(0.48 – 0.79) 0.37
(0.33 – 0.73)
81.28 0.003
Estimates and of addi�ve gene�c effects (A), dominant gene�c effects (D), shared environmental
effects (C) and unshared environmental effects (E) are presented under different gene�c models.
Both, for thiamine and thiamine monophosphate the best model according to the Akaike criterion
(AIC) was the model with addi�ve gene�c effects and environmental effects (AE). Thus, according to
this analysis, broad heritability of plasma thiamine was 54% and broad heritability of thiamine





Translational pharmacology includes target finding, drug screening, lead optimization, preclinical 
testing with functional assays in functional models, in vitro-to-in vivo extrapolation, and 
subsequent in vivo validation. The five publications, on which this thesis is built, include several 
of these tasks as illustrated in Figure 8. 
 
 
Figure 8: Integrative overview of the publications in this thesis. 
 
Data about OCT1 substrates is plenteously available, and traditional substrate criteria comprise a 
molecular weight below 600 Da, predominantly positive charge at pH 7.4 and lipophilicity. To 
expand the knowledge about OCT1 substrates and non-substrates exploratively, 18 
psychostimulants or hallucinogens, all of which meet the just-mentioned conventional criteria, 
were investigated. Out of these, only mescaline was identified as an OCT1 substrate, while other 
compounds were only transported by OCT2 or the high-affinity monoamine transporters NET 
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and DAT. Unlike the exploration of molecules with a different structure, an exploitational 
approach was used to predict novel OCT1 substrates on the basis of known ones. Results showed 
that a machine learning-based model is a suitable method for predicting substrates with high 
reliability. Since the use of two-dimensional models for machine learning-based prediction of 
substrates (as applied in our work) are not or only poorly able to predict the interaction of 
racemates with OCT1, stereoselective transport was investigated in vitro. Results of eight 
investigated known OCT1 substrates indicated that transport by polyspecific transporters, such as 
OCT1, facilitates translocation of enantiomers with significant stereoselectivity. 
The in vitro investigation of combined effects of uptake and metabolism, be it in the case of 
racemates, pure enantiomers, or substances without a stereocenter, requires the presence of a 
transporter and a metabolizing enzyme. Therefore, a method for the stable overexpression of two 
genes was developed. Testing substances for uptake and metabolism might be one way to 
investigate metabolic pathways integratively prior to clinical studies and improve the in vitro-to-
in vivo extrapolation. The search for a suitable biomarker that indicates OCT1 activity has been 
running for some time and several substances have already been proposed for this purpose. In a 
clinical study, we showed that thiamine might be transported by OCT1 in vitro, but does not serve 
as a biomarker for OCT1 activity. 
 
4.1 Cellular Uptake of Psychostimulants 
Screening for new substrates can be based on random selection of test compounds. It can also be 
guided by physicochemical and/or structural characteristics of known substrates. Here, we selected 
test compounds based on a single positive charge at pH 7.4 and a logD7.4 value of < 1. The low 
success rate in our study with regard to OCT1 substrates found (1 out of 18) is surprising, as in 
other datasets about 40 % of all test compounds were substrates (Hendrickx et al. 2013). It was 
surprising that despite its scaffold identity to the tested non-substrates, mescaline turned out to be 
an extraordinarily good OCT1 substrate. Specific structural properties of mescaline may set it 
apart from the other substances. This so-called activity cliff might provide further insights in OCT1 
binding and translocation processes (Stumpfe und Bajorath 2012). Previous studies did not find 
uptake of amphetamine or methamphetamine by OCT1 either (Wagner et al. 2017). The same 
study also reported the uptake of both compounds by OCT2, which was in part confirmed by our 
findings. The interaction of OCT1 with other substances from the group of psychostimulants 
cannot be ruled out, as these are diverse. Official regulations make working with these legally 
restricted substances more difficult, which means that there is a comparatively limited amount of 
data. Nonetheless, it is conceivable that other hallucinogens or psychostimulants can be 
transported by OCT1. In light of astonishingly different in vitro results for the structurally similar 
compounds tested, further exploration of this drug class might reveal more interesting insights. 
The proposed native role of OCT1 includes the elimination of endogenous amines (Zhang L. et 
al. 1997). Psychostimulants, such as the here investigated amphetamine or cocaine are known to 
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increase extracellular levels of monoamines norepinephrine, dopamine, and serotonin, by 
inhibition of the high-affinity monoamine transporters NET, DAT, and SERT (Di Chiara und 
Imperato 1988; Kuczenski und Segal 1997; Ritz et al. 1990). These neurotransmitters have also 
been shown to be substrates of OCT1 (Boxberger et al. 2014; Busch et al. 1996). In addition, also 
so-called false neurotransmitters have been described to be increased in blood and in the brain 
upon hepatic failure. These include β-hydroxylated phenylethylamines mimicking norepinephrine 
without respective effect (Fischer und Baldessarini 1971; Fischer et al. 1965). Some of these false 
neurotransmitters of endogenous or natural origin, such as hordenine, octopamine, 
phenylephrine, and synephrine have been described as OCT1 substrates for the first time during 
this work (see Publication 1). Overall, this context gives sufficient reason to further investigate the 
interaction of OCT1 with biogenic amines that can reach the CNS and interact with other 
transporters. For a better understanding of the interaction, psychostimulants and biogenic amines 
should be investigated with regard to their functions as substrates or inhibitors of OCT1 and 
monoamine transporters. Interestingly, OCT3 has been studied as a target for antidepressive 
medication (Hu et al. 2016; Zhu et al. 2012), further underlining the possible therapeutic value of 
insights into the substrate overlap of OCTs and MATs. 
 
4.2 Identification of novel OCT1 substrates by machine learning 
The machine learning-aided search for additional OCT1 substrates on the bases of known and 
published substrates and non-substrates led to the identification of additional high-affinity 
substrates. More then 80% of predicted substrates were experimentally confirmed. Previously 
published studies on screenings have already led to a general understanding of the characteristics 
of OCT1 substrates and inhibitors (Ahlin et al. 2008; Chen EC et al. 2017; Hendrickx et al. 2013). 
In silico prediction was used earlier to predict OCT1 inhibitors on a limited data basis only 
(Moaddel et al. 2007). 
Earlier screening for OCT1 substrates mainly focused on physicochemical properties. As shown 
in Publication 1, this can lead to a low success rate. Our approach combined both, the already 
existing knowledge about physicochemical properties of known substrates and the power of 
machine learning-aided prediction. This was done by using the machine learning model for 
substances inside the confined physicochemical space of already known substrates only. Of course, 
such an approach, which includes filtering the prediction set by molecular weight, logD7.4 and 
charge at pH 7.4, reduces the number of substrates predicted, but the rate of false-positively 
predicted substrates is reduced even more. For our study, the best available dataset of OCT1 
substrates was expanded by addition of in-house transport data from the last couple of years and 
comparable data from other recent sources (Baidya et al. 2020; Hendrickx et al. 2013; Meyer et al. 
2019). One crucial aspect for the quality of the prediction model is size and uniformity of the 
dataset. Respectable sizes have previously been achieved by testing OCT1 inhibition quantified by 
reduction of transport of a model substrate (Ahlin et al. 2008; Chen EC et al. 2017). However, an 
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inhibitor is not necessarily a substrate, as already discussed in early OCT1 studies (Grundemann 
et al. 1999; Koepsell 2020; Schlessinger et al. 2018). Inhibition can be achieved by several 
mechanisms and can also be allosteric only. We therefore solely relied on a smaller, pure transport 
dataset, committing to quality and specificity more than to quantity. 
The approach used in our study was prospective in contrast to previous studies which did 
validations with a subset of the initial data instead of acquiring a new validation set of thus far 
unknown substrates (Baidya et al. 2020). The success rate of predicted compounds was > 80 %, 
instead of around 40 % (percentage of substrate among substances in the dataset so far) (Baidya et 
al. 2020; Meyer et al. 2019). Approaches, such as the presented one, can very well be used for 
virtual screening to guide biological testing towards the more promising lead compounds 
(Kapetanovic 2008). 
Many of the compounds predicted and tested in our study belong to substance groups, which have 
previously been investigated (Koepsell 2020). The procedure we used can be described as an 
exploitation of previous findings and is contrary to an approach in which entirely new structures 
are tested and thus ‘explored’. This kind of exploitation does most probably not identify completely 
new, unrelated ligands. Therefore, additional random testing of compounds is still advisable. On 
the other hand, the computer-supported search seems to have filtered the positive properties of 
substrates exceptionally well, so that more high-affinity substrates were found than expected. 
For many years, there have been several reports about non-cationic OCT1 substrates, such as 
acyclovir or lamivudine (Dickens et al. 2012; Minuesa et al. 2009; Takeda et al. 2002). It is currently 
difficult to make predictions for neutral substances because there is too little information on 
transport and non-transport for substances from this chemical space for a model to learn from 
(Koepsell 2020). The set of compounds tested in our study was highly restricted (charge at 
pH 7.4 = +1, logD7.4 < 1), caused by the limited chemical space of the training set. It would 
therefore make sense to expand this space in the future by testing more ‘improbable’ substances. 
Even if the reward for this work is not guaranteed, predictions and insights beyond what is 
currently conceivable are reason enough to do so. 
Identification and characterization of additional novel OCT1 substrates will probably enable in 
silico-guided identification of common substructures, which distinguish substrates from non-
substrates or substrates from mere inhibitors in future. Since molecule transport is not just 
binding, but a process of binding, translocation and release, distinct chemical substructures could 
adversely affect only single steps in this process. Identification of structural commonalities by 
similarity clustering might therefore be able to predict the type of interaction of a respective drug 
and OCT1 in future. The successful application of machine learning for the prediction of novel 
substrates is a first step towards the integration of this technique into molecule screening routine 
for OCT1 substrates. However, one does not have to be satisfied with successively expanding the 
model with newly found substrates or non-substrates. The next goal could be the quantitative 
prediction of transport by a regression model. The successful application of this will require more 
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data points (Göller et al. 2020). First attempts based on the existing data set were not able to make 
a quantitative prediction (Jensen and Dücker, unpublished data). 
A non-linear model with many predictors was used in our study. This approach is good for 
accurate prediction, but does not allow the model to be interpreted well and could be referred to 
as a black box. It may also make sense to use simpler models that perform worse, but remain 
understandable for humans. 
 
4.3 Stereoselective uptake of adrenergic agonists and antagonists 
The investigation of the possibility of stereoselective transport has been neglected for years, 
though it is a well-known phenomenon in enzyme catalysis for decades (Hanson 1972). As 
reported in Publication 3, OCT1 uptake can be stereoselective. The most striking differences were 
found for the diastereomers fenoterol and formoterol. An interesting finding of our study was the 
inverted stereoselectivity for fenoterol with the highly homologous transporter OCT2. The 
hepatically expressed transporter OCT1 facilitates more strongly the uptake of the 
pharmacologically active enantiomer (R,R)-fenoterol, while renally expressed OCT2 showed 
preference for uptake of the inactive (S,S)-fenoterol. In the case of fenoterol, the main, but not the 
only, route of elimination is the liver (Dettli 1996; Dollery 1999). Ultimately, peripheral blood 
concentrations of fenoterol might therefore include an imbalance of both enantiomers, which is 
not detected under regular racemic quantification. As only (R,R)-fenoterol exerts the agonistic 
effect on the β2-adrenoreceptor, this imbalance would be highly interesting (Beigi et al. 2006). 
Genetically variability in OCT1 could further mediate differing drug efficacy (Tzvetkov et al. 
2018). 
Significant stereospecific transport of several β-adrenoreceptor antagonists via OCT1 could not 
be detected in our study, neither for acebutolol nor for atenolol. This finding was in line with 
previous studies, in which both compounds did not show significantly different pharmacokinetics 
of the respective enantiomers (Mehvar und Brocks 2001; Mehvar et al. 1990; Pearson et al. 1989). 
Our study showed that stereoselective transport through OCT1 can occur and this could have an 
impact on pharmacokinetics. Stereoselectivity should therefore always be assessed in future and 
should be reconsidered for all known racemic substrates of OCT1 retrospectively. 
 
4.4 A double‑Flp‑In method for stable overexpression of two genes 
The method developed and presented here uses two overexpression vectors, each with one gene 
of interest, for simultaneous transfection and subsequent directed stable integration. This 
approach is not the only one utilizing the fact that the Flp recombination site remains intact after 
the integration of a plasmid containing the exact same sequence (Ward et al. 2011). However, this 
is the first published protocol, which includes the validation of single integration of both vectors, 
which is the first step of achieving comparable gene expression. Based on its principle and 
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conformed by experimental experience, the Flp-In system is an overexpression system, which 
results in low variation of gene expression anyway (Seitz et al. 2015). Low variation of gene 
overexpression is one requirement for studying the effect of specific genetic variants 
comparatively. Other approaches, which provide overexpression of two or more genes, require 
thorough validation of expression strength (Fahrmayr et al. 2012). Moreover, the genetic 
background of cells might be altered by some techniques, as the loci for integration cannot be 
controlled entirely (Finn et al. 1989). Selection with several antibiotics simultaneously can be 
stressful for cells, leading to altered expression levels in triple-transfected cells compared to their 
double-transfected predecessors (Hirouchi et al. 2009). The double-Flp-In method with reading 
frameshifts by small insertion/deletion polymorphisms requires only one antibiotic. This can be 
beneficial for transfections of sensitive cell lines. In the end, the protocol of the double-Flp-In can 
be used like a toolbox, as validation is independent from the actual gene of interest. The results 
obtained and presented in Publication 4 are crossvalidated by results from studies investigating the 
uptake and metabolism of proguanil to cycloguanil in human hepatocytes (Matthaei et al. 2019). 
Therefore, double-transfected cell lines, which arise from the double-Flp-In method, can be 
suitable tools, for instance, to study hepatic uptake and metabolism. By changing the employed 
promoters, gene expression ratios of the two integrated genes could even be adapted to in vivo 
conditions, as shown for inducible co-expression systems (Baron et al. 1995). Besides the 
combined uptake and metabolism, possible applications for the double-Flp-In include additive 
cellular uptake by two transport proteins or uptake and efflux (to mimic hepatobiliary transport) 
(Cui et al. 2001; Fahrmayr et al. 2012). Also, the double Flp-In could be used in future to study 
effects of heterozygous genotypes, as both genes of interest are expressed with equal strength. The 
double Flp-In might therefore be a suitable tool to in the in vitro-to-in vivo translation. In addition, 
protein-protein interaction studies (e.g. investigation of binding parameters of two proteins) are 
a broad field in which the double-Flp-In could turn out valuable in future. 
 
4.5 Variability and Heritability of Thiamine Pharmacokinetics 
Biomarkers have been identified for many enzymes and transporters. As OCT1 is highly 
genetically variable and plays a role in elimination of a wide range of drugs, determining its activity 
by the help of an endogenous biomarker seems worthwhile, even though medication adjustment 
has not yet been implemented in guidelines for any in vitro substrate of OCT1. The essential 
nutrient thiamine (vitamin B1) has repeatedly been suggested as an OCT1 biomarker, and OCT1 
was said to alter hepatic thiamine disposition (Chen L et al. 2015; Chu et al. 2017; Liang X et al. 
2018). Thiamine was shown to be a substrate of OCT1, transported with low affinity but high 
capacity (Chen L et al. 2014; Kato et al. 2015). Unfortunately, previous studies on thiamine as a 
potential biomarker for OCT1 activity were solely conducted in mice in which plasma thiamine 
concentrations increased upon OCT1 knockout (Chen L et al. 2014). In contrast, in our clinical 
study in humans we were not able to find any differences in thiamine plasma concentrations 
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between the OCT1 genotypes. This discrepancy may not be surprising, as murine Oct1 is expressed 
in the kidney as well, where it contributes to tubular secretion (Holle et al. 2011). Knock-out of 
Oct1 in mice could have lead to reduced renal clearance, thereby enhancing the effects of hepatic 
Oct1. This has, for example, also been shown for the OCT1 substrate fenoterol (Morse et al. 2020). 
Thiamine is an essential nutrient for life and as a cofactor involved in fundamental biochemical 
reactions, such as the α-ketoglutarate dehydrogenase complex of the citric acid cycle. So it is not 
surprising that there are redundant uptake processes of thiamine and thiamine pyrophosphate 
(Ashokkumar et al. 2006; Nabokina et al. 2015; Smithline et al. 2012; Zhang K et al. 2014). The 
low affinity transport of thiamine via OCT1 appears to be an interesting interaction in vitro, but 
negligible in vivo, at least in humans. 
While the previously formulated hypothesis about OCT1 being the primary uptake transporter 
for thiamine in the liver, cannot be rejected completely by our investigations (Liang Y et al. 2015), 
results from in vitro studies on primary human hepatocytes showed reduced uptake upon OCT1 
inhibition only at an exceptional high thiamine concentration. 
Of course, other endogenous substances could still work as biomarkers for OCT1 activity. One 
possible candidate is isobutyrylcarnitine, which was found to correlate with a common OCT1 
variant in previous genome-wide association studies (Suhre et al. 2011). Other candidates are the 
biogenic amines, for example serotonin, which has been shown to be translocated by OCT1 (Chen 
L et al. 2014; Jensen 2017; Koepsell et al. 2003). However, the influence of other transporters and 
enzymes must be considered here, which makes the connection increasingly complex and difficult 
to understand. 
Ultimately, clinical studies, for example with preselected genotypes, can help to investigate further 
potential endogenous biomarkers. Such studies in humans are apparently necessary because 
rodents are not the appropriate organisms to model human OCT1 physiology (Dresser et al. 2000; 





While the publications which form this manuscript answered several questions on OCT1 they 
also lead to additional questions and interesting topics for future research. 
The publication on psychostimulants showed the translocation of mescaline by OCT1 in vitro. 
Further studies should clarify the impact of OCT1 polymorphisms on the in vivo uptake and 
elimination of mescaline, as only the minority of ingested mescaline is excreted unchanged via 
urine. Beyond that, also the effect of loss-of-function OCT1 variants on mescaline 
pharmacokinetics as well as pharmacodynamics under the currently popular recreationally used 
psychoactive brew ayahuasca, which contains the MAO-A inhibitor harmine and might amplify 
the effects of mescaline due to reduced degradation, might be worth studying, again, in 
dependence on the OCT1 genotype. Also, the fact that with mescaline only one OCT1 substrate 
was found amongst the 18 tested, does not mean that only a few cationic hallucinogens or 
psychostimulants are OCT1 substrates. The result could have turned out very differently if other 
substances had been selected. In this respect, testing additional psychoactive compounds could 
provide interesting insights into the OCT1-mediated uptake of these substances, which are 
widespread and usually consumed in an uncontrolled manner. Biochemically, analysis of close 
structural analogues of mescaline might contribute to a better understanding of what makes a good 
OCT1 substrate. 
The database of known OCT1 substrates and non-substrates presented in this work was already 
able to serve as foundation for machine learning-aided identification of novel substrates. However, 
the current database should not be considered as final, but a continuously expanding collection of 
data. In future, more compounds should be investigated regarding OCT1 transport, may it be by 
exploration of (groups of) completely unfamiliar structures or by exploiting knowledge about 
known substrates and testing structurally related compounds. Also, more not so obvious 
compounds, such as uncharged or even negatively charged compounds should be tested. If there 
is a high degree of similarity between these and the previously tested cationic substrates, the 
importance of the charge could require reevaluation.  
The database added to and curated in this work is the largest collection of commercially available 
drugs with their respective OCT1 transport properties and using identical methodology (Jensen 
et al. 2021a). An interesting next step is the evaluation of these compounds in their potency to 
inhibit the transport of probe drugs by OCT1. Together, the resulting database might serve as a 
powerful tool to distinguish transport or inhibition properties of additional compounds, or even 
predict so far unknown inhibitors. 
While our study showed stereoselective transport by OCT1 and other solute carriers, 
stereoselective inhibition of OCT1 has not yet been comprehensively investigated so far. It is quite 
conceivable that, like the uptake of substrates, the interaction with inhibitors will also turn out 
differently for enantiomers. Therefore, in the search for specific inhibitors, individual 
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enantiomers should be tested separately so that good enantiomer inhibitors are not watered down 
by a poorly performing counterpart. Moreover, clinical studies, in which OCT1 showed an effect 
on the pharmacokinetics of a racemic drug, should be reevaluated. Enantiospecific measurements 
should also be included in future studies with racemates if in vitro studies show stereoselective 
transport. A subsequent determination of the enantiomers will also be useful for our in vivo 
fenoterol study that was carried out. This project has already been started. 
The simultaneous transfection of two plasmids by using the double-Flp-In protocol was shown to 
serve as a proper technique for overexpression of two genes. Of course, numerous applications of 
this technique for investigating various questions are conceivable. The simultaneous 
overexpression of OCT1 and phase I enzymes (e.g. CYP2D6, CYP2C19) will help studying uptake 
and metabolism, and finding more substrates of OCT1 and CYP enzymes in a single assay. This is 
followed up by in an ongoing project of mine. Of course, one logical extension of double-
transfection is triple transfection or transfection with even higher multiplicity. While the 
approach used by us may in principle be extended to multiple transfection, the requirement of 
multiple selection antibiotics in optimal concentrations is one hurdle we are working on. Already 
now, several groups have already asked for the created plasmids to study protein-protein 
interactions, to integrate additional reporter genes, or to overexpress additional regulatory 
proteins. 
Finally, this thesis included a study, which rejected thiamine as a potential endogenous biomarker 
for OCT1 activity. Additional endogenous substances do show some correlation with OCT1 
activity very well, such as isobutyrylcarnitine. The mechanisms behind OCT1 activity and 
isobutyrylcarnitine blood concentration have not yet been figured out, and remain as one of my 
ongoing projects (Jensen et al. 2021b). Metabolomics studies should help finding other potential 
endogenous biomarkers. By comparing accumulation of metabolites in plasma samples of OCT1-
deficient individuals in comparison to OCT1-active individuals, endogenous OCT1 substrates 
might be found enriched in the OCT1-deficient study cohort, which serve as starting point for the 
future search for a suitable biomarker. This project using targeted and untargeted metabolomics 
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